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ABSTRACT 
 
Rationale & Hypothesis:  
ALS is a fatal neurodegenerative disorder for which a GGGGCC hexanucleotide repeat 
expansion in C9ORF72 has been identified to be the most common genetic cause. 
Pathologically, ALS is characterised by premature death of motor neurons. The 
inhibition of Phosphatase and Tensin Homologue Deleted on Chromosome Ten (PTEN) 
in the PI3K cell survival cascade has been found to promote cell survival, and a newly 
described drug Scriptaid has been found to offer neuroprotection through PTEN 
inhibition in this pathway. We hypothesised that inhibiting PTEN in cell models of ALS 
could improve cell survival. 
Methodology and Objectives:  
For this investigation, we aimed to generate and characterise induced pluripotent stem 
(iPS) cell-derived motor neurons as in vitro models of ALS, from C9ORF72-ALS patient 
and sex/age matched healthy control primary fibroblast cells. Our objectives were to 
determine how PTEN manipulation through inhibition with Scriptaid or knockdown 
with short hairpin RNA (shRNA) lentiviral particles affects cell number and survival, 
comparing the newly generated iPS-derived cell models to established cell models of 
ALS including Neuroblastoma spinal cord (NSC)-34 cells and the primary fibroblast cells 
the iPS cells were derived from. 
Findings: 
We were able to successfully differentiate iPS cells into neurons and motor neurons of 
intermediate maturity in both patient and control cells, with C9ORF72 patient cells 
maintaining hallmarks of the repeat expansion. Results revealed fibroblast cells from 
C9ORF72 cases exhibited significantly lower levels of basal PTEN compared to control 
cells, however after the conversion to iPS-derived motor neurons, no significant 
difference between patient or control levels of PTEN expression were identified. PTEN 
knockdown in iPS-derived cells was found to cause a concomitant increase in PI3K 
pathway activation, and revealed a significant protection of cell number for up to three 
weeks in patient cells compared to controls after manipulation. However, PTEN 
vi 
 
inhibition through the use of Scriptaid had no significant effect on activating this cell 
survival pathway or promoting motor neuron survival in our investigations. 
Conclusions and Future Avenues: 
Together, these results highlight that PTEN inhibition through genetic manipulation 
activates the PI3K cell survival pathway to promote a positive therapeutic effect in ALS 
iPS-derived cell models. However, small molecule modifier of PTEN Scriptaid does not 
promote motor neuron cell survival or activate cell survival pathways in the cell models 
of ALS tested, suggesting that future experiments should use alternative methods of 
inhibiting PTEN directly for successful patient therapies. Comparing models, iPS cells 
offer a promising cell model to investigate PTEN manipulation in ALS, however further 
work is still needed to optimise the differentiation protocol to improve maturity and 
functional parameters. 
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ULK1 Unc-51-like kinase 1 
UMN Upper motor neuron 
UPS   Ubiquitin protease system 
UT Untransduced 
VAPB   Vesicle-associated membrane protein-associated protein B 
VCP   Valosin-containing protein 
VPA  Valproic acid 
WT  Wild type 
WT-SOD1  Wild type SOD1 (see SOD1) 
αER α oestrogen receptor 
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1.1 AMYOTROPHIC LATERAL SCLEROSIS (ALS) 
 
First described in 1869 by Jean Martin Charcot (Charcot and Joffroy, 1869),  
Amyotrophic Lateral Sclerosis (ALS) is a devastating and fatal neurodegenerative 
disorder, resulting in the loss of both upper and lower motor neurons. As a form of 
motor neuron disease (MND), once symptoms present, patients are given a prognosis 
of progressive paralysis and eventually death within 2 to 5 years, most commonly 
through respiratory failure (Wood-Allum and Shaw, 2010, Chio et al., 2009). 
Nonetheless, many features such as clinical phenotype, rate of progression, age of 
onset and environmental factors are thought to influence lifespan in this 
heterogeneous disease, with some patients living for more than 10 years past 
diagnosis (Kiernan et al., 2011, Chio et al., 2009).  
Currently the only treatment option available is Riluzole, a benzothiazole that is 
believed to act by modulating glutamatergic pathways of release (Bensimon  et al., 
1994). However, it only extends life by up to four months, highlighting a clear need for 
disease modifying treatments that may ameliorate the symptoms and slow 
progression with a goal of extending the lifespan for those affected. 
 
1.1.1  EPIDEMIO LOGY  AN D CLINICAL CHARACTERI STI CS  O F ALS 
 
Epidemiologically, in western populations the disease has an incidence in Europe of 
2.08 per 100 000 and a prevalence of 5.4 per 100 000, whilst in North America, Canada 
and the USA have an incidence rate of 2.2 and 1.8 per 100 000 respectively (Chio et al., 
2013). When you look towards Asian populations, incidence drops significantly, for 
instance, China has an incidence rate of 0.6 per 100 000 (Chio et al., 2013). However 
interestingly, Japan has a high relative incidence of 2.5 per 100 000 (Chio et al., 2013). 
These comparisons firstly suggest a greater tendency for ALS in Caucasian populations. 
Secondly, the higher incidence rates in Japan and Scandinavian countries such as 
Norway (2.2 per 100 000) or Sweden (3 per 100 000), also suggests an effect from 
isolated cultures comprised of less diverse genepools, where interracial relationships 
are less common due to historical, cultural or language barriers. Overall, these patterns 
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suggest a genetic cause, including a postulated founder effect for Caucasian 
populations (Saeed et al., 2009, Smith et al., 2013). However, other contributors to 
country specific incidence rates could include environmental exposure to pesticides, 
diet, and lifestyle (Ingre et al., 2015), as well as differences in average life expectancy 
for that country, which may be important for an age of onset disease. 
ALS is also known to affect more men than women by up to 1.5 fold (Manjaly et al., 
2010, Harwood et al., 2012), however of note, when hereditary cases are isolated, the 
incidence has been found to be similar across both sexes, suggesting sporadic cases 
are related to the male sex (Kiernan et al., 2011). The majority of ALS cases, 90%, are 
sporadic (SALS) occurring with no family history of the disorder. The remaining 10% of 
cases are familial (FALS), and unfortunately, as age of onset is typically in midlife at 50+ 
years (Harwood et al., 2012), it means many familial sufferers will have already had 
children before diagnosis, potentially passing on any disease causing genetic material. 
Clinically, ALS can be isolated from other Motor Neuron Diseases (MND) such as the 
upper motor neuron (UMN) affected Primary Lateral Sclerosis (PLS) (Gordon et al., 
2006); the lower motor neuron (LMN) affected Progressive Muscular Atrophy (PMA); 
and childhood onset form Spinal Muscular Atrophy (SMA). This is due to ALS 
presenting a progressive nature, both upper and lower motor neuron degeneration, 
and subsequent muscle wasting (Ince et al., 1998, Ferguson and Elman, 2007). 
However, due to the similarity of ALS symptoms across these disorders, it is important 
to confirm a correct diagnosis as other forms of MND can have a better prognosis. Due 
to the gradual onset of symptoms, it can take a year on average for the patient to 
present to a neurologist. Diagnosis is largely made on clinical grounds, rather than one 
diagnostic test, although advances in electrodiagnostics, ultrasound, and transcranial 
magnetic stimulation are improving this picture (Simon et al., 2015). This means that 
patients who have been eventually diagnosed with ALS may not obtain access to 
Riluzole for up to a year, further limiting the small yet positive effects of the treatment. 
Recent work has highlighted improvements still need to be made in the genetic testing 
of patients with ALS, in particular linking ALS with FTD of which only 57% of clinicians 
in a recent survey test for in patients, despite a clear link between the two diseases 
(Vajda et al., 2017). Genetic testing should be factored into more diagnostic strategies; 
as we understand more that ALS could be a heterogeneous collection diseases, clinical 
4 
 
trials are often carried out with a particular focus on a single genetic subtype of ALS 
(Ludolph, 2017). 
In Caucasian population studies, ALS has been found to present itself with three main 
different phenotypes (Harwood et al., 2012) including limb-onset, which is the most 
common presentation of ALS; bulbar onset, characterised by slow, slurred speech and 
wasting of the tongue (Duffy et al., 2007); and respiratory onset, the least common 
presentation found in 2.7% of patients (Shoesmith et al., 2007). However, further 
classification can include advanced subtyping referring to the proportion of UMN or 
LMN degeneration to define distinct presentations; this suggests ALS is a syndrome of 
related diseases rather than an isolated condition (Al-Chalabi and Hardiman, 2013). 
Symptoms generally include: muscle weakness, fasciculations, emotional lability, 
behavioural changes, and weight loss. Additionally, extra neuronal involvement has 
been more recently associated with the disease, with up to 50% of patients also 
presenting other cognitive impairments such as frontotemporal dementia (FTD) 
(Ferguson and Elman, 2007, Ferrari et al., 2011, Lomen-Hoerth et al., 2002).  
 
1.2 THE GENETIC CAUSES ,  RELATED PATHOLOGY ,  AND DISEASE 
MECHANISMS UNDERLYING ALS 
  
Ninety Percent of ALS cases occur sporadically (SALS), which leaves the remaining 10% 
of familial ALS cases (FALS) to characterise any causative genes, proteins and pathways 
involved in disease pathogenesis and progression, in expectation that any novel 
modifiers will translate across to the SALS population (van Blitterswijk et al., 2012). For 
the 10% of inherited cases of ALS, multiple genes have been identified to cause 
disease, and these have been classified into ALS subtypes, further highlighting how ALS 
in reality represents a spectrum of many related diseases (Abel et al., 2012) (Table 1). 
Many of the mutations commonly associated with ALS are inherited in a Mendelian 
fashion, and approximately 60% of inherited cases can be accounted for by mutations 
in two genes, Superoxide dismutase 1 (SOD1) and Chromosome 9 open reading frame 
72 (C9ORF72) affecting up to 20% and up to 50% of FALS patients respectively. 
Nonetheless, whilst Mendelian inheritance suggests a monogenetic cause, of note, 
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C9ORF72 mutations show incomplete penetrance, with some carriers failing to get the 
disease, underlining the complexity of the genetics behind ALS. As currently 126 genes 
have been identified to cause or act as a modifier for ALS (ALS online database), of 
which for many the significance has yet to be elucidated, the focus below will be on 
the mutations and related pathology that have prominently impacted ALS research 
worldwide.
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Table 1.1: Important genes associated with hereditary ALS and FTD.  Genes, ALS subtype, chromosome locus, method of inheritance, their pathogenic mechanism and or 
functions, and reference. Abbreviations: ALS, amyotrophic lateral sclerosis; PD, Parkinson’s disease; FTD, fronto -temporal dementia; AD, autosomal dominant; AR, autosomal 
recessive; RNA, Ribonucleic acid; DNA, Deoxyribonucleic acid, Gene (in table). 
Gene Subtype Chromosome Inheritance Pathogenesis / Function Reference 
Superoxide dismutase 1 (SOD1) 
 
ALS 1 
 
 
21q22.11 
 
  
AD / AR Oxidative Stress (Rosen et al., 1993) 
 
Alsin (ALS2) 
 
ALS 2 2q33.2 
 
AR 
 
 
Endosomal trafficking and  
Cell signalling 
 
(Yang et al., 2001) 
Unknown 
 
ALS 3  
 
18q21 AD 
 
Unknown (Hand et al., 2002) 
Senataxin (SETX) 
 
ALS 4 9q34.13 
 
 
AD 
 
 
RNA processing and 
transcription regulation 
(Chen et al., 2004) 
 
Spatacsin (SPG11) 
 
ALS 5 
 
15q14-q21.1 
 
AR 
 
DNA Damage Repair; 
Axonal Growth 
(Orlacchio et al., 2010)  
Fused in sarcoma (FUS) ALS 6 
 
16p11.2 AD / AR 
 
RNA processing and 
transcription regulation 
(Kwiatkowski et al., 2009, 
Vance et al., 2009) 
 
Unknown 
 
ALS 7 
 
20p13 
 
AD  
 
Unknown (Sapp et al., 2003) 
 
Vesicle-associated membrane 
protein-associated protein B (VAPB) 
 
ALS 8 20q13.33 AD Endosomal trafficking and  
Cell signalling 
 
(Nishimura et al., 2004) 
Angiogenin (ANG) 
 
ALS 9 
 
14q11.1 
 
AD 
 
 
RNA processing and 
transcription regulation 
(Greenway et al., 2006) 
TAR DNA-binding protein (TARDBP) ALS 10 1p36.22 AD RNA processing and 
transcription regulation 
(Sreedharan et al., 2008) 
Polyphosphoinositide phosphatase 
(FIG4) 
 
ALS 11 
 
6q21 
 
AD 
 
Endosomal trafficking and  
Cell signalling 
 
(Chow et al., 2009) 
Optineurin (OPTN)  
 
ALS 12 
 
10p13 
 
AD / AR 
 
Endosomal trafficking and  
Cell signalling; Autophagy 
(Maruyama et al., 2010) 
 
7 
 
Ataxin 2 (ATXN2) ALS 13 12q23-q24.1 AD Oxidative stress (Elden et al., 2010) 
Valosin- containing protein (VCP) ALS 14 9p13-p12 AD Autophagy (Johnson et al., 2011) 
Ubiquilin 2 (UBQLN2) ALS 15/X 
 
Xp11.21 X-Linked Protein Degradation  
Aggregation; Autophagy 
(Deng et al., 2011) 
σ Non-opiod receptor 1 (SIGMAR1) 
 
ALS-16/FTD 9p13.3 
 
AD 
 
Protein Degradation  
Aggregation 
(Luty et al., 2010, Al-Saif et al., 
2011) 
Chromatin modifying protein 2B 
(CHMP2B) 
ALS-17 
 
3p12.1 AD Endosomal trafficking and  
Cell signalling; Autophagy 
(Parkinson et al., 2006) 
Profilin 1 (PFN1)  
 
ALS-18 17p13.3 
 
AD Cytoskeletal; 
Axonal Growth 
(Wu et al., 2012) 
 
v-erb-b2 avian erythroblastic 
leukemia viral oncogene homolog 4 
(ERBB4) 
ALS-19 2q33.3-q34 AD Neuronal Development (Takahashi et al., 2013) 
Heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1) 
ALS-20 12q13.1 AD RNA processing and 
transcription regulation 
(Kim et al., 2013) 
Matrin 3 (MATR3) ALS-21 5q31.2 AD RNA processing and 
transcription regulation 
(Johnson et al., 2014) 
Tubulin alpha 4a (TUBA4A) ALS-22 2q35 AD Cytoskeletal  
Chromosome 9 open reading frame 
72 (C9ORF72) 
ALS-FTD-1 
 
 
9q21-q22 
 
 
AD 
 
RNA processing and 
transcription regulation 
(Renton et al., 2011, DeJesus-
Hernandez et al., 2011) 
coiled-coil-helix-coiled-coil-helix 
domain containing 10 (CHCHD10) 
ALS-FTD-2 22q11.23 AD Mitochondrial (Smith et al., 2014) 
Sequestosome 1 (SQSTM1) ALS-FTD-3 5q35 AD Protein Degradation  
Aggregation; 
Autophagy 
(Fecto et al., 2011) 
TANK Binding Kinase 1 (TBK1) ALS-FTD-4 12q14.2 AD Autophagy (Cirulli et al., 2015, 
Freischmidt et al., 2015) 
Microtubule-associated protein tau 
(MAPT) 
ALS-dementia-PD 17q21 AD Cytoskeletal; 
Axonal Growth 
(Hutton et al., 1998) 
D-amino acid oxidase (DAO) — 12q24 AD Glutamate excitotoxicity (Mitchell et al., 2010) 
Never in mitosis gene a (NIMA) 
related kinase 1 (NEK1) 
— 4q33 Unknown Unknown (Kenna et al., 2016) 
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1.2.1  SUP ERO XI DE D IS MUT AS E 1  (SOD1) 
 
In 1993, mutations in a gene which encodes for a 153 amino acid metalloenzyme 
called superoxide dismutase (SOD1) were identified as the first mutations to cause ALS 
(Rosen et al., 1993). These mutations were subsequently identified to contribute to 
around 20% of FALS cases and up to 3% of SALS. However, the mutation is not in a 
single location, with over 150 gene variations identified according to the ALS online 
database (http://alsod.iop.kcl.ac.uk/Overview/gene.aspx?gene_id=SOD1). 
Endogenous SOD1 acts to prevent toxicity from oxidative stress by binding to copper 
and zinc ions which together can metabolize superoxide free radicals to stop them 
from causing cellular damage. Originally, due to finding a reduced activity of the 
enzyme, it was proposed that disease was caused due to loss of function of the protein 
(Rosen et al., 1993, Deng et al., 1993) leading to investigations into oxidative stress. 
However, when the gene is mutated in disease, SOD1 misfolds and aggregates are 
formed. It has also been suggested that these aggregates cause motor neuron cell 
death in a toxic gain of function mechanism which causes a disease phenotype in cells 
(Bruijn et al., 1998).  
Interestingly, a more recent review of SOD1 activity re-visited the loss of function 
hypothesis, highlighting that in 48 mutations in papers reporting reduced SOD1 
enzymatic activity from 1993 to 2012, an average of 58% reduction in activity is found 
(Saccon et al., 2013); a reduction which others have suggested could be caused by the 
aggregates themselves (Yoon et al., 2009). As papers present contrasting opinions as to 
whether or not experimentally induced increases or decreases in SOD1 does not cause 
(Bruijn et al., 1998) or causes (Graffmo et al., 2013) ALS like phenotypes, the 
endogenous function and therefore dysfunction of this protein in disease still remains 
to be elucidated. Recently, evidence has been gathering to suggest SOD1 aggregates 
act in a prion-like way, helping to propagate and spread ALS to other cells (Lee and 
Kim, 2015). Nevertheless, these aggregates although found in small quantities are still 
found in ALS patient tissue and are therefore postulated to play an important role in 
disease (Jonsson et al., 2004). 
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1.2.2  TAR  DNA  B IN DIN G PR OTEIN  43  (TDP-43) 
 
SOD1 containing aggregates are the longest known pathogenic aggregates thought to 
be involved in both FALS and SALS (Bunton-Stasyshyn et al., 2014). However, this 
proteinopathy is not found in all cases of ALS and was superceeded when 
hyperphosphorylated TAR DNA Binding protein 43 (TDP-43) inclusions were found to 
be the major constituent of a more commonly found marker of ALS of ubiquitinylated 
protein aggregates. These TDP-43 inclusions were found in 97% of patient tissues in 
SALS, FALS, and FTD, and interestingly only FALS SOD1 and FUS related tissues do not 
display this pathology (Neumann et al., 2006, Arai et al., 2006, Mackenzie et al., 2007). 
This discovery was a breakthrough for characterising this common pathological marker 
for the disease and it was soon identified that TDP-43 underwent aberrant trafficking 
moving from its predominant nuclear location in healthy tissues to the cytoplasm, in a 
mechanism potentially causing pathogenesis (Lagier-Tourenne and Cleveland, 2009). 
TDP-43 is encoded by the gene TARDBP, and is a 43 KDa Deoxyribonucleic acid (DNA) 
and Ribonucleic acid (RNA) binding protein (Ou et al., 1995), which in its nuclear 
location acts to regulate the stability and splicing of RNA transcripts. The role of TDP-
43 also extends to auto-regulation, with TDP-43 found to modify its  own protein levels 
through the self-splicing of transcripts (Polymenidou et al., 2011). Due to the aberrant 
cytoplasmic location of TDP-43 in ALS, it has been implicated in multiple mechanisms 
of motor neuron injury including: regulating cellular stress due to forming into stress 
granules when exposed to oxidative stress (Colombrita et al., 2009), intracellular 
mRNA transport (Ishiguro et al., 2016), and synaptic transmission in the processes of 
neuronal cells (Diaper et al., 2013). However, like many pathological aggregates found 
in neurodegenerative disease, identifying whether TDP-43 aggregation is a cause or a 
consequence of disease remains an important aim for further investigations. 
Nonetheless, recent work is linking TDP-43 loss of function to impaired endosomal 
trafficking, finding a reduced number of Rab11-associated endosomes upon TDP-43 
knockdown which results in slow recycling of surface receptors important for tropic 
signalling (Schwenk et al., 2016). Studies like this are helping to build a picture of how 
this protein miss-location can cause ALS, but further work remains to be done to 
support such findings and link results to newer mutations such as that in C9ORF72.   
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1.2.3  CHRO MOSO ME 9  OP EN READIN G FR AME 72  (C9ORF72)   
 
In the 23 years since Rosen et al. first identified the gene encoding the free radical 
scavenger Superoxide Dismutase 1 (SOD1) as a causative agent in 20% of FALS cases, it 
was not until 2011 that any of the newer genes discovered were thought to affect a 
greater proportion of FALS sufferers than SOD1. This was when two teams 
simultaneously proposed a new gene, Chromosome 9 open reading frame 72 
(C9ORF72) to be the most common genetic cause of ALS to date (Renton et al., 2011, 
DeJesus-Hernandez et al., 2011). The mutation affects up to 50% of FALS cases (van 
Blitterswijk et al., 2012, Cooper-Knock et al., 2015c), around 7% of apparently sporadic 
patients (Renton et al., 2011, Sabatelli et al., 2012, van Blitterswijk et al., 2012) and is 
linked to FTD (Orr, 2011, van Blitterswijk et al., 2012), as well as other 
neurodegenerative disorders (Cooper-Knock et al., 2015c) implying the importance of 
investigations into C9ORF72 due to the widespread nature of the mutation. 
Fascinatingly, the expansion mutation has also been found in healthy individuals 
suggesting incomplete penetrance and a possible multifactorial pathogenesis (Harms 
et al., 2013). 
The mutation in C9ORF72 is a GGGGCC hexanucleotide repeat expansion in intron 1 of 
the C9ORF72 gene. In healthy individuals, less than 30 repeats are found, however in 
disease, between 30 and over 1000 repeats are reported to contribute towards both 
ALS and FTD (Renton et al., 2011, Rutherford et al., 2012, van der Zee et al., 2013). 
Although a threshold for disease has been reported in mouse models (Jiang et al., 
2016), and there have been correlations found between dysregulated splicing and 
repeat length (Cooper-Knock et al., 2015a), researchers are only just beginning to 
gather evidence suggesting that expansion repeat length correlates with factors such 
as onset, progression, severity or anticipation (Dafinca et al., 2016). 
The function of the protein product of C9ORF72 has yet to be revealed, but as the gene 
is highly conserved, with mice and rats showing respectively 98.75% and 97.1% amino 
acid similarity to the human form, it is thought to have an important biological 
function. There are three isoforms of C9ORF72 called variants 1-3. Variant 2 encodes a 
222 amino acid protein also known as the short form, whilst variants 1 and 3 encode a 
481 amino acid protein known as the long form(DeJesus-Hernandez et al., 2011). Both 
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variants are thought to be highly transcribed in neuronal cells (Suzuki et al., 2013). 
Although commercially available C9ORF72 antibodies may lack the desired specificity 
to accurately delineate the subcellular location of C9ORF72, and it is possible the 
protein is present at a low abundance in cells, attempts have been made in identifying 
its distribution. C9ORF72 has been found to be located in both the nucleus and 
cytoplasm of cells, with different isoforms potentially carrying different functions due 
to their location, for example isoform 1 has been found to accumulate at the synapses 
of cells (Atkinson et al., 2015). Its location has also been described as dynamic, moving 
between the nucleus and the cytoplasm during development (Ferguson et al., 2016). 
Others have found the short form can translocate from the nuclear membrane to the 
plasma membrane in disease, suggesting roles in nucleocytoplasmic transport (Xiao et 
al., 2015). Mouse studies have pointed to expression in embryonic and early postnatal 
neurons, including expression in multiple areas of the brain such as the cortex, 
hippocampus, olfactory bulb, along with high expression in the spinal cord grey matter 
and dorsal root ganglia (Koppers et al., 2015, Suzuki et al., 2013, Jiang et al., 2016, 
Ferguson et al., 2016). This reported high expression in neural tissue suggests a specific 
importance to these cells which could explain why neurons are so affected by its 
malfunction. As the mutation is an intronic expansion rather than a coding mutation, 
misregulated expression or dysregulated RNA splicing could cause this malfunction. 
The C9ORF72 protein has not been fully structurally characterised, albeit publications 
have identified a sequence homology to Differentially Expressed in Normal and 
Neoplasia (DENN) proteins which suggest a Guanine Exchange Factor (GEF) function 
for Rab GTPases in regulating intramembrane traffic (Levine et al., 2013, Zhang et al., 
2012a). Indeed C9ORF72 has been found to co-localise with several Rab proteins in 
neuronal and motor neuronal cells (Farg et al., 2014) which supports this hypothesis, 
although this result remains to be clarified with more specific antibody preparations.  
Of note, a recent paper has added further evidence to this theory, proposing C9ORF72 
interacts with Rab1a as part of a regulatory pathway for the initiation of autophagy 
(Webster et al., 2016). The study found that C9ORF72 when ablated from HeLa cells or 
primary motor neurons, prevented autophagy initiation. They later found that 
C9ORF72 interacts with Unc-51-like kinase 1 (ULK1) as part of the autophagy initiation 
complex, and also bound to Rab1. They proposed that the role of C9ORF72 was to act 
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as a Rab1 effector, recruiting Rab1 to ULK1, which regulates the trafficking of ULK1 in 
the early stages of autophagy (Webster et al., 2016); this was in contrast to a Rab GEF 
role proposed by previous studies (Farg et al., 2014). 
The mechanism for C9ORF72 related pathogenesis in ALS has naturally been the 
objective of a number of different investigators work and has led to several schools of 
thought. These include haploinsufficiency, where having only one functional copy of 
the allele for the gene results in a reduction in the amount of protein product, in a 
proposed loss of function mechanism (Gijselinck et al., 2012). To add to this, a toxic 
gain of function mechanism has been suggested, where transcription of the repeat in 
both directions results in aberrant extended repeat-containing RNA transcripts. These 
transcripts then form into RNA foci and affect protein translation by sequestering RNA 
binding proteins from their roles elsewhere, thus causing a cascade of problems such 
as alternative splicing or modifications in gene expression (Harms et al., 2013). Finally, 
it has been shown that the GGGGCC repeat is translated into hydrophobic dipeptide 
repeat (DPR) proteins that may aggregate intracellularly (Mori et al., 2013b). The 
mechanism for this has been hypothesised to be due to repeat associated non-ATG 
translation initiation; translation not from a start codon but due to hairpin formation 
of the repeat-containing RNA (Pearson, 2011, Zu et al., 2011, Kovanda et al., 2015).  
Neuropathologically, C9ORF72 cases have been associated with TDP-43 skein-like and 
neuronal cytoplasmic inclusions, as well as p62 inclusions, Bunina bodies, and 
ubiquitylated inclusions (Cooper-Knock et al., 2012). However, a portfolio of evidence 
has now included new molecular pathology such as RNA foci and di-peptide repeat 
proteins as additional hallmarks of the C9ORF72 repeat expansion. Nevertheless, 
although, this pathology is suggestive of a toxic gain of function mechanism of 
pathogenesis (Gendron et al., 2013, Cooper-Knock et al., 2015b, Mori et al., 2013a), 
studies have yet to find a correlation between DPR protein aggregates and disease 
(Davidson et al., 2016).  
1.2.4  C9ORF72  EXP ERI MEN TAL MODELS  AN D L I MI TATION S  
 
Due to the significance of C9ORF72 mutations in ALS with the repeat affecting up to 
50% of familial cases, as well as a high prevalence in SALS populations (7-10%), there is 
a high research need for robust cell models containing the pathogenic expansion. 
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However, a caveat to the excitement C9ORF72 has created in the field of ALS research 
is the fact that the CG rich mutation has previously slowed down the generation of cell 
and animal models containing the repeat expansion. This is due to technical difficulties 
in repeat primed PCR methods to demarcate expansions of more than 30 repeats, as 
screening is hampered by the secondary structure formed by the repeat expansion 
which leads to instability in the receiving vector (Renton et al., 2011). The extreme 
length of the expansions has also proved technically challenging for the generation of 
transgenic mice due to presenting germline somatic instability and bacterial artificial 
chromosome (BAC) instability. Therefore only recently, conditional knockout and 
overexpression animal models of C9ORF72 have surfaced with different outcomes. 
Significantly to the field, the effect of C9ORF72 ablation in mice appeared at first not to 
cause a degenerative motor neuron phenotype, nor present any motor defects akin to 
that seen in SOD1 mouse models. Koppers et al. were one of the first groups to 
discover that conditional knockout C9ORF72 mice did not display degeneration of 
motor neurons, poor motor function, nor changes in survival. However they did find a 
significantly lower body weight in models which is akin to the human patient 
phenotype who also experience weight loss in disease. Of interest, later studies, show 
that homozygous knockout C9ORF72-mice, display unique symptoms of enlarged 
spleens and lymph nodes, a reduced life expectancy and, in contrast to the previously 
published results, mild motor deficits (Jiang et al., 2016). However, Jiang and 
colleagues also found comparative results in increased weight loss, suggesting some 
overlap with models generated. In more recent results, in contrast to their own 
previous reports, Koppers et al. have found that ablation of C9ORF72 does cause 
reduced survival, and also reported splenomegaly and increased lymph node size 
(Sudria-Lopez et al., 2016). However, mice still did not show any motor neuron defects, 
with the reported reduced survival hypothesised to be due to immune deficiencies in 
mice (Sudria-Lopez et al., 2016). Together, the lack of neurodegeneration in these mice 
models supports the theory that loss of C9ORF72 does not result in 
neurodegeneration, suggesting haploinsufficiency may not be the cause of disease in 
ALS. 
When the C9ORF72 BAC transgenic mice were generated to express the repeat 
expansion at different lengths, at first no obvious signs of neurodegeneration or motor 
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neuron dysfunction were found (Peters et al., 2015, O'Rourke et al., 2015). These 
studies also failed to find any TDP-43-related pathology commonly found in C9-ALS 
patients; however, they did find the presence of molecular pathology related with C9-
ALS in the form of RNA foci and DPR protein aggregates which were thought to 
increase in prevalence with age and showed the BAC constructs were being expressed. 
More recent work using similar transgenic lines also found no motor neuron loss, no 
reduced performance in motor functional tests or TDP-43 pathology (Jiang et al., 
2016). However, they did find evidence of cognitive impairment in high repeat 
containing models and interestingly an age and repeat length associated increase in 
both foci and DPR products (Jiang et al., 2016). This could suggest that the foci and 
DPR products may not be a cause for the neurodegenerative phenotype, but are a 
consequence of the mutation or even a protective response which is activated to a 
higher extent with factors such as age, disease severity, and repeat length. Of recent 
note, a new study has generated a C9 BAC transgenic mouse expressing the expanded 
repeat, which in contrast to previous studies found abnormalities in gait, reduced 
survival, a progressive phenotype, degeneration of spinal motor neurons, and RNA-
related and TDP-43 pathology which collectively Lui et al. describe as a motor neuron 
disease phenotype (Liu et al., 2016). With C9 mouse models failing to recapitulate 
disease phenotypes across multiple groups this could reflect the different animal 
genetic backgrounds and laboratory conditions tested, including differences in level of 
expression, size and timing of expression. However, it also could mean that presence 
of the mutation alone does not cause disease; an important finding as similar 
sequence homology from mouse to human C9ORF72 suggests a translatable 
phenotype for humans. If this is true, potentially a second hit, for example with 
environmental factors or cellular stressors, is required for pathogenesis in C9-ALS. 
Nevertheless, without a solid consensus on the effect C9ORF72 mutation to the motor 
neurons and phenotype of the mice models generated, results still suggests multiple 
mechanisms including the possibility of both loss and gain of function contributing to 
pathogenesis.  
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1.3 ALS:  A  MULTIFACTORIAL DISEASE  
 
Key players in ALS are reactive oxygen species (ROS); free radicals that upon 
accumulation in neuronal cells, cause aberrant cytotoxic (Shaw et al., 1995) and 
genetic oxidative damage (Chang et al., 2008b). Accumulation is thought to occur 
partly from the malfunction of free radical scavengers such as SOD1, generating rather 
than removing ROS (Wiedau-Pazos et al., 1996). The evidence for this has been found 
in ALS patient post-mortem examinations which have increased and thus pathogenic 
levels of oxidation (Shaw et al., 1995), as well as studies which have found increased 
levels of ROS such as hydrogen peroxide in familial forms of the disease compared to 
sporadic and control cases (Said Ahmed et al., 2000). 
Neuronal support cells, such as astrocytes have also been implicated in the progression 
of ALS, for instance, deleting mutant SOD1 in astrocytes has been found to slow the 
progression of disease (Yamanaka et al., 2008). Interestingly, the presence of 
conditioned media from mutated SOD1 astrocytes can cause motor neuron cell death 
(Rojas et al., 2014), suggesting the astrocytes release a substance that is toxic to motor 
neurons and indicating that the astrocytes may initiate disease in other cells. 
Suggested components of toxicity released by astrocytes include increased release of 
the precursor of nerve growth factor which can cause an aberrant increase in p75 
receptors and signalling from them in motor neurons, while a reduction in lactate 
release is thought to also trigger motor neuron death due to a lack of nutritional 
support (Ferraiuolo et al., 2011). To add to this, media from mutant SOD1 astrocytes 
has been found to cause increased persistent sodium channel currents in motor 
neurons, resulting in toxic hyper-excitability of the cells and a highlighting another 
potential mechanism of disease (Fritz et al., 2013). Recent studies have suggested that 
this hyper-excitability may be the start of a cascade that results in increased calcium 
uptake, mitochondrial dysfunction, and therefore increased release of ROS which 
trigger c-abl cell death cascades in motor neurons (Rojas et al., 2015), again pointing 
towards astrocytes as the cells which initiate or at least contribute towards motor 
neuron cell death. 
Mitochondrial dysfunction is another major contributor to pathogenesis in ALS, with 
neuronal mitochondria from ALS SOD1 G93A murine models exhibiting dysfunctional 
16 
 
calcium uptake (Damiano et al., 2006). This coupled with increased glutamatergic 
signalling from enhanced 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid 
(AMPA) and N-Methyl-D-aspartic acid (NMDA) receptor expression or activity (van 
Zundert et al., 2012, Williams et al., 1997) and reduced removal of glutamate from the 
synaptic cleft by excitatory amino acid transporter 2 (EAAT2), can increase levels of 
intracellular calcium and thus is likely to create a pathophysiological feedback loop 
between motor neuron excitotoxicity, failed mitochondrial calcium buffering and ROS 
production by mitochondria (Grosskreutz et al., 2010). This has formed the basis of the 
excitotoxicity neurodegeneration hypothesis, where excessive glutamatergic synaptic 
activity leads to calcium overload, increased membrane excitability and motor neuron 
cell death (Cleveland and Rothstein, 2001). To add to this, protein aggregates in 
mutant SOD1 ALS cases have been found to cluster in the intermembrane space of 
mitochondria, promoting further mitochondrial dysfunction (Wong et al., 1995). As the 
mitochondria’s main role is in the production of energy, upon their failure, the 
reduction in energy stores could lead to an escalating cycle of motor neuron injury. An 
example includes reduced axonal transport, which in motor neurons is vital due to 
their long processes requiring a higher than normal energy demand. Indeed, defects in 
axonal transport have been identified in mutant SOD1 mice (Bilsland et al., 2010, De 
Vos et al., 2007) and may be an early event in degeneration (Williamson and Cleveland, 
1999). 
 
Other forms of cellular transport are also implicated in ALS, including 
nucleocytoplasmic transport and nuclear export. Ran- mediated nucleocytoplasmic 
transport uses Ran GTPases modulated by RanGEF in the nucleus and RanGAP in the 
cytoplasm to mediate the trafficking of cargo from the nucleus and the cytoplasm in 
the cell (Stewart, 2014). It has been suggested that the hexanucleotide repeat 
expansion in C9ORF72 may contribute to defects in nucleocytoplasmic transport and 
lead to cellular stress and disease propagating mechanisms. Due to hairpin formation 
of the transcribed repeat, the secondary structure is thought to cause the binding of 
proteins including nucleolin which is found in the nucleolus of cells (Haeusler et al., 
2014). This interaction was specific to patient cells and was found to cause nucleolar 
stress, as identified by a dispersed nucleolus (Haeusler et al., 2014). Later work by the 
same group, this time in Drosophila melanogaster animal models, identified impaired 
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nuclear import due to expression of the expansion, and were able to rescue this defect 
using antisense oligonucleotide (ASO) therapy targeted to the complex secondary 
structures formed by the repeat (Zhang et al., 2015a). Further studies in flies 
corroborating this have found failed RNA nuclear export and morphological defects in 
the nuclear envelope (Freibaum et al., 2015), while screens in both Drosophila 
melanogaster and Saccharomyces cerevisiae have found Ran-mediated 
nucleocytoplasmic transport and nuclear pore components to be associated with DPR 
protein mediated cellular toxicity (Jovicic et al., 2015, Boeynaems et al., 2016). 
Intracellular transport, trafficking and the regulation and degradation of cellular 
components have also been connected to ALS pathogenesis. Autophagy, in particular 
macro-autophagy, is the catabolic degradation of intracellular components through 
formation of a double membrane-bound vesicle encapsulating components for 
lysosomal-bound degradation. Autophagy defects have been previously linked to 
Parkinson’s disease and Alzheimer’s disease (Harris and Rubinsztein, 2012), but 
recently the process has been postulated to play an important role in C9ORF72-related 
ALS. Proteomic analysis to identify C9ORF72 binding partners have discovered a 
complex forming between C9ORF72 and WDR41 a 52 KDa protein whose function is 
unknown, as well as between C9ORF72 and Smith-Magenis syndrome chromosome 
region 8 (SMCR8), a 105 kDa protein containing a DENN domain which has previously 
been known to interact with autophagy initiator proteins (Sellier et al., 2016). Of note, 
Sellier and colleagues also found the complex interacts with Rab proteins including Rab 
8 and Rab39b, a finding which supports the previous notion that C9ORF72 acts as a 
GEF (Farg et al., 2014). This theory is also supported by the identity of other Rab8 
interactors which include Optineurin (OPTN) and TANK binding kinase 1 (TBK1); 
proteins which are mutated in ALS subtype 12 and ALS-FTD type 4 respectively (Table 
1). Further to this theory, when C9ORF72 is knocked down via short hairpin RNA 
(shRNA), it prevents the initiation of autophagy, supporting mouse model evidence 
that C9ORF72 ablation can cause lysosomal accumulation (O'Rourke et al., 2016). More 
recent work also links the initiation of autophagy in C9ORF72 ALS. A study by Webster 
et al. found C9ORF72 interacts with Rab1, and suggested in contrast to Farg et al. that 
C9ORF72 does not act as GEF for Rab proteins but instead acts as an effector, helping 
to bring together components for the initiation of autophagy (Webster et al., 2016). 
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In the childhood form of MND, Spinal Muscular Atrophy, the SMA determining gene, 
survival motor neuron 1 (SMN1) (Lefebvre et al., 1995), has roles in building small 
nuclear ribonucleoproteins and splicing pre-messenger ribonucleic acid (pre-mRNA). 
As mutations to SMN1 were found to be causal to disease pathogenesis (Burghes and 
Beattie, 2009), this has led to predictions for a role of RNA processing, transcriptional 
regulation, and RNA binding in MND pathology due to the similarity of cells affected. 
Of note, the nuclear protein TDP-43 prominently associated with ALS has been found 
to bind to and possibly modulate many RNAs implicated in neurodegenerative 
disorders and examples include Fused in Sarcoma (FUS), Tau, Ataxin as well as binding 
to itself (Sephton et al., 2011). To add to this, the ever increasing knowledge of 
C9ORF72 pathology has found that the aberrant RNA may also sequester RNA binding 
proteins (RBPs) which could propagate disease in ALS by causing dysregulation of RNA 
metabolism and splicing. Heterogeneous nuclear ribonucleoproteins (hnRNPs), 
amongst other RBPs, have been shown in a number of studies to bind to C9ORF72 and 
include hnRNPs A1, A2/B2, A3, F, H, K and U, ADARBP2 and PURα as probable 
candidates (Donnelly et al., 2013b, Sareen et al., 2013, Haeusler et al., 2014, Cooper-
Knock et al., 2015b, Cooper-Knock et al., 2014). Whilst these studies may not fully 
reveal the normal function of the C9ORF72 protein, they indeed reveal factors and 
pathways which are aberrant and potentially underpin disease pathogenesis in ALS. 
 
1.4 PTEN  AS A NEURONAL TARGET  
 
Over recent years, a building portfolio of work on phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) has shifted the focus of research on this 
established tumour suppressor, from cancer (Myers et al., 1997, Steck et al., 1997) to 
neurodegenerative disorders. The reason for this lies in the proposed neuroprotective 
features of PTEN inhibition. PTEN inhibition has been found to not only increase 
neuronal cell survival and reduce apoptosis, but also to improve axon growth and 
branching in neuronal cell and animal models  (Ning et al., 2004, Shi et al., 2011a, 
Zhang et al., 2012b).  
PTEN is strongly expressed in central nervous system (CNS) neuronal cells, mirroring 
the expression of interactor phosphatidylinositide 3-kinase (PI3K) (Lachyankar et al., 
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2000). The highest expression is found in mature neurons, whereas low levels of PTEN  
are found in immature astrocytes, an expression which is lost in maturity (Lachyankar 
et al., 2000). In neuronal development, PTEN controls neuronal differentiation 
(Lachyankar et al., 2000) and axonal growth (Kwon et al., 2006), and is essential to 
development, with mice showing embryonic lethality when PTEN is mutated in tissues 
(Suzuki et al., 1998). 
PTEN is located in both the cytoplasm and nucleus of neuronal cells (Lachyankar et al., 
2000, Ning et al., 2010) and there is evidence to suggest that the subcellular 
localisation of neuronal PTEN reflects varying mechanistic actions. Cytoplasmic PTEN 
modulates apoptosis (Li et al., 2009) and when PTEN is located in specific cytoplasmic 
sub-compartments, it can initiate additional roles such as associating with 
mitochondrial membranes and the endoplasmic reticulum for control of calcium 
signalling and release that can cause apoptosis (Bononi et al., 2013, Zhu et al., 2006). 
Nuclear PTEN is postulated to work independently from cytoplasmic roles, thought to 
control G1 cell cycle arrest (Chang et al., 2008a, Liu et al., 2005) and may even confer 
neuroprotection as opposed to the cell survival suppression in the cytoplasm (Goh et 
al., 2014). As nuclear pools of phosphatidylinositol 3, 4, 5 triphosphate (PIP3) have 
been found to be resistant to PTEN (Lindsay et al., 2006), this discovery along with the 
finding that nuclear PTEN is unable to modulate v-akt murine thymoma viral oncogene 
homolog (AKT) phosphorylation and activation (Liu et al., 2005) suggests distinct 
mechanistic roles for the compartmentalised protein. Notably, studies have identified 
that PTEN can accumulate in the nuclei of post-mitotic neurons after injury, suggestive 
of an activated neuroprotective mechanism (Howitt et al., 2012, Zhang et al., 2013). 
Significant recent work has also identified a novel 75KDa species of post-translationally 
modified PTEN, of which small ubiquitin-like modifier (SUMOylation) promoted the 
nuclear localization of PTEN (Bassi et al., 2013). The same study found loss of nuclear 
PTEN increased sensitivity of the cells to DNA damage, again implying that nuclear 
PTEN expression confers a protective phenotype (Bassi et al., 2013). In simultaneously 
published findings, an alternative translation codon was identified, which encodes an 
additional 173 amino acid domain at the beginning of the N terminus to create an 
alternative 75KDa longer version of PTEN termed PTEN-L (Hopkins et al., 2013). This 
longer form of PTEN was also found to inhibit the AKT pathway through the 
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phosphatase domain, but most remarkably it can be secreted from cells to interact 
with additional receptors and can be used as an external agent to reduce basal AKT 
phosphorylation (Hopkins et al., 2013). It was recently found that PTEN-L also has 
distinct roles in membrane binding compared to wild type PTEN, suggesting unique 
intracellular targets which may be of significance to cell survival (Masson et al., 2016). 
These fascinating findings also suggest that it may be possible to use a cell penetrating 
form of PTEN as a therapeutic; if found to be amenable to modulation to phosphatase 
inactive forms the therapeutic potential of PTEN could be extended even further. 
Indicators that this pathway is an important target in neuronal cell death were first 
learned from studies which found an increase in the inactive phosphorylated form of 
PTEN after middle cerebral artery occlusion (Omori et al., 2002). Additionally, when 
the downstream effectors of PTEN: PI3K, AKT and pAKT, were seen to have increased 
expression after nerve crush injury (Ito et al., 1996) and up-regulation in rat post-
ischemic cerebral cortex (Cai et al., 2009), this coupled with promoted motor neuron 
survival (Namikawa et al., 2000), suggested an endogenous activation of the AKT cell 
survival pathway in the face of injury. This work implied that neurons attempt to 
promote their own survival after acute injury, prompting the question as to whether 
this occurs in chronic neurodegenerative disease. 
Whilst increased neuronal cell survival is a vital parameter in identifying a promising 
therapeutic strategy, it is also important to discover if surviving neurons are both 
functional and confer an ability to regenerate after injury and in disease. Park and 
colleagues in 2008 (Park et al., 2008), used adeno-associated (AAV) viruses expressing 
Cre floxed mice for PTEN mediated deletion, to show after retinal ganglion cell injury, 
along with increased survival, an increased and robust axon regeneration beyond the 
sites of insult, therefore identifying that PTEN deletion enables axons to overcome the 
hostile environment in and around the lesion. PTEN deletion in other neuronal cell 
types such as adult corticospinal neurons, retinal ganglion cells, and SMN-deficient 
motor neurons, was also found to increase the ability of neurons to grow and form 
synaptic like structures (Liu et al., 2010, Huang et al., 2017). The next logical steps were 
to identify if these axons reach their intended targets and secondly, to perform 
electrophysiology experiments to examine how functional the regenerated axons 
become. These steps were undertaken in subsequent work where PTEN knockdown 
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was found to increase branching, neurite outgrowth, myelinated axon regrowth, axon 
number and more importantly accelerated compound muscle action potentials, 
indicative of neuronal cell functionality (Danilov and Steward, 2015, Singh et al., 2014). 
Li et al. in 2015 explored a similar hypothesis and found that AAV depletion of both 
PTEN and suppressor of cytokine signalling 3 (SOC3) genes in mice promoted long-
distance axonal regeneration after nerve crush injuries, evoked excitatory post 
synaptic currents through glutamatergic synaptic transmission, and promoted return 
of locomotive function, highlighting a possible cocktail of cellular targets which may 
underpin the beneficial effects of PTEN deletion (Jin et al., 2015). Finally, despite 
zebrafish models, unlike mammalian models conferring an ability to recover from CNS 
injury, upon inhibition of one of the two zebrafish homolog genes for PTEN, PTENa, 
zebrafish were found to also show improved regeneration of axons and locomotor 
recovery after spinal cord injury (Liu et al., 2014). This result further supported the use 
of PTEN inhibition to promote neuronal cell survival and cell growth.  
 
 
1.5 PTEN  AND THE PHOSPHATIDYLINOSITIDE 3-KINASE  (PI3K)  
CELL SURVIVAL CASCADE  
 
The PTEN gene is found on chromosome 10q23.3 and encodes a 55 KDa protein which 
was first identified in 1997 (Steck et al., 1997, Datta et al., 1999). It consists of a C-
terminal domain with roles in regulation, stability, protein to protein interactions via 
the PEST sequence, as well as a PDZ binding motif for binding to the plasma membrane 
(Lee et al., 1999) and acting as a scaffold for other proteins to regulate contact polarity 
dependent cell signalling pathways. For example, PTEN binds to PTPN13 a protein 
tyrosine phosphatase, via the PDZ binding motif to mediate some of its tumour 
suppressor activities (Sotelo et al., 2015). The N-terminal domain has roles as a dual 
specificity protein and lipid phosphatase (figure 1.1) (Lazar and Saltiel, 2006). The 
pathways of cell survival mediated by v-akt murine thymoma viral oncogene homolog 
(AKT) are regulated by the lipid phosphatase activities of PTEN, whilst the protein 
phosphatase activities of PTEN dephosphorylate tyrosine, serine, and threonine 
22 
 
Figure 1.1:  PTEN structural diagram 
PTEN is a 403 amino acid long protein comprising a PIP2 binding sequence from residues 6 to 15, 
an N-terminal HCXXGXXR containing sequence for phosphatase activity from residues 15 to 186 
(purple), a C2 domain from residues 186 to 351 (pink), and a C terminal region from residues 352 
to 403 containing the PEST sequence (blue stripes) (350 to 375) and PDZ binding motifs (401 to 
403) for regulation, stability, protein to protein interactions and binding to the plasma 
membrane. The blue stalks highlight serine and threonine phosphorylation points. Abbreviations: 
PIP2, phosphatidylinositol 4,5 bisphosphate, PEST, proline -glutamic acid-serine-threonine; PDZ, 
post synaptic density protein (PSD95)- Drosophila disc large tumour suppressor (Dlg1)- Zonula 
occludens-1 protein (zo-1). 
 
residues (Myers et al., 1997), and are postulated to play a role in neuroprotection 
(Ning et al., 2004).  
 
 
 
 
 
 
 
 
 
PTEN is proposed to be a good target for neuronal survival due to the role of PTEN in 
the PI3K cell survival pathway. PTEN is a dual phosphoinositide 3 phosphatase, which 
means it has the ability to dephosphorylate residues on phosphatidylinositol 3, 4, 5 
triphosphate (PIP3) to  form phosphatidylinositol 4, 5 bisphosphate (PIP2), reducing 
the total levels of PIP3  in vivo (Maehama and Dixon, 1998). This is important as PIP3 
binds to AKT which causes its relocation to the cell membrane (Datta et al., 1999), 
where it is activated through phosphorylation. AKT in its phosphorylated and active 
form can promote cell survival due to inhibiting components of cellular apoptosis 
pathways including, Bcl2/BclxL- associated death protein (BAD) (Datta et al., 1999) 
(figure 1.2). Additional downstream components of the PI3K pathway are also of 
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importance to neuronal cells, and include mammalian target of rapamycin (mTOR) 
known to be involved in the phosphorylation of Serine 6 Kinase (S6K) which in turn 
phosphorylates the ribosomal protein Serine 6 (S6) which can promote axon 
elongation from protein synthesis (figure 1.2). The key driver of this pathway is 
phosphatidylinositide 3 kinase (PI3K), which acts opposite to PTEN by phosphorylating 
and converting PIP2 to PIP3 thus promoting cell survival through AKT activation. 
However, important interactors in this pathway also include glycogen synthase 3β 
(GSK3β) which acts in a negative feedback loop with PTEN. Whilst GSK3β can inactivate 
PTEN, PTEN can also inactivate GSK3β through AKT mediated phosphorylation of 
GSK3β serine residues, thereafter modulating glycogen synthesis (Frame and Cohen, 
2001).  
With PTEN regulation in mind, rather than turning on a constitutively active cell 
survival pathway, the focus of research has been on controlling the action of PTEN 
through the inhibition of its dephosphorylating activities, in order to promote cell 
survival through altered inhibition of the pathway. However, other benefits may also 
be realised. Apart from associations with the cell membrane in the PI3K pathway, PTEN 
is also known to bind to and interact with extrasynaptic N-Methyl-D-aspartic acid 
(NMDA) receptors. Studies have shown that when PTEN levels are experimentally 
decreased, a reduction in NMDA receptor activity, levels of expression and a 
promotion of cell survival have been identified (Ning et al., 2004). Secondary activities 
of PTEN such as interactions with NMDA receptors could be utilised to promote 
additional therapeutic effects, especially as increased NMDA receptor calcium induced 
excitotoxicity is an important  part of the pathogenesis of neurodegenerative disorders 
(van Zundert et al., 2012).  
PTEN is regulated through many different mechanisms and cellular interactors which 
are of significance to neurodegenerative disorders. Neural precursor cell-expressed 
developmentally down regulated gene 4 (NEDD4), is involved in controlling PTEN for 
nuclear transport and degradation through the ubiquitin proteasome system (UPS) 
(Trotman et al., 2007, Christie et al., 2012, Wang et al., 2007) and it was recently 
identified that this system could also be used to secrete PTEN through exosomes (Putz 
et al., 2015). Post-translational modification of PTEN, specifically involving nitric oxide 
(NO) signalling and nitrosylation, are also important in regulating PTEN (Numajiri et al., 
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2011). Increased levels of s- nitrosylated PTEN levels have been found in Alzheimer’s 
disease (AD), Parkinson’s disease (PD), and stroke patient brains, and this nitrosylation 
can be mediated by endogenously produced NO (Kwak et al., 2010). Alongside this, it 
has been found that the role of nitrosylation could be to mark PTEN for degradation 
via NEDD4, as a reduction in NEDD4 also stopped a nitrosylation-mediated reduction in 
PTEN (Kwak et al., 2010). Studies have suggested that the relationship between PTEN 
and NEDD4 might be more complex than previously thought as PTEN may also 
negatively regulate NEDD4 and promote axon outgrowth via activated protein 
translation machinery (Hsia et al., 2014). Gene expression of PTEN has been found to 
occur through trans-activation by p53 (Stambolic et al., 2001), with which it can 
physically associate via the C2 domain (Freeman et al., 2003). However, studies have 
found that PTEN can self-regulate its own expression by increasing the expression and 
stabilisation of p53, independent of its lipid and protein phosphatase activities (Tang 
and Eng, 2006). This evidence is important as it proposes that PTEN holds greater 
autoregulation of its activities, operating as both a negative and a positive regulator 
and potentially offering a level of protection via feedback loops that promote cell 
survival along the PI3K pathway, as well as being able to manipulate its own 
transcription.  
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Figure 1.2: Schematic representation of the PTEN- AKT-mTOR pathway and downstream 
effectors. RTKs allow the binding of ligands activating PI3K. PTEN acts to dephosphorylate PIP3 to 
PIP2 whilst PI3K phosphorylates PIP2 to PIP3. PIP3 binds to and causes the translocation of AKT to 
the cell membrane where it phosphorylates and subsequently promotes the sequestration of cell 
death component BAD and blocks GSK-3β glycogen synthase inhibition. mTOR is also activated by 
AKT so mTOR can now phosphorylate S6K which in turn phosphorylates the ribosomal protein 
Serine 6 and 4EBP promoting cell growth and translation. TSC2 a GTPase activating protein involved 
in a complex with TSC1, a scaffolding protein, normally inhibits mTOR via Rheb, however when it is 
phosphorylated by AKT, TSC1 is inactivated so mTOR is then activated. A negative feedback loop 
from S6K separates IRS1 from its normal binding to PI3K. Rapamycin inhibits mTOR 
Abbreviations: RTK, Receptor tyrosine kinase;  PIP2, phosphatidylinositol 4,5 bisphosphate; PIP3, 
phosphatidylinositol 3,4,5 triphosphate; PI3K, phosphatidylinositide 3-kinase; BAD, Bcl2/BclxL- 
associated death protein; GSK-3β, glycogen synthase kinase 3 β; mTOR, mammalian target of 
rapamycin; S6K, Serine 6 Kinase ; 4EBP1, Eukaryotic Initiation factor 4E binding protein; eIF4E, 
Eukaryotic Initiation factor 4E; IRS1, Insulin receptor substrate 1; TSC1/2, tuberous sclerosis 1/2; 
MDM2, mouse double minute 2 
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1.6 PTEN  AND MOTOR NEURON DISEASES  
 
In ALS the characteristic dying back of neuronal processes and the premature death of 
motor neurons is a prominent aspect of the phenotype (Pun et al., 2006, Fischer et al., 
2004). However, as multiple mechanisms of disease and conflicting hypotheses for 
pathogenesis are currently being deliberated, identifying one target can be difficult, 
particularly if there are still questions as to whether or not the abnormalities are 
causal or consequential of disease. This perhaps explains why promoting the survival 
of the cells that are affected in ALS, the motor neurons, is an attractive therapeutic 
objective and research direction. 
Aberrant oxidative and glutamatergic stress are prominent features of ALS, and 
interestingly research has found links between oxidative stress and the cell survival 
pathways it negatively affects. A study by Chang et al. identified that under increased 
oxidative stress there is a prevention of PTEN nuclear export by a p53 dependent 
mechanism, which might be to not only activate p53 mediated cell cycle arrest, but 
also to act as a dual mechanism to prevent the accumulation of cytoplasmic PTEN, 
thought to have a pro-apoptotic effect (Chang et al., 2008a). Gary and Mattson 
illustrated that overexpression of wild type PTEN in neuronal cells increased the levels 
of apoptosis, as well as glutamate-induced apoptosis. When PTEN was knocked down, 
the heterozygous mice showed increased survival of neurons in excitotoxic conditions 
(Gary and Mattson, 2002) in an important link to not only MND but other 
neurodegenerative disorders where glutamate induced excitotoxicity can be a key 
driver to degeneration.  
As PTEN depletion seemed to be an appropriate tool to promote phosphorylation of 
AKT and thus pathways of survival and growth, multiple attempts experimentally to 
modulate the behaviour of PTEN have been conducted in motor neuron disease 
research. As expected, PTEN depletion in models of MND were shown to increase the 
phosphorylation of AKT and of the components downstream in the pathway including 
BAD, S6 and mammalian target of Rapamycin (mTOR), coupled with a decrease in 
apoptosis (Kirby et al., 2011, Ning et al., 2010, Ning et al., 2004, Shi et al., 2011a). 
Moreover, work conducted on two different cell models of MND- SMN deficient mice 
(Ning et al., 2010) and murine G93A SOD1 motor neurons (Kirby et al., 2011)- 
27 
 
demonstrated higher neuronal survival rates. PTEN silencing via systematic delivery of 
self-complementary recombinant adeno-associated virus (scAAV9) vectors resulted in 
an increase in the life span of SMN deficient (SMAΔ7) mice, implying PTEN knockdown 
could be a good therapeutic target for SMA, a childhood form of motor neuron disease 
(Little et al., 2015), however as a monogenetic form of MND the focus of research 
currently lies in gene therapy of the mutated gene to treat the cause of SMA. 
Interestingly, a significant reduction of active pAKT level has been found in ALS patient 
motor neurons (Dewil et al., 2007) as well as a failure to up-regulate S6K involved in 
axon growth (Wagey et al., 1998), pointing to a potential malfunction of this pathway 
in disease. In contrast, gene expression profiling studies in 2011 found 34 genes 
involved in apoptosis were differentially expressed in human SOD1 motor neurons 
compared to controls, with a decrease in PTEN expression and an increase in 
expression of pro-survival components such as AKT and PI3K (Kirby et al., 2011). In this 
study, the motor neurons were laser capture micro-dissected from human post-
mortem material therefore were inevitably those that had persisted through the 
disease process. It is possible that an activated endogenous neuroprotective 
mechanism occurs in surviving motor neurons whilst those that die have a reduction in 
the activity of this cell survival pathway. Indeed, recent studies on ALS patient induced 
pluripotent stem (iPS) cells have identified an increased cell death response as well as 
a 50% and 75% reduction in anti-apoptotic components downstream of the PI3K 
pathway of Bcl2 and Bcl XL respectively (Dafinca et al., 2016). Furthermore, in 2017 
innovative new studies developing inducible cell models of C9ORF72-ALS, found that 
partial PTEN knockdown was protective against toxicity previously identified in the cell 
models (Stopford et al., 2017). However of note, the same study also identified a single 
nucleotide polymorphism (SNP) in PTEN, a missense change that results in loss of PTEN 
function, which associated with protection against ALS. These studies are indicative 
that upstream targeting via PTEN inhibition or reduction in function could promote a 
return to normal cell death regulation in disease, whilst also confirming this target for 
treatment could offer protection against cell death in ALS specifically. 
A recent study has implicated a prominent nucleolar protein, nucleolin, in ALS 
pathogenesis. In cases of C9ORF72-realted ALS, (Renton et al., 2011, DeJesus-
Hernandez et al., 2011), nucleolar stress has been revealed in patient iPS-derived 
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motor neurons compared to control cells, with nucleolin appearing more dispersed in 
the disease-related cells (Haeusler et al., 2014). Another recent study discovered that 
PTEN when localised to the nucleolus, co-localises with nucleolin and contributes 
towards nucleolar homeostasis (Li et al., 2014). In the same study, when nucleolar 
PTEN was knocked down, they noticed an increased number of nucleoli and a change 
in nucleolar morphology, in keeping with the work of Haeusler and colleagues. 
Interestingly, this relates to a study performed in 2003 by Borgatti et al. (Borgatti et al., 
2003) where they found that upon stimulation, AKT translocates to the nucleus with 
pAKT found to co-immunoprecipitate with nucleolin. These studies suggest a potential 
link between PTEN and AKT nuclear localisation in a possible mechanism to activate 
ribosome biogenesis and intrinsic cell survival pathways simultaneously. With nucleoli 
morphological changes identified in both ALS and in PTEN manipulation studies, PTEN 
may also be a potential therapeutic target to rescue the nucleolar defects recently 
reported in ALS.  
 
1.7 PTEN  AND OTHER NEURODEGENERATIVE DISEASES  
 
1.7.1  PTEN  AND PAR KINS ON ’S  D I S EAS E  
 
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the progressive 
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) of 
the midbrain. Dopaminergic neurons project to the striatum which is important in 
coordinating movement. PD is characterised by aberrant motor symptoms comprising 
resting tremor, bradykinesia, and rigidity. PTEN has regulatory roles on PTEN induced 
kinase 1 (PINK1) a 581 amino acid protein expressed throughout the brain which has 
been postulated to control mitochondrial oxidative phosphorylation and stress. 
Mutations in PINK1 contribute towards autosomal recessive early onset PD (Valente et 
al., 2004, Glasl et al., 2012). Cytosolic PINK1, much like cytosolic PTEN, is important in 
dopaminergic neuronal survival (Haque et al., 2008). However, PINK1, in contrast to 
PTEN, is thought to endogenously promote neuronal survival via mechanisms 
controlling oxidative stress (Petit et al., 2005). Evidence to support this has been found 
in PINK1 overexpression models, which not only enhance neuronal survival, but also 
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reduce the formation of ROS, in a thapsigargin induced model of oxidative stress (Li 
and Hu, 2015).  
Distinct from PINK1, PTEN has also been implicated in PD directly. Conditional 
inactivation of PTEN using a Cre-LoxP system driven by a dopamine transporter to 
acquire specific deletion of PTEN in dopaminergic neurons, caused an increase in the 
number of neurons located in the SNc (Diaz-Ruiz et al., 2009). Moreover, specific 
deletion of PTEN in this way is neuroprotective against 6-hydroxydopamine (6OHDA ) 
induced models of PD, with recorded survival rates of 51% (Domanskyi et al., 2011) 
and 89% (Diaz-Ruiz et al., 2009) of SNc tyrosine hydroxylase (TH) positive neurons. 
Other mouse models of PD have found PTEN-deficient dopamine neurons display 
enhanced survival and neurite outgrowth when transplanted into the depleted 
striatum of parkinsonian mice (Zhang et al., 2012b), whilst genetic mouse models show 
that the loss of PTEN rescues locomotor defects (Domanskyi et al., 2011). In another 
link to oxidative stress, knockdown of PTEN reduced the levels of ROS in hippocampal 
cell models of PD and cerebral ischemia (Zhu et al., 2007), again verifying that targeted 
PTEN manipulation may ameliorate many other types of neuronal degeneration where 
oxidative stress is implicated (Xu et al., 2014). When constitutively active, AKT has also 
been found to offer neuroprotection against 6OHDA PD models through increased 
survival and reduced axonal loss (Ries et al., 2006), which supports the concept that 
manipulating the PI3K pathway is a valid neuroprotective strategy. 
 
1.7.2  PTEN  AND ALZHEI MER ’S  D I S EAS E  
 
Alzheimer’s disease (ALZ) is the most common neurodegenerative disorder affecting 
over half a million people in the UK alone. Most commonly, ALZ presents symptoms of 
memory loss and progressive cognitive dysfunction, whilst neuropathological tissues 
contain neurofibrillary tangles (NFTs) comprising hyper-phosphorylated tau, as well as 
insoluble β-amyloid (Aβ) plaques. In similar findings to other neurodegenerative 
investigations, PTEN immunoreactivity was found to be increased in organo-typic slice 
cultures in synthetic Aβ peptide models of ALZ, coupled with a decrease in active 
phosphorylated AKT, and as expected, an increase in cell death (Nassif et al., 2007). 
However, the relationship of PTEN in ALZ may be more complex. The pathology of 
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PTEN distribution in ALZ neurons shows a decrease in total protein levels of PTEN as 
well as increases in phosphorylated AKT, mTOR at the AKT target site Ser2448 (Chiang 
and Abraham, 2005), and 4EBP1, which correlate with disease progression (Griffin et 
al., 2005, Rickle et al., 2006, Li et al., 2005, Tramutola et al., 2015). Recently, increased 
phosphorylation of PI3K has also been found in ALZ and mild cognitive impairment but 
not in preclinical ALZ or controls (Tramutola et al., 2015). This response could indicate 
an up-regulation of the PI3K pathway in ALZ, which may be a reflection of an effort to 
rescue damaged neurons with increased protein synthesis and activated cell survival 
pathways. Nevertheless,  recent studies have shown promising results by inhibiting 
PTEN in mouse models of ALZ, finding that inhibition rescued synaptic function and 
ameliorated defects in long term potentiation (LTP) in hippocampal neurons 
highlighting the cross-degenerative potential of targeting this pathway in neuronal 
cells (Knafo et al., 2016). 
 
1.8 PTEN  AND CANCER  
 
With PTEN holding such a prominent role in cell survival pathways it is not surprising 
that before connections with neurodegeneration were established, PTEN was 
implicated in cancer. As a tumour suppressor gene, PTEN was discovered to be 
mutated in some forms of cancer including glioblastoma, breast, prostate, and kidney 
cancers (Myers et al., 1997, Steck et al., 1997). PTEN has also been linked to: Cowden 
disease (CD), a syndrome that presents multiple benign hamartomas and predisposes 
to breast and thyroid cancers; the associated Lhermitte-Duclos Disease (LDD) which 
causes seizures due to increased cerebellar glial cell growth; and juvenile polyposis coli 
(Liaw et al., 1997).  
Genetically, the connection to cancer is thought to involve a loss of heterozygosity 
(LOH) of the PTEN tumour suppressor gene on chromosome 10q23.3 (Sano et al., 
1999, Bostrom et al., 1998). At a cellular level, the important role of PTEN in 
preventing downstream activation of cell survival and growth pathways was 
demonstrated in experiments where wild type PTEN introduced into PTEN deficient 
glioma cells suppressed their growth, a suppression that was abolished with an 
inactive form of PTEN (Furnari et al., 1997). Additionally, constitutively active AKT and 
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increased phosphorylation of AKT and S6 have been found in various models of PTEN 
deficiency (Groszer et al., 2001, Suzuki et al., 1998, Backman et al., 2001, Stambolic et 
al., 2000).  
Glioblastoma multiforme is the most common and most malignant glioma with a high 
connection to LOH of PTEN (Liu et al., 1997, Myers et al., 1997). Recent studies have 
found that specific Glioblastoma multiforme-associated mutations in PTEN prevent 
PTEN localisation to the cell membrane and nucleus in a lipid phosphatase dependent 
mechanism, which reduces the stability of PTEN generating enzymatically inactive 
proteins which can no longer regulate AKT signalling(Yang et al., 2017). PTEN has been 
found to localise endogenously in neural tissues in the nuclei, cytoplasm as well as in 
the processes of various neurons, yet interestingly is absent from neurotrophic 
support cells such as astrocytes (Cai et al., 2009, Lachyankar et al., 2000). This may 
explain why in some studies no PTEN mutations have been identified in astrocytomas 
(Duerr et al., 1998) and infers that in cases of glioblastoma genesis, the natural low 
expression of PTEN may be a pathogenic cause. With less endogenous protein levels at 
the outset any further reduction via haploinsufficiency or LOH could be detrimental. 
Importantly, the associated LOH of PTEN in cancer is more common later rather than 
earlier in tumour development (Myers et al., 1997). Further to this, recent work has 
also found that loss of PTEN was more common in brain metastasise in comparison to 
primary tumours, and is a loss which is micro-environment specific, meaning it can be 
restored on exposure to a different environment (Zhang et al., 2015b). Of note, the 
study also found that astrocytes may release exosomes containing PTEN targeting 
microRNAs which act on other cells to promote metastases. 
In work selectively deleting PTEN in mature glial and neuronal cells of the cerebellum, 
no tumour formation was observed (Marino et al., 2002). One reason for this could be 
due to the post-mitotic non-proliferative nature of cerebellar neurons, which like 
motor neurons may be more resistant to neoplasia and thus more responsive to PTEN 
depletion. However, it could also be related to the above mentioned lack of PTEN 
involvement in tumorigenesis (Xiao et al., 2005). Therefore, if PTEN inhibition was used 
therapeutically for regenerative purposes, a transient inhibition would perhaps be 
beneficial to avoid potential late tumour involvement, besides the importance of 
specifically targeting neuronal cells of interest. 
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1.9 PTEN  AND SMALL MOLECULE INHIBITION  
 
Whilst many of the PTEN depletion models mentioned above involving methods such 
as viral vector mediated knockdown make excellent models experimentally, and the 
technicalities of gene therapy are constantly being perfected to allow administration of 
therapeutic agents past the blood brain barrier via the AAV9 serotype (Valori et al., 
2010, Dayton et al., 2012, Foust et al., 2009), unfortunately, results are effective 
primarily in new born mice and applications of gene therapy research clinically are 
hindered by slow movement through to clinical trials. Therefore, other options for 
PTEN downregulation such as the use of PTEN inhibitors as therapeutics are 
compelling, and perhaps quicker alternatives. As small molecule inhibition provides a 
titratable and reversible response, in comparison to irreversible permanent gene 
therapy knockdown which may result in off-target effects, it presents an attractive 
solution for manipulation of a tumour suppressor protein which has in the past been a 
concern.  
In 2004, Bisperoxovanadium (BpV) compounds were found to be new non-toxic PTEN 
inhibitors (Schmid et al., 2004) and when used in vivo in adult rats after spinal cord 
injury, an increased number of motor neurons was recorded at the injury site 6 weeks 
later compared to saline treated controls (Walker et al., 2012). Notably, Walker et al. 
found that administration of BpV improved coordinated limb movement compared to 
controls (Walker et al., 2012) and further evidence includes: BpV treatment reducing 
neuronal cell death post-ischemia and oxygen glucose deprivation (Shi et al., 2011a, 
Zhao et al., 2013, Zhao et al., 2016); increasing the regenerative ability of injured 
peripheral sensory neurons in vivo (Christie et al., 2010); and during in vitro human 
embryonic stem cell derived neuronal progenitor cell studies, a dose dependent 
increase in neurite outgrowth after BpV treatment was discovered (Wyatt et al., 2014). 
In recent studies, Walker and colleagues have further validated the use of BpV 
compounds for PTEN inhibition, where they have also included oligodendrocytes and 
Schwann cells in the neuroprotective and increased functional effects of BpV 
administration in models of spinal cord injury (Walker and Xu, 2014, Walker et al., 
2015). In addition, the positive effects of PTEN inhibition have been found to work in 
other neuronal functions specifically in injured neurons, including the ability to rescue 
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a previously identified reduction in hippocampal long-term potentiation (LTP) and 
memory, caused by anaesthetic use (Wang et al., 2015b). In an interesting connection 
with pathological glutamate dependent excitotoxicity, BpV when administered to 
Sprague-Dawley rats in a model of subarachnoid haemorrhage, decreased Glutamate 
receptor 1 (GluR1) AMPA receptor subunit expression (Chen et al., 2015). Comparably, 
our work also found PTEN knockdown can reduce AMPA receptor GluR1, GluR2 and 
GluR3 subunit expression and decrease AMPA induced whole cell currents in iPS 
derived MNs (Yang et al., 2014a). Therefore, PTEN small molecule inhibition modulates 
multiple aspects of PTEN machinery, meaning it may be possible to ameliorate 
simultaneous neurodegenerative mechanisms of action through this target.     
 
1.10 THE ADVENT OF INDUCED PLURIPOTENT STEM (IPS)  CELLS  
 
In 2006, Kazutoshi Takahashi and Shinya Yamanaka published findings which greatly 
advanced the field of genetic engineering, due to their discovery of four defined 
factors which induce pluripotency in differentiated somatic cells (Takahashi and 
Yamanaka, 2006). By demonstrating the ability to reprogram somatic cells into an 
embryonic–like stem cell state, their finding proved so innovative that Shinya 
Yamanaka shared the Nobel Prize in Physiology or Medicine with Sir John B Gurdon in 
2012, for the discovery that mature cells can be made to become pluripotent, 
(https://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/).  
To induce pluripotency in somatic cells, at first the group isolated 24 genes thought to 
confer the maintenance of pluripotency in early embryos and embryonic-stem (ES) 
cells. After a process of careful elimination, 4 were revealed as sufficient to reprogram 
mouse embryonic and adult fibroblast cells to a progenitor-like state when retrovirally 
transduced into the cells (Takahashi and Yamanaka, 2006). The factors were octamer-
binding protein 3/4 (Oct 3/4); krüppel-like factor 4 (Klf4); c -v-myc avian 
myelocytomatosis viral oncogene homolog (c-myc); and sex determining region Y(SRY)-
box 2 (SOX2). After a battery of confirmatory tests, comparing their similarity to ES 
cells by identifying the transduced cells ability to differentiate into any cell type of the 
body, as well as their ability to continuously self-renew, the cells were coined induced 
pluripotent stem (iPS) cells (figure 1.3).  
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When iPS cells were inevitably later generated from human dermal fibroblasts 
(Takahashi et al., 2007), these new cell models brought with them the anticipation of 
producing “designer cells” for use in human regenerative medicine, due to the ability 
of iPS cells to be converted into any cell type of interest. One example would be in vivo 
re-integration of motor neurons to replace those lost in ALS, as by generating cells 
from the patient’s own tissues, any difficulties surrounding transplanted cell rejection 
can in theory be mitigated (Liu and Zhang, 2010). Important for this, later work by 
Thompsons group also identified Nanog and Lin28 could replace c-myc and Klf4, as 
when combined with Oct3/4 and Sox2 they were also sufficient to reprogram human 
somatic cells to pluripotency (Yu et al., 2007). Therefore, this work revealed new 
methods which may circumvent difficulties around potential viral integration into the 
host genome with the use of transcription factors such as c-myc. 
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1.10.1  AMYOT ROP HI C LAT ER AL SCLEROSI S  AND IPS  CELL TECHNOLO GY  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several aspects of ALS make it an ideal candidate for in vitro iPS cell modelling. Firstly, 
unlike other cells from the human body, motor neurons cannot be obtained from living 
donors and post-mortem material may not accurately represent disease pathogenesis 
or progression, as these are the cells that have endured the disease and therefore only 
represent the final stages of ALS. In addition, the degeneration and loss of motor 
Figure 1.3: Schematic of iPS cell generation and differentiation.  Somatic cells from patients with 
ALS or controls without ALS are removed and exposed to four reprogramming or Yamanaka factors 
(SOX2, Oct 3/4, c-myc, and Klf4) via retroviral transduction. Factors induce pluripotency in somatic 
cells to generate induced pluripotent stem cells with ability to self -renew and differentiate into 
any cell type of the body. iPS cells are directly dif ferentiated into the cell of choice for 
investigation, in this instance the motor neuron. Abbreviations: octamer -binding protein 3/4 (Oct 
3/4); krüppel-like factor 4 (Klf4); c -v-myc avian myelocytomatosis viral oncogene homolog (c -
myc); and sex determining region Y(SRY)-box 2 (SOX2); induced pluripotent stem (iPS)  
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neurons as a fundamental characteristic of ALS highlights an obvious need for the 
production of human cellular models to mimic the cells which degenerate. Therefore, 
iPS-derived cell models of motor neurons could provide an ongoing supply of motor 
neuron-like cells for investigation. Secondly, alternative methods to model ALS each 
hold inherent limitations. For example, embryonic stem (ES) cell models of both 
human and non-human origin have been used in the past with some success in ALS 
research (Di Giorgio et al., 2007). However, it is difficult to produce ES cells which are 
disease and patient specific (Takahashi et al., 2007); a particularly pertinent point for a 
disease which manifests in later life, as the ES cells would have to be obtained before 
disease onset from foetal tissue. Alongside this iPS derived-cell models are able to 
provide a tangible model of a disease with an unknown genetic background, for 
example sporadic forms of the disease. Finally, there is no need to overcome the 
inherent technical challenges of manipulating a large repeat expansion with iPS-
derived cell models, important in the light of recent genetic mutations discovered in 
C9ORF72 (DeJesus-Hernandez et al., 2011) . Even now, although animal models of 
C9ORF72 are available, unlike SOD1 animal models of the past (Gurney et al., 1994, 
Bruijn et al., 1997), they have been found to present weaker phenotypes and do not 
fully recapitulate disease, possibly due to poor representation of repeat length 
(Koppers et al., 2015, Peters et al., 2015). Of note, mouse models with stronger 
phenotypes of ALS, such as that of the SOD1 mutant mouse, have failed to generate 
any drugs that ameliorate disease more than the currently prescribed Riluzole 
(Benatar, 2007). Whilst these studies may reflect the poor ability of mouse models of 
all genotypes to accurately recapitulate the human disease of ALS, as the expansion 
mutation is found to be naturally stably expressed in fibroblasts and iPS cells, it makes 
them a relevant model for investigating this form of ALS.  
Dimos et al. were the first group to make use of the newly discovered technology for 
ALS by reprograming human fibroblast cells from an 82 year old female with a familial 
SOD 1-realted form of the disease (Dimos et al., 2008). Whilst it is likely that the 
mechanisms underpinning disease occur years before symptoms present, this study 
confirmed that mature motor neuron-like cells as evidenced by marker expression, can 
be developed as models for the disease. Additional studies have generated motor 
neurons for other forms of motor neuron disease, including spinal muscular atrophy 
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(SMA) a childhood form of the disease (Ebert et al., 2009). In contrast to the previous 
study, fibroblast cells from a child were converted to iPS cells which were shown to 
effectively reprogram, differentiate into motor neurons and glia, and mimic traits of 
SMA including showing reduced SMN transcripts, an indicator of disease (Ebert et al., 
2009). Furthermore, in an extension of the work by Dimos and colleagues, studies have 
been able to measure neuronal cell electrical activity, generating mature electrically 
active cells capable of displaying action potentials on depolarising stimulation 
(Karumbayaram et al., 2009, Sareen et al., 2013, Wainger et al., 2014, Devlin et al., 
2015). 
Together, this evidence suggests human iPS-derived cell models of ALS are an excellent 
resource to model the human disease of ALS. They provide an opportunity to examine 
how motor neuron-like cells react to disease modifying treatments, which due to their 
similarity to their human counterparts, could provide a more accurate representation 
of the endogenous response in patients and lead to translatable clinical findings.  
 
1.11 CONCLUSION  
 
As PTEN has a central role in cell survival pathways, it is important to exert caution in 
relation to using PTEN manipulators as therapeutic agents. Although the balance can 
be tipped in favour of either cell death and neurodegeneration or cell survival and 
tumorigenesis in certain disease states, this does not mean that the PTEN signalling 
pathway cannot be targeted for disease modifying treatments, as long as specific and 
carefully controlled neuronal targets were established beforehand. For example when 
PTEN knockdown is employed, to avoid systemic deletion and limit targeting to the 
disease affected cells, only specific viral or promoter selection could be used. 
Interestingly, collective studies point to the idea that PTEN manipulation will need to 
vary across neurodegenerative targets, in particular reference to the results found in 
ALZ research discussed above. In addition creative new techniques for PTEN 
manipulation will need to be further investigated, especially as new methods have 
been recognised from molecules that interact with PTEN endogenously such as NEDD4. 
Overall, these studies identify possible endogenous mechanisms to mediate 
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neuroprotection in neurodegenerative diseases, underscore the importance of PTEN in 
multiple cases of neuronal cell survival and qualifies PTEN manipulation as an 
important therapeutic target for many forms of neurodegeneration. 
In ALS, the specific degeneration of motor neurons is a consistent and causative 
feature of disease, which subsequently removes their important function from the 
human body. Whilst many interesting studies have identified new potential causes for 
ALS, identifying new genes of interest, including that of C9ORF72, we are still in the 
process of identifying why these mutations cause ALS and why the more prevalent 
sporadic ALS population is also affected. Whilst these studies are imperative to 
understanding the disease as a whole, by identifying techniques to target the survival 
of the cells which die in ALS, it may help provide translatable and quicker therapies 
which may supersede the poor alternatives currently available for patients. 
The advances in genetic engineering, cellular and molecular biology now mean we 
work in an era with exciting and potentially life changing methodologies. Induced 
pluripotent stem cell technology is one of these. These new models of disease could 
potentially act as better models of ALS than those currently available for several 
reasons. The patient iPS cell-derived motor neurons would contain pathogenic genetic 
changes inherently as they would be generated from somatic cells containing the 
mutation, which would also mean they would be human in origin. Additionally, as 
motor neuron- like cells they would be a near example of the cells affected in ALS 
including characteristics such as being post-mitotic and non-dividing: an advantage 
compared to some of the current models used for ALS research, for example 
Neuroblastoma spinal cord (NSC)-34 cells which do not have these features. Therefore, 
by employing the use of a cellular model which not only counteracts caveats found in 
other cell models for ALS research, but provides new opportunities to discover 
therapies for ALS in a self-renewing capacity, together in combination with previously 
established cell models, we may be able to make steps towards ameliorating the 
devastating disease of ALS. 
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1.12 AIMS AND OBJECTIVES  
 
1.12.1  PTEN  MANIPULATIO N   
 
The primary aims of this project are to identify if PTEN manipulation via inhibition of its 
activity or reduction of the total protein levels positively impacts the survival pathways 
and thus cellular survival of cell models of Amyotrophic Lateral Sclerosis (ALS). We will 
first work up methodologies in simpler and established cell lines and models of ALS 
including NSC-34 cells and primary fibroblast cells, whilst optimising iPS differentiation 
protocols. We will study the role of PTEN modulation using small molecule activators 
and knockdown, with a goal of comparing the effects of PTEN manipulation across all 
the models investigated. We will note how the changes in PTEN status affects 
components of the AKT cell survival cascade, as well as monitor the effect on cell 
survival through cell number in patient and control cells. We will also note any changes 
in the differentiation and maturation of iPS cells to motor neurons after PTEN 
manipulation through motor neuron cell counts, to identify whether or not the genetic 
background of mutated C9ORF72 makes a difference to the positive effects previously 
seen in PTEN manipulation studies in ALS and neurodegenerative research.  
 
 
1.12.2  IPS  CELL D I FFER EN TIATION AN D CHAR ACT ERI SATION  
 
We aim to generate induced pluripotent stem (iPS) cell- derived motor neurons, by 
using three age and sex matched patient and control fibroblast cells with a genetic 
background from the newly discovered C9ORF72 hexanucleotide repeat expansion, 
proposed to be implicated prominently in ALS pathogenesis (Renton et al., 2011). The 
originating iPS cells will be converted from patient and control fibroblast cells, via 
transfection with retroviral vectors encoding 4 Yamanaka Factors, and will be 
subsequently directed into the fate of motor neurons. The cells will be monitored and 
tracked in their progression to a neuronal and motor neuronal identities by techniques 
such as immunocytochemical (ICC) staining of generated cells with known markers of 
differentiation. Once generated, by examining the cell survival through the number of 
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these iPS derived cells, we can determine if any differences occur between basal 
control and C9ORF72- ALS iPS derived cells, which will highlight any patient specific 
vulnerabilities of the model. For a final authentication of the motor neurons 
generated, electrophysiological studies will be performed to identify the ability of 
motor neurons to generate action potentials and convey electrical characteristics 
associated with a mature motor neuron. In a further step, characterisation will also 
include examining the maintenance of the expansion in the cell models post-
differentiation via identification of ALS-specific molecular pathologies. This will be 
observed through the presence of newly established hallmarks of the hexanucleotide 
repeat expansion, including RNA foci and the presence of dipeptide repeat proteins, 
which will be identified through RNA FISH and ICC techniques respectively. Their 
identification if any, will also act to further validate or negate proposed hypotheses of 
C9ORF72-related causes of pathogenesis in ALS. 
This thesis aims to study the potential role of modulating PTEN in the PI3K pathway 
in motor neuron models of ALS, using both genetic engineering and small molecule 
approaches. This is with the hope of validating the pathway and finding a potential 
therapeutic agent that could translate to a human clinical trial. 
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 :  MATERIALS AND METHODS  CHAPTER 2
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2.1 CELL CULTURE  
 
2.1.1  NEURO BLAS TO MA SPIN AL CO RD (NSC)-34  CELL CULTUR E  
 
Neuroblastoma Spinal cord (NSC-4) cells were cultured on 10cm2 NunclonTM Surface 
plates (Nunc) in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) with 10% Fetal 
Calf Serum (Biosera) and additional 1% L- glutamine (Lonza). The NSC-34 cells that 
were stably transfected with pIRESneo (Clontech, Saint-Germain France) using 
Lipofectamine 2000 (Invitrogen) with empty vector (pIRES cells), pIRESneo containing 
wild type human SOD1 (WT SOD1 cells), or pIRESneo containing mutant human SOD1 
G93A (G93A cells). For the WT SOD1, pIRES and G93A cells, G418 Sulphate (250µg/ml) 
(Geneticin) was used to select for the vector. Cells were split no more than 1 in 5, and 
harvested by washing the cells gently from the plates.  Due to the high metabolic 
activity of the cells, a full media change was required every 2 to 3 days. Cell stocks 
were defrosted into 10cm2 dishes by adding warm media to the frozen vial and plating 
immediately to 10ml of media without G418. When they had reached a confluence of 
30- 40% density, G418 was then added. All cells were kept at 37˚C in humidified 
incubators with 5% carbon dioxide.  
 
2.1.2  PRI MARY  F I BRO BLAST  CELL CULT UR E  
 
Primary Human Fibroblasts cells were cultured from skin biopsies produced in SITraN 
by Anne Gregory and the technical team from three C9ORF72 positive ALS patients 
(C9ORF72) and three aged and sex matched controls (Control) (Table 1). All samples 
were collected after correct ethical permission was granted (REC 12/YH/0330 NRES 
Committee Yorkshire & the Humber-Sheffield). Cells were cultured in 75cm2 NunclonTM 
treated flasks blue filter cap (Nunc) or 10cm2 plates in Dulbecco's Modified Eagle's 
Medium (DMEM) (Gibco) with 10% Foetal Bovine Serum (FBS) (Biosera), 1% Penicillin 
Streptomycin (Lonza), 1% Minimum Essential Medium Non-Essential Amino Acid 
(Gibco) and 1% GlutaMAXTM(Gibco) (full media). Cells were kept at 37˚C in humidified 
incubators with 5% carbon dioxide.  
43 
 
Cells were harvested by removing media from the flasks and washing twice with 
Phosphate Buffered Saline (PBS) to remove any remaining media. For each flask or 
plate, 5ml or 4ml respectively of 1X Trypsin (Lonza) was added and vessels were 
incubated at 37˚C for 2 minutes or until the cells had detached from the base of the 
flask. Subsequently 10ml of Full media from the cells was added to quench the trypsin. 
Cells were then spun down at 400g relative centrifugal force (RCF) for 4 minutes and 
re-suspended in 12ml of media for splitting between flasks or plates.  
 
Table 2.1: Aged and sex matched primary fibroblast cells from C9ORF72 patient s and controls. 
Pair C9ORF72 CONTROL 
 Code Sex / Year of 
birth 
Code Sex / Year of 
birth 
1 FIBMND 3009 Female / 
1952 
CON 159 Female / 
1949 
2 FIBPAT 206 Female / 
1945 
CON 195 Female / 
1944 
3 FIBMND 3026 Male / 1962 CON 170 Male / 1948 
 
 
2.1.3  HUMAN  EMBR YONI C K I DN EY  (HEK)  293  CELL CULT UR E  
 
Human embryonic kidney (HEK) 293 cells were cultured in 10cm2 NunclonTM surface 
plates (Nunc) with 10% FBS and 1% Penicillin Streptomycin (Lonza). Cells were grown 
until 80% confluence on which they were split no more than 1 in 5 via gently washing 
the cells from the plate, without the use of enzymes. Cells were kept at 37˚C in 
humidified incubators with 5% carbon dioxide.  
Cells were harvested by removing media from the flasks and gently washing the cells 
from the base of the plate. Cells were then spun down at 400 RCF for 4 minutes and 
re-suspended in 12ml of media for splitting between plates.  
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2.1.4  IPS  CELL MAIN T EN AN CE AND D IFFERENTI ATIO N  
 
The iPS cells were grown on a monolayer. The monolayer was prepared by first coating 
a T25 cm2 NunclonTM flask (Nunc) with 0.1% gelatin (Sigma) and then adding a layer of 
mouse embryonic fibroblast (MEF) cells. The MEF cells were previously treated with 
10μg/ml mitomycin-C (American Type Culture Collection), an antineoplastic antibiotic 
that inhibits DNA synthesis to prevent the division of fibroblasts yet allowing the cells 
to survive and produce key proteins such as LIF (Leukemia inducing factor) which 
support the renewal of stem cells. 
The iPS cells were first cultured in “iPSC media” containing DMEM/F12 (Gibco), 20% 
knockout serum replacement (KSR, Gibco), 1% non-essential amino acids (NEAA, 
Gibco), 1% GlutaMAX (Gibco), 0.1 mM β-mercaptoethanol (Sigma), 4ng/ml basic 
fibroblast growth factor (bFGF, Invitrogen), 1% penicillin streptomycin (Lonza) and 
were incubated at 37°C, 5% CO2. The media was changed every 24 hours until colonies 
had formed.  
In order to generate motor neurons, iPS colonies were passaged using 1mg/ml 
collagenase type IV (Gibco), triturated into smaller cell clumps and plated onto T25 cm2 
flasks with a layer of MEF cells at 80 % confluence, or onto 4, 10mm coverslips (VWR 
International) in CELLSTAR® 35x10mm culture dishes with 4 inner rings (Grenier Bio-
one). For each media change throughout differentiation, the cells in T25 flasks were 
kept in 4ml of media, whilst the cells plated onto coverslips were kept in 2ml of media.   
For days 1 and 2 of differentiation, the colonies were cultured in iPSC media, 
containing 10 µM Y27632 Rho-associated kinase inhibitor to enhance single cell 
survival, 0.2 µM LDN193189 for neuralization and 20 ng/ml bFGF (Invitrogen) to 
enhance growth. On day 3, cells were maintained in a “neural induction media” 
comprised of “iPS media” without β-mercaptoethanol, but with added 2μg/ml heparin 
(Sigma), and 1% N2 supplement (Gibco). On day 5, 1μM all-trans retinoic acid (RA, 
Sigma) along with 0.4 µg/ml ascorbic acid (Sigma), and 10ng/ml brain derived 
neurotrophic factor (BDNF, Sigma) was added to modulate and enhance the 
differentiation and maturation of neurons.  On day 7 hedgehog signalling was initiated 
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by application of 200 ng/ml sonic hedgehog (SHH, R&D Systems) and 1μM 
purmorphamine (PUR, Selleckchem) until day 29 when the media was changed to 
“neurobasal media” (Invitrogen) containing 1% NEAA, 1% GlutaMAX, 1% penicillin 
streptomycin, 2% horse serum, 2% B27 supplement (Gibco),  with 1μM RA, 10ng/ml 
insulin-like growth factor (IGF, Gibco), 10ng/ml glial derived neurotrophic factor 
(GDNF, Gibco), 10ng/ml ciliary neurotrophic factor (CNTF, Sigma), 1µM adenosine 3',5'-
cyclic monophosphate (cAMP, Sigma). At day 30, cells were dissociated with 1X trypsin 
(Lonza) and plated onto poly-DL-ornithine hydrobromide (Sigma) and natural mouse 
laminin (Invitrogen) coated culture dishes or 10mm coverslips (VWR International). 
Cells were plated on coverslips at densities of 5000, 10 000, 20 000 or 40 000 cells per 
coverslip; 20 000 cells per 12 well; and 100 000 to 200 000 cells per 6 well. At day 30, 
cells were cultured in the same media as above with addition of 200 ng /ml ascorbic 
acid (Sigma). Cells were cultured up to 12 weeks, maintained at 37˚C in humidified 
incubators with 5% carbon dioxide.
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Table 2.2: iPS cell differentiation protocol, including schedule for addition of factors  and concentrations used. 
Day of Differentiation Media Factor Concentration Supplier Additional Information 
1-2 iPS Media Y27632 Rho-associated kinase 
inhibitor 
 
LDN193189 
 
 
 
 
 
 
 
basic Fibroblast Growth Factor 
(bFGF) 
10 μM 
 
 
0.2 μM 
 
 
 
 
 
 
 
20 ng/ml 
LTK Laboratories 
(#Y1000) 
 
Biovision 
(#1995-5,25) 
 
 
 
 
 
 
Gibco 
(#PHG0264) 
Enhances single cell survival 
(Watanabe et al., 2007) 
 
Inhibits BMP type I receptors which 
co-ordinate endoderm and 
mesoderm developmental 
patterning to promote 
differentiation of neural progenitor 
cells from human pluripotent stem 
(Boergermann et al., 2010) 
 
Growth enhancement  and 
mitogenic agent, important for SHH 
expression (Kitchens et al., 1994) 
3- 4 
 
Neural Induction 
Media 
n/a n/a n/a n/a 
5- 6 Neural Induction 
Media 
All trans-Retinoic acid 
 
 
 
 
1 μM 
 
 
 
 
Sigma (#R2625) 
 
 
 
 
Induces caudal neurons and 
promotes differentiation of neurons 
through the modification of 
neuronal cell surface receptors 
(Scheibe and Wagner, 1992) 
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Ascorbic acid 
 
 
Brain-Derived Neurotropic factor 
(BDNF) 
 
0.4 μg/ml 
 
 
10ng/ml 
 
Sigma 
(#A1300000) 
 
Sigma 
(#B3795) 
 
Enhances differentiation (Takahashi 
et al., 2003) 
 
Neurotrophic, enhances survival and 
differentiation of neurons (Jones et 
al., 1994) 
7-16 Neural Induction 
Media 
All trans-Retinoic acid  
 
Brain Derived Neurotropic factor 
(BDNF) 
 
Sonic Hedgehog (SHH) 
 
 
 
Purmorphamine (PUR) 
1 μM 
 
10 ng/ml 
 
200 ng/ml 
 
 
 
 
1 μM 
See above 
 
See above 
 
BioLegend 
(#597204) 
 
 
 
Selleckchem 
(#S3042) 
See above 
 
See above 
 
Ventralisation through morphogen 
patterning midline structure of the 
spinal cord and brain (Carpenter et 
al., 1998) 
 
Activates Hedgehog pathways by 
binding and activating smoothened 
(Sinha and Chen, 2006) 
17-29 Neurobasal Media All trans-Retinoic acid  
 
Adenosine 3’, 5’- cyclic 
monophosphate (cAMP) 
1 μM 
 
1 μM 
 
See above 
 
Sigma (#A9501) 
 
See above 
 
Determinant of neuronal 
differentiation. Important second 
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Insulin-like Growth Factor 1 (IGF-1) 
 
 
 
 
Glial-Derived Neurotrophic Factor 
(GDNF) 
 
 
 
 
 
Ciliary Neurotrophic Factor (CNTF) 
 
 
 
 
 
10 ng/ml 
 
 
 
 
10 ng/ml 
 
 
 
 
 
 
10ng/ml 
 
 
 
 
 
Gibco 
(#PHG0071) 
 
 
 
Gibco 
(#PHC7045) 
 
 
 
 
 
Gibco 
(#PHC7015) 
messenger for neurotransmitter 
induced receptor stimulation 
(Stachowiak et al., 2003) 
 
Family members of insulin-like 
growth factors structurally 
homologous to proinsulin 
 
 
 
Promotes the survival and 
differentiation of dopaminergic 
neurons in culture, and prevents the 
apoptosis of motor neurons (Lin et 
al., 1993) 
 
Neurotropic factor supporting 
survival of neurons and regulates 
their differentiation and maturation 
(Vergara and Ramirez, 2004) 
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30-42+ Neurobasal Media All trans-Retinoic acid  
 
Adenosine 3’, 5’- cyclic 
monophosphate (cAMP) 
 
Insulin-like Growth Factor 1 (IGF-1) 
 
Glial-Derived Neurotrophic Factor 
(GDNF) 
 
Ciliary Neurotrophic Factor (CNTF) 
 
Ascorbic acid  
 
2-mercaptoethanol 
1 μM 
 
1 μM 
 
 
10 ng/ml 
 
10 ng/ml 
 
 
10ng/ml 
 
0.2ug/ml 
 
0.1mM 
See above 
 
See above 
 
 
See above 
 
See above 
 
 
See above 
 
See above 
 
Gibco (#21985-
023) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A potent reducing agent used to 
prevent toxic levels of oxygen 
radicals in media 
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2.2 CELL LYSIS  
 
For pelleting cells to store at -80°C for future lysis, cell pellets were re-suspended in 
1ml sterile PBS, and cells were transferred to a 1.5ml tube for centrifugation at 400g 
RCF for 4mins. Next, the PBS was completely removed to produce a dry pellet which 
was stored at -80°C. All cells were lysed via membrane, nuclear, and cytoplasmic 
fractionation using 50μl of lysis buffer per pellet of 1 000 000 cells, containing: Radio 
immunoprecipitation assay (RIPA) buffer, complete Mini, EDTA free Protease Inhibitor 
cocktail (Roche) and PhosSTOP, phosphatase inhibitor cocktail (Roch) and kept on ice 
for 20 minutes. Next cells were centrifuged at 10,800g RCF for 10 minutes at 4˚C, and 
the supernatants were collected for protein determination using a Bradford assay.  
 
2.3 PROTEIN DETERMINATION  
 
In the Bradford assay for protein determination, 2µl of 1, 0.5, 0.25, 0.125, 0.0625 and 
0.03125 mg/ml Bovine Serum Albumin (BSA) (Sigma) was added to 50µl of Coomassie 
Protein Assay Reagent (Thermo Scientific) to produce a standard curve. Next 2µl of cell 
lysate, diluted in PBS to 1 in 10 and 1 in 20, was added to 50µl of Coomassie Protein 
Assay Reagent. Wells were carefully mixed with a multichannel pipette and any 
bubbles were popped with a needle. Absorbance was read at 595nm using a 
PHERAstar FS plate reader (BMG labtech) and values were calculated from raw data 
using Microsoft Excel. 
 
2.4 WESTERN BLOTTING  
 
2.4.1  SODIUM DO DECY L S ULP HA TE POLY ACRY LAMI DE  GEL 
ELECTRO PHO R ESI S  (SDS-PAGE) 
 
For western blot analysis, cell lysate protein extracts, previously measured for protein 
concentrations were added to Lamelli sample buffer (4x) and made up to volume with 
ddH2O (table 2). The samples were vortexed and heated at 95°C for 5 minutes in order 
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to reduce and denature the proteins, and the samples were finally spun in a microfuge 
to ensure the whole volume of the sample was collected. 
 
Table 2.3: Preparation for Lamelli buffer (10ml) 
Lamelli Sample Buffer (4X)  
Glycerol 4ml 
10% SDS 2ml 
Bromophenol blue 0.25mg 
Stacking Gel Buffer (table) 2.5ml 
Β-mercaptoethanol 0.5ml 
dH2O to 10ml 
 
40μg/μl of denatured protein cell lysates were resolved by 10% sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (table 3 and 4) used with a 5% 
stacking gel (table 5 and 6). Gels were run at a constant voltage in running buffer (table 
7) at 50V for 30 minutes or until through the stacking gel, and then 120V until the dye 
front reached the base of the gel.  
 
Table 2.4: Preparation for separating gel buffer (100ml, pH adjusted with HCL and NaOH)  
Separating Gel Buffer pH 8.8  
Tris Base  18.17g 
10% SDS  4ml 
dH2O  to 100ml 
 
Table 2.5: Preparation for separating gel for SDS-PAGE (For 2 gels of 1.5mm thickness)  
 10% Separating Gel (ml) 
H2O 9.3ml 
30% Acrylamide 7.2ml 
Separating Gel Buffer 5.7ml 
10% APS 0.336μl 
Tetramethylethylenediamine (TEMED) 0.15μl 
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Table 2.6: Preparation for Stacking gel buffer (100ml, pH adjusted with HCL and NaOH)  
Stacking Gel Buffer pH 6.8  
Tris Base 6.06g 
10% SDS 4ml 
dH2O To 100ml 
 
 
Table 2.7: Preparation of Stacking gel for SDS-PAGE (for 2 gels of 1.5mm thickness)  
 5% Stacking Gel (ml) 
H2O 2 
30% Acrylamide 0.6 
Stacking Gel Buffer 0.888 
10% APS 0.056 
TEMED 0.10 
 
  
Table 2.8: Preparation of Running buffer for SDS-PAGE (700ml) 
Running Buffer  
Tris-Glycine (5X) 200ml 
H2O 490ml 
10% SDS 10ml 
 
 
2.4.2  IMMUNO BLOT TIN G  
 
Proteins were transferred to a methanol rinsed polyvinylidene difluoride (PVDF) 
membrane (Millipore) according to the manufacturer’s instructions under constant 
current 250mA for 1 hour 30 minutes, or 40mA overnight on ice in transfer buffer 
(table 8). To check that the transfer was successful and to confirm equal loading, 
membranes were probed with Ponceau dye for 30 seconds. Next, to remove the 
Ponceau, membranes were washed with Tris-Buffered Saline with Tween 20 (TBST) for 
10 minutes. Subsequently, membranes were blocked to prevent non-specific binding 
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of primary antibodies in 5% BSA-TBST (Sigma) rolling for 1 hour at room temperature 
or overnight rolling at 4˚C. Membranes were incubated overnight with primary 
antibodies (table 9) made in 5% BSA-TBST. Next, membranes were washed 3 times for 
15 minutes in TBST at room temperature and then probed with the appropriate 
secondary antibodies made in TBST for 1 hour rolling at room temperature (table 10).   
 
Table 2.9: Preparation of transfer buffer for SDS-PAGE (1000ml) 
Transfer Buffer  
Tris-Glycine (5x) 200ml 
Methanol 150ml 
dH2O 650ml 
 
 
Table 2.10: Primary antibodies used for Western Blotting  
Antibody Molecular 
Weight 
(kDa) 
Species Concentration Supplier 
Phospho-
AKT(Ser473) 
(D9E) XP 
60 Rabbit 
Monoclonal 
1:500 Cell Signaling 
Technology 
AKT(pan) (C67E7) 60 Rabbit 
monoclonal 
1:500 Cell Signaling 
Technology 
PTEN (26H9) 54 Mouse 
monoclonal 
1:1000 Cell Signaling 
Technology 
pPTEN (s380)  54 Rabbit 
polyclonal 
1:1000 Cell Signaling 
Technology 
GAPDH  37 Rabbit 
monoclonal 
1:10 000 Cell Signaling 
Technology 
 
Table 2.11: Secondary antibodies used for Western Blotting  
Antibody Species Concentration Supplier 
Goat anti-rabbit HRP Rabbit polyclonal 1:5000 Dako 
Goat anti-mouse HRP Mouse polyclonal 1:5000 Dako 
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2.4.3  IMAGE CAPT URE AN D DEN SITO MET RY  ANALYSI S  
 
Protein bands were visualized with a chemiluminescence detection system (Biological 
industries) and a G-BOX imaging system with GeneSnap software (Syngene). Blots 
were captured using Intelli Chemi which detects the signal from the membrane to 
generate a sub-saturated image. 
To determine the relative levels of protein for each immunoblot, densitometry analysis 
on GeneTools (Syngene) software was used. Manual band quantification was used with 
automatic background correction, to measure percentage raw volume and quantity for 
each band. Protein levels were determined as a fraction to loading control 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Where more than one 
membrane was required, each membrane contained both a basal and vehicle control, 
which was used as a baseline to normalise to, to ensure consistency. 
 
2.5 BIOCHEMICAL ASSAYS  
 
2.5.1   3-(4,5-D I MET HY LT HI AZOL-2-Y L)-2,5-D IP HEN YLT ETR AZO LIUM 
BRO MI DE (MTT)  ASS AY  
 
To measure cell viability, NSC-34, primary human fibroblasts, and iPS derived cells 
were plated in a Cellstar® 96 well culture plates (Greiner bio-one), in 100µl of the 
correct full media for the cell type and left for 3 days to attach. Cell viability was 
assessed by adding 0.1 volumes of 5mg/ml thiozolyl blue tetrazolium bromide (Sigma) 
in PBS to each well and the plate was incubated for 1 hour (NSC-34 cells) or 6 hours 
(primary human fibroblasts, iPS- derived motor neurons) so the insoluble purple 
formazan product could be formed in viable cells. Next, the formazan product was 
dissolved in 20% sodium dodecyl sulphate (Sigma) in 50% dimethyl formamide (Sigma), 
pH 4.7 (SDS/DMF) and mixed at room temperature on an orbital shaker for 1 to 2 
hours. Once the crystals had fully dissolved, the solution was mixed with a 
multichannel pipette and bubbles popped before absorbance was read at 595nm using 
a PHERAstar FS plate reader (BMG labtech). 
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2.5.2  LACTAT E DEHY DRO GEN AS E (LDH)  AS S AY  
 
A Thermo Scientific Pierce LDH Cytotoxicity Assay Kit (Thermo-fisher) was used to 
measure cell cytotoxicity via LDH release into the media. Firstly, primary human 
fibroblasts, and iPS derived cells were plated in 96 well culture plates, in 100µl of the 
correct full media for the cell type and left for 3 days to attach. Duplicate wells were 
plated for each of the 6 control and patient cell samples and extra wells were plated 
also in duplicate for spontaneous and maximum LDH controls. Cytotoxicity was 
measured via collection of the media from all conditions, samples and time points, as 
well as from spontaneous and maximum LDH controls for quantification of cellular 
cytotoxicity following protocol in the Thermo Scientific Pierce LDH Cytotoxicity Assay 
Kit. Absorbance was read at 490nm and 680nm using a PHERAstar FS plate reader 
(BMG labtech).  
 
2.5.3  CYQUANT®  CELL PR OLI FER ATION  AS S AY  
 
A CyQUANT® Cell Proliferation Assay Kit (Invitrogen, #C7026) was used to measure cell 
number and proliferation. Primary human fibroblasts, were plated in triplicate in 96 
well culture plates in 100µl of full media and left for 3 days to attach. The plates were 
then washed once with sterile PBS to remove any remaining media containing phenol 
red to avoid interference with the reading, and plates were then frozen at -80°C. When 
ready to perform the cell count the cells were thawed and instructions were followed 
according to the CyQUANT® Cell Proliferation Assay Kit following the protocol for the 
cell proliferation assay including a serial dilution of cells to quantify cell number. 
Fluorescence was read at 480/520nm for CyQUANT® GR dye bound to nucleic acids. 
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2.6 MODEL CHARACTERISATION AND ASSAY DEVELOPMENT  
 
2.6.1  IPS-  DERIV ED CELL CO UNT S-  6  TO  12  WEEK S  POST  
D IFFERENTI ATION  
 
For basal iPS-derived cell counts differentiated iPS cells were first plated at 6 weeks of 
differentiation. For PTEN knockdown assays, cells were first plated at 5 weeks of 
differentiation, to allow for the additional period of lentiviral vector treatment at 6 
weeks of differentiation. For both cell counting assays, cells were plated at a density of 
1000 cells per 10mm coverslip, with 4 coverslips plated for each sample, patient or 
control, and if applicable condition, untransduced, green fluorescence protein (GFP), 
Scrambled or PTEN knockdown.  
Manual cell counts were performed by counting the 4 separate coverslips for each 
sample and condition. Three random fields of view per coverslip at a 10x objective 
were used in each cell count covering 80% of the total coverslip. Cells counts were 
taken each week from week 7 up to 12 weeks of differentiation and the same 
coverslips were tracked counted at each cell count. 
 
2.6.2  F IBRO BLAST  SCRI PT AI D TREAT MEN T  FO R  DO SE R ES PONS E AS S AY S 
AN D WES TERN  BLO T ANALY SIS    
 
For the treatment of primary human fibroblast cells with Scriptaid (Calbiochem), 750 
000 cells were plated onto 10cm2 plates (western blotting) or 1000 cells per well were 
plated into 96 well plates (dose response assays) and left to attach for 48 hours. Prior 
to treatment the media was replaced with 10ml of serum free media (minimum media) 
for a serum starvation for 2 hours in order to reduce growth factor receptor activation. 
This was subsequently replaced with 10ml minimum media containing 0.3% DMSO 
(vehicle), or 3µM, 10μM or 30μM of Scriptaid with a final DMSO concentration of 0.3%. 
Control plates were also set up for non-treated control with cells growing in full media 
(basal). Cells were incubated for 24 hours at 37˚C and finally harvested for western 
blot analysis as previously described in sections 2.2, 2.3 and 2.4, or assayed for dose 
response as previously described in section 2.5. 
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2.6.3  IPS-DERIV ED CELL SCRIPT AID TR EAT MENT  FOR  DO SE R ESPO NS E 
AS S AY S AN D  WEST ER N BLO T AN ALY SIS   
 
For the treatment of differentiated iPS cells with Scriptaid, firstly 100 000 cells were 
plated onto 6 well plates (western blotting) or 2000 cells per well were plated into 96 
well plates (dose response assays) and left to attach and left to attach for 3 days. The 
iPS cells were then grown in serum free media containing 0.3% DMSO (vehicle), or 
3µM, 10μM or 30μM of Scriptaid with a final DMSO concentration of 0.3%. Control 
plates were also set up for non-treated control with cells growing in full media (basal). 
Cells were incubated for 24 hours at 37˚C and finally harvested for western blot 
analysis as previously described in sections 2.2, 2.3 and 2.4 or assayed for dose 
response as previously described in section 2.5. 
 
2.6.4  IPS-DER IVED CELL SCRIPT AID TR EAT MENT  FOR MO TOR  NEURO N 
CELL COUN TS  
 
For the treatment of iPS cells during the differentiation process, iPS cells were plated 
on coverslips in their undifferentiated state. They were incubated with one of the 
following: 3μM Scriptaid for treated conditions, 0.3% DMSO for vehicle control 
conditions, or full media only for basal control conditions. The incubation period 
occurred either for 24 hours at day 0, or week 2, 4, or 6 of differentiation in a single 
application of the drug, or each week at weekly intervals from day 0.  At the end for 
the differentiation protocol at 6 weeks, the cells were fixed as described above and 
dual stained for choline-O-acetyltransferase (ChAT) and neuron-specific class III β-
tubulin (Tuj1) as described in the protocol for immunocytochemistry.  
 
2.6.5  IMMUNO CYTO CHEMI ST RY  
 
For immunocytochemistry undifferentiated iPS cells and those differentiated for 2, 4, 
6, 9 and 12 weeks were stained. The media was removed from the cells and they were 
washed once in 1ml Dulbecco's phosphate-buffered saline (dPBS) (Gibco) to remove 
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cell debris. Cells were then fixed in sterile filtered 4% paraformaldehyde (PFA, Sigma) 
in PBS for 15 minutes at room temperature. Permeabilization and blocking was 
achieved by exposing cells to a buffer of 0.25% Triton-PBS with 10% goat serum 
(Gibco). Cells were incubated overnight (unless otherwise stated) at 4°C with the 
primary antibody (table 11). The primary antibody was then removed completely and 
cells were washed 3 times for 5 minutes in 1ml PBS. The appropriate fluorescent 
secondary antibody was then applied for 2 hours in the dark at room temperature 
(table 12). Next the secondary antibody was removed and the cells were incubated 
with Hoechst 1μg/ml (Cell Signalling Technologies) for 5 minutes at room temperature 
in the dark, and the cells were finally washed 4 times for 10 minutes in 1 ml PBS. 
Coverslips were mounted onto glass twin frost 0.8-1mm microscope slides (Fisher 
brand) using 10µl fluorescent mounting medium (Dako) and left to dry completely, in 
the dark, before sealing with clear nail varnish. Slides were stored at 4°C in dark, until 
visualisation using an IN CELL Analyser 2000 (GE Healthcare). 
 
Table 2.12: Primary antibodies, concentrations and incubation periods.  
Primary Antibody Host/Isotype Concentration Incubation Supplier 
TuJ-1 (neuron-
specific class III β-
tubulin) 
Mouse 
Monoclonal 
IgG2A 
1:100 Overnight, 4°C Neuromics 
(#MO15013) 
Anti-Beta III 
Tubulin 
Chicken 
Polyclonal 
IgY 
1:100 Overnight, 4°C Chemicon 
International 
(#AB9354) 
Anti-SSEA4 
(stage-specific 
embryonic 
antigen 4) 
Mouse 
Monoclonal 
IgG3 
1:50 Overnight, 4°C  Invitrogen  
(#41-4000) 
MAP-2 
(microtubule 
associated 
protein) 
Mouse 
Monoclonal 
IgG1 
1:50 Overnight, 4°C Neuromics  
(#MO30000) 
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ChAT (choline-O-
acetyltransferase) 
Mouse 
Monoclonal 
IgG, Kappa 
1:50 3 Days, 4°C Neuromics 
(#MO20019) 
Anti-TRA-1-60  Mouse 
Monoclonal 
IgM 
1:50 Overnight, 4°C Invitrogen  
(#41-1000) 
c-Myc Rabbit 
Affinity 
purified 
(EQKLISEEDL) 
1:100 Overnight, 4°C Neuromics 
(#RA25085) 
HB9/pan MNR2 Mouse 
Monoclonal 
IgG1,Kappa 
Light chain 
1:50 Overnight, 4°C Developmental 
Studies 
Hybridoma Bank 
(DSHB) (81.5C10) 
Islet 1/2 (H-120) Rabbit 
polyclonal 
1:50 Overnight, 
4°C 
Santa Cruz 
Biotechnology (# 
sc-30200) 
Anti-GA Mouse (clone 
5F2) 
 Overnight, 4°C Gifted by Dieter 
Edbauer 
TDP-43 Rabbit 
polyclonal 
1:200 Overnight, 
4°C 
Proteintech 
(#10782-2-AP) 
PTEN (Y184) Rabbit 
monoclonal 
1:50 Overnight, 
4°C 
Abcam 
(#ab32199) 
 
Table 2.13: Secondary Antibodies, concentrations and incubation periods  
Secondary 
Antibody 
Isotype Concentration Incubation Supplier 
Rabbit Anti-
Mouse FITC 
Polyclonal 
IgG 
1:200 2 hours, room 
temperature 
Dako (#F0232) 
Rabbit Anti-
Mouse TRITC 
Polyclonal 
IgG 
1:200 2 hours, room 
temperature 
Dako (#R0270) 
Swine Anti Rabbit 
TRITC 
Polyclonal IgG 1:200 2 hours, room 
temperature 
Dako (#R0150) 
Swine Anti-Rabbit Polyclonal 1:200 2 hours, room Dako (#F0205) 
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FITC IgG temperature 
Alexa Fluor 488 
Goat Anti Chicken 
IgG (H+L) 1:500 2 hours, room 
temperature 
Invitrogen 
(#A11039) 
Alexa Fluor 488 
Donkey Anti- 
Rabbit 
IgG (H+L) 1:1000 2 hours, room 
temperature 
Invitrogen 
(#A21206) 
Alexa Fluor 555 
Donkey Anti- 
Mouse 
IgG (H+L) 
 
 
1:1000 2 hours, room 
temperature 
Invitrogen 
(#A51570) 
 
 
2.6.6  RNA  FLUOR ES CENT  IN  SIT U HYBRI DIS ATIO N (RNA  FISH)   
 
All solutions were made in DEPC treated ddH20. Coverslips fixed with 4% PFA (as 
described above) placed in a 24 well plate were incubated at 66°C for 1 hour in 
hybridisation buffer containing, 100mg/ml dextran sulphate, 2X saline sodium citrate 
buffer pH5 with citric acid (SSC), 50mM sodium phosphate pH 7, 50% formamide. A 5’ 
TYE-563-labelled LNA (16-mer fluorescent)-incorporated DNA probe was used against 
the sense RNA hexanucleotide repeat (Exiqon Inc, batch #607323) or antisense RNA 
hexanucleotide repeat (Exiqon Inc, batch #610331). Both sense and anti-sense probes 
were heated for 75 seconds to 80°C then placed immediately on ice to denature the 
probe. Next, coverslips were incubated with 100μl of hybridisation buffer containing 
400ng/ml probe overnight at 66°C. The coverslips were then washed with 500μl of a 
high-stringency wash solution of 2X SSC/0.1% Tween 20 for 5- 10mins at room 
temperature. This was then removed and the coverslips were then washed three times 
in a second wash solution of 0.1X SSC for 10 minutes at 65°C. If cells were to be 
exposed with a primary antibody in addition to RNA FISH, a UV crosslinking step was 
added to ensure the probe was not washed away in subsequent washing procedures. 
Coverslips kept in 0.1X SSC wash were placed in a tray with ice and exposed to 
0.3J/cm2 energy per area in a TL-2000 ultraviolet translinker (Ultra-Violet Products). 
Coverslips were next incubated either with primary antibodies for 
immunocytochemistry as described above, and incubated with Hoechst 1μg/ml (Cell 
Signalling Technologies) for 5 minutes at room temperature in the dark, or only 
incubated with Hoechst stain if the probe was to be visualised alone. The cells were 
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finally washed 4 times for 10 minutes in 1 ml PBS. Coverslips were mounted onto the 
glass slides (Fisher brand microscope slides twin frost 0.8-1mm) using 10µl mounting 
medium (Dako) and left to dry completely before sealing with clear nail varnish. Slides 
were stored at 4°C in dark, until images were obtained using a SP5 confocal 
microscope (Leica). 
 
2.6.7  ELECTRO PHYSIO LO GY  
 
Differentiated iPS cells plated onto coverslips at a density of 30 000 cells per coverslip 
were measured for recordings at 6, 7, 8, 9 and 10 weeks post-differentiation. 
Coverslips were placed into a bath on an upright microscope (Olympus) containing the 
extracellular solution at pH7.4 composing of 150 mM NaCl, 5.4  mM KCl, 2  mM MgCl2, 
2 mM CaCl2, 10 mM HEPES, 10 mM Glucose osmolarity,~305 mOsm/Kg. The internal 
solution of the pipette was composed of 140mM K+-gluconate, 10 mM KCl, 1 mM 
MgCl2, 0.2mM EGTA, 9 mM NaCl, 10 mM HEPES, 0.3 mM Na
+-GTP, and 3 mM Na+-ATP 
adjusted to 298 mOsm/Kg at pH7.4. For both solutions glucose, EGTA, Na+-GTP, and 
Na+-ATP were added fresh on each day of the experiment. All recordings were 
performed at room temperature and all reagents for solutions were purchased from 
Sigma. 
Electrodes for patch clamping were pulled on a Sutter P-97 horizontal puller (Sutter 
Instrument Company) from borosilicate glass capillaries (World Precision Instruments) 
to produce a tip resistance of 3-5.5MΩ.  
To identify the motor neurons present, cells were visualised using the microscope x40 
objective, and those with a triangular cell body and processes to indicate a motor 
neuronal morphology were selected (figure 2.3). In order to not disturb the cell, each 
recording is from a single cell and a minimum of 4 cells were used per condition. 
Recordings from cells were amplified using Multiclamp 700B patch-clamp amplifier 
(Molecular Devices) in current-clamp mode to measure depolarized evoked action 
potential firing in the cells using a 10 step protocol for a duration of 500 miliseconds, 
injecting current from -40pA , every 20pA. As well as this a voltage-clamp mode was 
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used to measure currents. To ensure a good seal during patch clamp, cells were 
monitored for the shape of the pulse (figure 2.3). Recordings were acquired at ≥10 kHz 
using a Digidata 1440A analogue-to-digital board and pClamp10 software (Axon 
Instruments).   
Whole-cell capacitance (Cm), input resistance (Ra), series resistance (RS) and resting 
membrane potential (RMP) values were measured during the recording using 
pClamp10 software. Only cells with an Rs<20MΩ, a RMP more hyperpolarized than 
−40 mV and Ra>500 MΩ were included in data analysis. Electrophysiological data were 
analysed using Clampfit10 software (Axon Instruments).  
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a 
b 
c 
d 
e 
f 
g 
Figure 2.1: Electrophysiology of iPS-derived Motor Neurons. a-b) Images of iPS cells plated for 
electrophysiology. c-d) Images of iPS cells selected for recording based on morphology including a 
triangular cell body and processes. e) Image of a flat line pulse which corresponds with the current 
detected between the pipette and the external solution. f) Membrane seal or cell attached 
configuration producing a square pulse which corresponds with the membrane blocking the pipette 
tip, at this point the membrane is inside the pipette. g) Whole cell configuration where the pipette 
connects with the whole cell after the membrane seal has been broken . 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
2.7 MICROSCOPY AND IMAGE ANALYSIS  
 
2.7.1  CON FO CAL M I CRO S COP Y  
 
Visualization of sense and anti-sense foci was performing using the Leica SP5 confocal 
microscope using an x63/1.4 oil immersion objective lens. Images were taken at high 
resolution taking a Z-stack comprised of images at a 0.13μm thickness throughout the 
whole nuclear volume of each cell analysed. More than 30 iPS-derived cells from each 
sample were imaged and counted for RNA foci. 
 
2.7.2  IN  CELL ANALYS ER AN D WO RKS TATION  AN ALYSI S  
 
Images of iPS-derived cells from immunocytochemistry experiments was performed on 
the IN CELL Analyser 2000 (GE Healthcare) automated microscope, taking images on 
coverslips with all channels set to 2D deconvolution. A minimum of 5 random fields of 
view were imaged for each coverslip and images were taken using the large camera air 
objectives of 10x (Nikon, 0.45 NA), 20x (Nikon, 0.75 NA) or 60x (Nikon 0.70 NA). 
For analysis of images taken with the INCELL automated microscope, the IN Cell 
workstation analyser was used to quantify total cell numbers, and the number of 
motor neurons in the population as assessed by dual staining for ChAT and Tuj1. A 
threshold was set for the intensity of the staining for all channels used, and motor 
neuron counts were obtained by cells that showed co-localised expression of ChaT, 
Tuj1 and with an associated DAPI nucleus kernel (figure 2.1).  
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2.7.3  QUANTI FI CATION  O F TDP-43  LO CALIS ATIO N AN D CELL CO UNT S  
 
For the quantification of the localisation of TDP-43 staining in all cell populations, cells 
were manually traced on ImageJ for the whole cell including the nucleus, cytoplasm 
and processes, and a separate trace was made for the nucleus mask, generated using 
DAPI. The total area of the whole cell as well as the minimum, maximum and mean 
intensity of TDP-43 staining was recorded (figure2.2). The total area of the nucleus 
including the minimum, maximum and mean intensity of TDP-43 staining was also 
recorded.  The intensity of each cell TDP-43 staining for the whole cell and the nucleus 
was calculated, normalising for total cell area. The results generated an intensity of 
TDP-43 staining for the whole cell and an intensity of TDP-43 staining for the nucleus, 
which was used to determine TDP-43 mislocalisation. A minimum of 50 cells per cell 
line were quantified. 
 
 
 
Figure 2.2: Quantification of Motor Neurons using the INcell Workstation Analyser.  Top row 
highlights Cells labelled green for Tuj1, blue for DAPI or red for ChAT were quantified for intensity 
of fluorescence set for each respective channel. Bottom row indicates cells selected for counts in 
each channel that meet the threshold intensity staining for each respective channel.  
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2.8 PTEN  KNOCKDOWN (KD) 
 
2.8.1  ESTABLI SHIN G COMMERCI AL LENTIVI RAL MOI  USIN G GFP  
CONT RO L LEN TIVIR AL PAR TICLES  IN  HEK  AN D IPS  CELLS   
 
Using GFP control lentiviral particles (Santa Cruz Biotechnology) of the same titre 
(1x106 Infectious Units) of the viral particles for PTEN knockdown (KD) (Santa Cruz 
Biotechnology) and Scrambled controls (Santa Cruz Biotechnology), the appropriate 
multiplicity of infection (MOI) was established for HEK cells and iPS-derived cells. HEK 
cells were plated into 96 well plates at 1000 cells per well in triplicate wells and iPS-
derived cells were plated in duplicate onto 10mm coverslips previously coated with 
poly-DL-ornithine and laminin at a density of 2000 cells per coverslip, placed in 
CELLSTAR® 35x10mm culture dishes with 4 inner rings. After 24 hours (HEK) or 72 
hours (iPS-derived cell) of culture in vitro post-plating, the appropriate volume of virus 
(table 14) was added to each well or coverslip for the cell number plated and MOI 
investigated (1, 2, 5) made up to a final volume of 100µl (HEK) or 50μl (iPS) with 
appropriate media for the cell type used. For the iPS-derived cells, after 4-6 hours the 
Figure 2.3 Quantification of Cellular TDP-43 Staining. Whole cell and nuclei traces 
were made for each cell within a mixed population including glial cells (shown here), 
and the intensity of TDP43 (green) in each respective area was quantified. 
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dishes containing coverslips were topped up with 2ml fresh media, which was replaced 
every 24 hours for the following 7 days. Untransduced controls were treated with 
100µl of media without viral particles to maintain the same conditions for all cells 
analysed. The volume of virus was calculated using the following formula: 
cells ofNumber 
Titre x  virusof Volume
MOI  .  
After 3-5 days (HEK) or 7 days (iPS) in culture, determination of transduction efficiency 
was assessed by cells, counting total transfections of GFP staining in transduced cells 
against total cell numbers. 
 
Table 2.14: Volume of GFP Control Lentiviral particles (1x10
6
 IFU), PTEN ShRNA virus (1x10
6
 IFU), 
and control ShRNA Virus (1x10
6
 IFU) calculated per coverslip at different cell densities plated.  
 
 
2.8.2  PTEN  KNO CK DOW N WI TH PTEN  S HRNA  IN  HEK  293  CELLS  AN D 
IPS-DER IVED CELLS  
 
Cells were cultured in the previously described media for the cell type investigated and 
were plated at 10 000 cells (HEK 293 cells) or 20 000 cells (iPS-derived cells) per well in 
12 well plates. After 24 hours (HEK 293 cells) or 72 hours (iPS-derived cells), for each 
condition 4 wells were transduced at an MOI of 5 previously established with GFP 
transduction. The virus was made up in media to a final volume of 500µl per well, with 
either the lentiviral particles for PTEN ShRNA: sc-29459 (Transduced) 1 x106 IFU 
 
Cell 
Number 
MOI (volume required to achieve) 
1 2 5 10 30 
1000 1µl 2µl 5µl 10µl 30µl 
2000 2µl 4µl 10µl 20µl 60µl 
3000 3µl 6µl 15µl 30µl 90 µl 
4000 4 µl 8µl 20µl 40µl 120µl 
5000 5µl 10µl 25µl 50µl 150µl 
10 000 10µl 20µl 50µl 100µl 300µl 
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(infectious units of virus), control ShRNA: sc-108080 (Scrambled) 1 x106 IFU. The 
untransduced controls were given a media change without virus to maintain the same 
conditions for the cells. Three days (HEK 293 cells) or seven days (iPS-derived cells) 
later, cells were harvested from the plates and a Bradford assay was performed for 
protein determination as described above. Identification of PTEN knockdown was 
performed via western blot analysis probing for total PTEN, pPTEN, pAKT, AKT(pan) 
and GAPDH (table 10) using previously described protocols. 
 
2.9 STATISTICAL ANALYSIS AND DATA PRESENTATION  
 
Unless otherwise stated in the figure, all experiments were performed in triplicate in 
three independent experiments. All statistical analysis was performed using GraphPad 
Prism version 6 software (GraphPad Software). Data represent the mean of the three 
patient, or three control cell lines ± standard error of the mean, and were analysed 
with either students T test, or Two-way ANOVA as stated in the corresponding figure 
legend. Where drug treatment groups were used, each treatment group was 
normalised to vehicle control and results were expressed as a percentage of the 
control group mean. 
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 :  CELL CULTURE MODELS OF AMYOTROPHIC CHAPTER 3
LATERAL SCLEROSIS (ALS)  TO INVESTIGATE PTEN  
INHIBITION  
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3.1 INTRODUCTION  
 
3.1.1  PHOS PHATI DYLI NOSI TI DE  3-KIN AS E  (PI3K)  PAT HW AY  
MODULATION  FOR  PTEN  IN HI BITION  
 
The phosphatidylinositide 3-kinase (PI3K) pathway is a well described cell cascade 
important in survival and growth (Chalhoub and Baker, 2009). The pathway itself is 
controlled by a positive regulator and a negative regulator, PI3K and phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN) respectively, of which PTEN has 
been proposed to be an important target for research in neurodegeneration (Ismail et 
al., 2012). PTEN is a tumour suppressor gene which in its unphosphorylated and active 
form, acts as a phosphoinositide 3 phosphatase, dephosphorylating 
phosphatidylinositol 3, 4, 5 triphosphate (PIP3) to phosphatidylinositol 4, 5 
bisphosphate (PIP2) in vivo (Maehama and Dixon, 1998). The consequential reduction 
in the levels of PIP3 also reduces cell survival, as the role of PIP3 is to bind to and cause 
the translocation of v-akt murine thymoma viral oncogene homolog (AKT) towards the 
cell membrane (Datta et al., 1999). At the cell membrane, AKT is able to phosphorylate 
and subsequently promote the sequestration of cell death components such as 
BCL2/BCLXL- associated death protein (BAD) and GSK-3β (glycogen synthase kinase 3 
β), preventing them from implementing apoptotic cascades towards cell death and 
thus promoting cell survival (Datta et al., 1999). It is thought that by acting upstream of 
this pathway, preventing the action of PTEN or increasing phosphorylation of PTEN, to 
shift PTEN to its inactive form, it is possible to promote cell survival due to increased 
AKT phosphorylation by PIP3. 
Methods to block the action of PTEN for a desired pro-survival effect have taken two 
main forms in previous research, which are PTEN knockdown, to reduce PTEN protein 
expression (Yang et al., 2014a), and inhibition of PTEN with direct small molecule 
inhibitors. However more recently, work with histone deacetylase (HDAC) inhibitors 
which act to counteract endogenous transcriptional repression, have built a portfolio 
of evidence towards utilising these non-direct modulators of the PI3K pathway to 
provide a protective effect in neural cells.  
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In eukaryotic cells, DNA is organised into a compacted structure called chromatin, 
which is made up of nucleosomes consisting of DNA linked to histone proteins. The 
histones, connected to DNA can be post-translationally modified via the addition or 
removal of acetyl groups to lysine residues. This acetylation and deacetylation is 
controlled by histone acetyltransferases (HATs) or histone deacetylases (HDACs) 
respectively, and is important in conferring an open or closed structure of chromatin. 
Acetylation allows the chromatin structure to become more open and relaxed, to allow 
access for transcriptional machinery to activate transcription. On the other hand, 
deacetylation promotes a more closed structure causing transcriptional repression.  
Evidence for using HDAC inhibitors for neuroprotection is varied. Studies have found 
increased survival after oxidative stress when cortical neurons were exposed to HDAC 
inhibitors (Kozikowski et al., 2007). In investigations examining the re-growth of 
neurons after injury, HDAC inhibition has been found to be neuroprotective against 
oxidative stress and also been found to promote the growth of neuronal projections 
(Rivieccio et al., 2009). Of note to the field, in 2012 a HDAC inhibitor called Scriptaid 
was found to decrease motor deficits, promote motor function consistently for 4 
weeks after injury, as well as increase neuronal survival when delivered after traumatic 
brain injury in an in vivo mouse model of controlled cortical impact (Wang et al., 
2012a). What was particularly interesting about this work, was that Scriptaid was also 
shown to reduce the levels of active PTEN available by increasing the phosphorylation 
of PTEN, alongside increasing phosphorylated AKT, in what was thought to be the 
mechanism behind the pro-survival effect (Wang et al., 2012a). These PTEN inhibitory 
effects as well as an increase in motor function, declined in the presence of an AKT 
inhibitor, providing evidence for AKT pathway involvement. Although the researchers 
were unable to investigate a direct mechanism of action for how Scriptaid modulated 
these pathway components, it suggested the changes found were more likely to arise 
from an indirect response of PTEN and thus AKT to the drug (Wang et al., 2012a). Later 
work by the same group in microglia and oligodendrocyte cells, proposed GSK3β as a 
component which mediated the phosphorylation and inactivation of PTEN, by reducing 
the total levels of active PTEN available (Wang et al., 2015a), and maintaining an 
indirect mechanism of the action of Scriptaid on this pathway, describing Scriptaid as a 
PTEN modulator. 
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Scriptaid is a cell permeable  pan-HDAC inhibitor and a member of the hydroxamic acid 
group of HDAC inhibitors which also includes trichostatin A (TSA) (Hahnen et al., 2008). 
Hydroxamic acid HDAC inhibitors work by binding to zinc ions present on the HDAC 
active site (Finnin et al., 1999). Scriptaid is reported to have one of the lowest toxicities 
for inhibitors in this group, for example when histone deacetylases purified from rat 
liver were analysed, inhibition at highly potent doses, -log 6.73 ± 0.02 (0.19μM) were 
found when tested for half maximum inhibition (IC50) of total HDAC activity (Hahnen et 
al., 2008). To add to this, although inhibition of individual HDAC activities vary, for 
HDACs 1, 2, 3 and 6, proposed to be important for neurodegenerative research 
(Sancho-Pelluz et al., 2010, Hahnen et al., 2008, Simoes-Pires et al., 2013), the IC50’s  for 
each of these HDACs were found to be less than 10nM (Shi et al., 2011b). Further 
studies have found that Scriptaid at 6μM concentrations resulted in a more than 100 
fold increase in histone acetylation in cultured PANC-1 cells, a human pancreatic 
carcinoma cell line, and reported limited effects on survival (80% survival) on MDAMB-
468 cells, a human mammary carcinoma cell line (Su et al., 2000). Collectively, as these 
studies highlighted a potential therapeutic effect via PTEN modulation, low levels of 
toxicity in the cells tested, coupled with a review of the literature which revealed 
limited previous investigations of Scriptaid in neurodegenerative disease research, it 
prompted us to consider it an interesting and novel method for modulating PTEN in 
the ALS cell model systems we had readily available and were developing.  
 
3.1.2  AMYOT ROP HI C LAT ER AL SCLEROSI S  (ALS)  CELL MO DEL SY ST EMS  
 
Neuroblastoma spinal cord 34 (NSC-34) cells are a mouse neuronal hybrid immortal 
cell line created by Neil Cashman’s group in 1992. These cells hold selected desirable 
characteristics of primary mouse motor neurons and are found to be motor neuron-
like due to: their expression of mature cholinergic neuronal enzyme Choline Acetyl 
transferase (ChAT); the ability of differentiated cells to generate action potentials; 
their expression of motor neuronal cytoskeletal proteins; as well as displaying acetyl 
choline receptors (Cashman et al., 1992). However, unlike post-mitotic primary motor 
neurons which require longer and more complex methods to obtain and develop 
successfully in culture, NSC-34 cells grow rapidly taking around 5-10 days in culture. To 
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add to this, NSC-34 cells can be transfected with human SOD1 mutations, for example 
G93A, to create a model which not only mimics motor neurons but is also a model of 
ALS. These cell lines were used along with NSC-34 cells transfected with wild type 
human SOD1 (WT SOD1) and empty vector (pIRES cells) controls, to establish if PTEN 
manipulation promotes survival in these models of ALS. 
As an additional model to investigate the effects of PTEN manipulation on cellular 
models of ALS, primary patient fibroblast cells were used. As previously discussed, the 
ability to differentiate iPS cells to motor neurons as models for ALS has been recently 
established in several bodies of work (Dimos et al., 2008, Donnelly et al., 2013a, 
Haeusler et al., 2014). An important aim for this project detailed in later chapters 4 and 
5, was to develop a neurological model from the newly discovered C9ORF72 genotype, 
of iPS-derived motor neurons, which were to be used as a further model for PTEN 
manipulation. The iPS cells used later in this thesis are originally derived from the same 
three pairs of age and sex matched patient and control fibroblast cells used in this 
chapter, the details of which can been found outlined in chapter 2. This is particularly 
important as any effects seen from PTEN manipulation in fibroblast cells may give 
insights into the response later seen in iPS-derived motor neurons. In addition, any 
forthcoming work yields directly comparable results, as by comparing the effect of 
PTEN manipulation both before and after the iPS cell to motor neuron transition, it 
could reveal interesting changes in the response of components in the PI3K pathway, 
which may be indicative of motor neuron and fibroblast specific effects.  
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3.2 AIMS AND OBJECTIVES  
 
The aims of the work described in this chapter are to identify if Scriptaid treatment can 
modulate the components of the PI3K cell survival pathway to promote survival in 
NSC-34 cell models of ALS, as well as primary C9ORF72-ALS patient fibroblast cells and 
their matched controls. As BpV had been extensively used in previous studies, Scriptaid 
was chosen as a novel PTEN modulator for investigation in ALS. Firstly, a series of 
biochemical assays will determine from a range of doses which can be safely used to 
treat both cell model systems recruited without seeing negative effects. Cellular 
viability will be measured using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
bromide (MTT) assays to determine how the drug affects cell survival. Additionally, we 
will use cellular cytotoxicity assays to determine the levels LDH release after Scriptaid 
treatment, whilst CyQuant assays will identify how Scriptaid affects cell number and 
proliferation. Finally, we will then identify if Scriptaid modulates the PI3K cell survival 
pathway components, in stressed conditions in comparison to basal and untreated 
controls. Western blot analysis, will document changes in the levels of PTEN and AKT, 
but more importantly the phosphorylation of AKT at serine 473 which indicates 
activation of the cell survival pathway which we are ultimately aiming to turn on. On 
completion, this work will tell us how Scriptaid modulates PI3K pathway components, 
which could result in positive changes in cell survival in cell models of ALS to our 
knowledge previously un-investigated with this drug. 
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3.3 NEUROBLASTOMA SPINAL CORD (NSC34)  CELLS AS MODELS 
FOR PTEN  MANIPULATION IN ALS 
 
3.3.1  NEURO BLAS TO MA SPIN AL COR D (NSC34)  CELLS  SHOW  H I GH 
SEN SITIVIT Y  TO  SCRIP T AID TR EAT MENT  
 
Scriptaid is reported to have an IC50 of less than 5nM for HDACs 1, 2, and 6, and less 
than 9nM for HDAC 3 (Shi et al., 2011b). For total HDAC inhibition, an IC50 of 0.19μM 
has been identified (Hahnen et al., 2008). However, studies on PANC-1 cells identified 
6μM as an optimal concentration to use for HDAC inhibition with limited toxicity (Su et 
al., 2000), whilst 0.1, 1, and 10μM concentrations were used in synaptogenesis studies 
on rat hippocampal neuron and fibroblast co-cultures, where 1μM and 10μM were 
found to actively increase total synapsin intensity by 1.5 fold (Shi et al., 2011b).  
Although some have reported nM activity, we decided to choose concentrations, 
derived from active concentrations of Scriptaid cited in previously published literature 
on neuronal populations (Shi et al., 2011b). Neuroblastoma Spinal Cord (NSC-34) cells 
were therefore treated with Scriptaid for 24 hours to assess the viability of the cells 
when exposed to the drug at 1μM and 10μM concentrations.   
Firstly a 3-(4, 5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) assay 
was performed to measure the cellular viability via metabolic activity from the 
reduction of a yellow tetrazolium salt dye. In viable cells NADH reduces the dye which 
increases with increased Nicotinamide adenine dinucleotide (NADH) activity in the 
cells. The result of the reaction is a purple formazan product which once quantified by 
spectrophotometry, acts as a measure for cellular changes in viability. By doing this, 
we would be able to establish the dose at which we can use Scriptaid without it 
exerting toxic negative effects on cellular viability.  
The results in NSC-34 cell models showed a significant decrease in the viability of the 
cells at both concentrations tested, across all three NSC-34 cell models including WT 
SOD1 and pIRES controls (figure 3.1). There were no significant differences between 
the three different NSC-34 cell lines tested within treatment conditions, and no 
significant disease specific effects were found, suggesting all cell models reacted 
negatively to the drug. The greatest effects were found at the highest concentration 
tested on piRES controls, with the lowest effects found in G93A mutant SOD1 models 
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FIGURE 3.1:  The effects of Scriptaid on NSC-34 cell viability as measured by MTT assay. Results 
revealed significant declines in cellular viability at both 1μM and 10μM concentrations of the drug 
in both controls WT SOD1 and pIRES NSC-34 cells, as well as in ALS mutant SOD1 (G93A) NSC -34 
cells.  (Data presented as percentage of vehicle control, mean of  n=3 independent experiments. 
±SEM *p=<0.05, **p=<0.005 ***p=<0.0005, analysed with two-way ANOVA)  
at 10 μM whose viability still dropped below vehicle control, but not to significant 
levels (figure 3.1). Because two concentrations with a difference of 10 fold were tested, 
but the level of toxicity found was similar, it suggests the NSC-34 cell response to 
Scriptaid is that of greatly reduced viability.  Lower concentrations at 0.01μM and 
0.1μM were also tested with limited replicates (n=2), however they also showed 
greatly reduced viability, with an average of 39% and 44% viability across all three cell 
lines (data not shown), therefore were not investigated further because of this.  
Consequently, as significantly reduced cell survival was found after exposure to the 
drug at concentrations in the region of previously published results, NSC-34 cell 
models of ALS were found to be too sensitive to Scriptaid. As a result, further 
investigations to identify levels of AKT activation via stress assays and western blot 
analysis were not performed in these cell models as it was considered that a better, 
less sensitive cell model of ALS should be used for subsequent experiments. 
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3.4 FIBROBLAST CELLS AS MODELS FOR PTEN  MANIPULATION IN 
ALS 
 
At the time this project began, the field of ALS research had an exciting new discovery; 
a mutation in a new gene designated Chromosome 9 Open Reading Frame 72 
(C9ORF72) which was found to be the most common genetic cause of ALS to date 
(DeJesus-Hernandez et al., 2011, Renton et al., 2011). As described in chapter 1 the 
mutation was found to be a hexanucleotide repeat expansion of GGGGCC in intron 1 of 
the gene C9ORF72. Consequently, as at the time no cell models existed for the 
C9ORF72 mutation in ALS, and primary fibroblast cells derived from patients with 
C9ORF72- related ALS were readily available, it was felt adding this fibroblast cell 
model with this feature would have provided valuable insights into PTEN manipulation 
on a previously unexplored mutational background, especially if a therapy became 
available which may have positive effects for both sporadic and familial forms due to 
the shared cell survival pathway. 
Fibroblasts from patients by skin biopsy were produced in house by Anne Gregory and 
the technical team in SITraN. Although fibroblasts are slow growing, requiring 14-21 
days in culture to develop, compared to NSC-34 cells which take 5-10 days, and are 
cells which are not affected in ALS, they have been found to show aberrant disease-
related features. These include reduced mitochondrial respiration (Allen et al., 2014), 
as well as expression of pathology related to the disease found in motor neurons, 
including RNA foci, hallmarks of the C9ORF72 mutation (Lagier-Tourenne et al., 2013), 
and reduced nuclear TDP43 protein (Sabatelli et al., 2015). Of note, the NSC-34 cell 
models previously used in this chapter were a SOD1 model of ALS, which is not only a 
rarer ALS-causing mutation, but research using this mutation has failed to produce any 
effective  therapeutic interventions for ALS since its discovery (Gong et al., 2000, 
Boillee et al., 2006, Miller et al., 2006). Therefore, using fibroblast cells without these 
characteristics but with a relevant genotype of interest made them an excellent 
additional cell model to study. 
 
3.4.1   F I BRO BLAST  CELLS SHOW LOW  SEN SITIVI TY  T O SCRIP TAI D 
TR EAT MENT   
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Fibroblast cells were first measured for levels of viability via an MTT assay after 
exposure to Scriptaid for 24 hours, at 3μM, 10μM, 30μM and 50μM concentrations to 
examine if the drug had any effects on cell survival.  
Results across all three pairs of fibroblast cells tested revealed a steady decline in 
viability with increasing concentration (figure 3.2). Between vehicle treated conditions 
and 3µM, as well as between vehicle and 10µM doses, no significant changes in cell 
viability were noted, suggesting using 3µM or 10µM concentrations on cells would not 
be detrimental for the cellular viability in both patients and controls. However, at 
higher concentrations beyond 10µM detrimental effects on viability were found, with 
both patients and controls showing a significant decline in cellular viability at 30µM 
and 50µM doses, compared to vehicle and 10 µM conditions, suggesting toxic effects 
on fibroblast cell viability.  
 
 
 
 
 
 
 
 
FIGURE 3.2:  The effects of Scriptaid on fibroblast cell viability as measured by MTT assay. Three 
matching pairs of primary fibroblast cells  revealed no significant changes in cellular viability  
between vehicle and 3µM or vehicle and 10µM doses. Both controls (1) and patients (2) exhibited 
significant declines in cell viability between 10µM doses and concentrations labelled above 
However, C9ORF72 ALS patients revealed a significant reduction in viability between vehicle and 
30µM doses (3). (Data presented as percentage of vehicle control, mean of n=9 independent 
experiments. ±SEM, 1= significant difference between control Scriptaid dose labelled and control 
Scriptaid at 10µM, 2= significant difference between C9ORF72 Scriptaid dose labelled and C9ORF72 
Scriptaid at 10µM, 3= significant difference between C9ORF72 Scriptaid dose labelled and C9ORF72 
vehicle. *p=<0.05, **p=<0.005, ****p=<0.0001. Analysed  with two-way ANOVA, Bonferroni’s 
correction) 
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Whilst the MTT assay is a widely used test for cellular viability and toxicity, the test is 
not without its limitations. Although the MTT readout is a classed as a measure of 
cellular viability, the cells ability to reduce the dye also represents the rate of 
mitochondrial metabolism in the cell, which is in turn representative of the rate of 
NADH production from glycolysis, therefore MTT assays could be classed as 
mitochondrial test (Berridge et al., 2005, Riss TL, 2013 ). Instances where this would 
affect readouts include for example, fibroblast cells in a confluent monolayer which 
may have different metabolic rates compared to those that are not, as well as cell line 
to cell line differences in metabolic rates possibly having an effect on the readout.  
As a cell measurement that relates to mitochondrial activity is used to describe 
viability, it is possible that treatment with Scriptaid may inhibit mitochondrial activity 
without causing cell death. Therefore, in addition to the MTT assay, we also performed 
other biochemical assays for confirmation, including the lactate dehydrogenase (LDH) 
assay for cellular cytotoxicity. The LDH assay requires the use of the media, for a 
cumulative measure of LDH release from damaged cells which can be quantified in a 
colorimetric assay.  As the monolayer of cells were not required, the experimental 
design allowed for multiplexing options, meaning that the MTT data and LDH data 
could be obtained from the same cells treated on the same day, under the same 
conditions, increasing the reliability of comparisons between them.  
Results revealed no significant change in LDH cytotoxicity at any concentration tested, 
suggesting the reductions in viability seen at higher doses in the previously performed 
MTT assay were not due to increased cell death, but due to an inhibited growth rate 
(figure 3.3). Results also revealed no significant difference in patient cells compared to 
controls with the shape of the response, suggesting both cell lines reacted similarly to 
Scriptaid (figure 3.3). Consequently, as no significant changes in cytotoxicity were 
found at any concentration tested compared to vehicle control, the data indicates that 
Scriptaid is non-toxic to fibroblast cells. 
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FIGURE 3.3  Determination of LDH cytotoxicity of Scriptaid treatment on fibroblast cells. Fibroblast 
cells revealed no significant changes in cytotoxicity between vehicle and drug treated conditions  or 
between patient and controls at all treatment conditions. (Data presented as percentage of LDH 
cytotoxicity, mean of n=9 independent experiments. ±SEM. Analysed with two-way ANOVA, 
Bonferroni’s correction) 
 
 
 
 
 
 
 
 
 
 
The MTT and LDH assays revealed limited toxicity of the fibroblast cells to Scriptaid, 
however to identify if cell number was affected, a final biochemical assay to measure 
cell number and proliferation, a CyQuant® assay, was performed. CyQuant® assays are 
a measure for fluorescence rather than absorbance, therefore the use of this 
additional test offsets any concerns with regards to the sensitivity of biochemical 
assays using absorbance measures such as MTT and LDH assays, which are generally 
regarded as less sensitive than fluorescence methods (Riss TL, 2013 ). 
CyQuant® assays were performed on all three fibroblast pairs after treatment with 
Scriptaid for 24 hours at 3μM, 10μM, 30μM and 50μM concentrations. Results across 
all three cell pairs showed a trend towards a decline in cell number in both patients 
and controls with increasing concentration (figure 3.4). However no significant changes 
in cell number were identified, further suggesting the reduced cellular viability seen in 
MTT assays above was not due to cell death, but due to inhibited growth rate. 
Additionally, no significant difference was found in cell number between patients and 
controls under any condition highlighting that patient fibroblast growth was not 
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affected by disease. Overall, the CyQuant® assay results suggest Scriptaid had little to 
no effect on cellular proliferation, which coupled with the toxicity data obtained from 
MTT and LDH assays above, also implies minimal cell death on application of the drug.  
 
 
 
3.4.2  PATI ENT  F IBRO BLAST  CELLS  SHOW  LOW  LEV ELS  OF PTEN  BUT  
SCRI PT AID TR EAT MENT DO ES  NOT  MO DULAT E  T HE PI3K  CELL 
SURVIV AL PATHWAY .  
 
The previous biochemical assays showed fibroblast cells tolerated treatment with 
Scriptaid well, therefore it was next decided to look at how the PI3K cell survival 
pathway responded to Scriptaid treatment in patient and control samples. As the 
fibroblast cells are not affected in ALS, to emulate stressed conditions, a stress assay 
was conducted on the cells where serum withdrawal acted as the stressor (Simm et al., 
FIGURE 3.4: The effects of Scriptaid on fibroblast cell number and proliferation as measured by 
CyQuant assays. Fibroblast cells revealed no significant changes in cell number between vehicle 
and drug treated conditions or between patient and c ontrol grouped data across all treatment 
conditions. (Data presented as percentage of vehicle control, mean of n=9 independent 
experiments. ±SEM. Analysed with two-way ANOVA, Bonferroni’s correction) 
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1997, Arrington and Schnellmann, 2008). Patients and controls were observed for 
differences in activation of PI3K pathway components in both basal and stressed 
conditions, and comparisons were made between them. The same three pairs of 
fibroblast cells used in the above experiments were treated with Scriptaid at 3μM, 
10μM, and 30μM concentrations for 24 hours and subsequently collected, lysed and 
measured for protein expression levels via western blotting. The PI3K pathway 
components probed for included phosphorylated AKT(Ser473) (pAKT), total AKT(pan) 
(AKT), total PTEN (PTEN) and GAPDH (loading control) which were chosen on a basis 
that they would point to activation or inactivation of the PI3K cell survival pathway. 
The western blot is a representative image of one pair of the 3 pairs of fibroblasts, 
whereas the graphs are the summation of the all 3 pairs. Western blotting revealed 
that in basal conditions patients exhibited significantly lower levels of PTEN and pAKT 
compared to controls (figure 3.5 b, c), suggesting that in patient fibroblasts cells these 
pathway proteins are present in lower quantities, possibly indicative of a disease-
related trait. Interestingly, when stressed conditions were applied with serum 
withdrawal, controls showed a significant decline in total PTEN, pAKT, and total 
AKT(pan) in all stressed conditions, whilst patients show no significant changes in total 
PTEN or pAKT(figure 3.5). This indicates a potential resistance to serum withdrawal-
induced stress in patient cells.  
Upon treatment of the cells with Scriptaid, little to no effect on total PTEN or pAKT 
protein expression was found in both patients and controls, when compared to vehicle 
control (figure 3.5 b, c). A trend towards increased protein levels of pAKT (figure 3.5 c) 
and the ratio of pAKT to total AKT (figure 3.5 e) was found with increasing dose, 
however these effects were not significantly above vehicle control. These results 
suggest that Scriptaid does not have a measurable effect as on the PI3K cell survival 
pathway measured by Western blot analysis. 
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a 
b c 
d e 
CTL       C9+ CTL       C9+ CTL       C9+ CTL       C9+ CTL       C9+ 
Basal Vehicle 3μM 10μM 30μM 
PTEN 
pAKT 
AKT(pan) 
GAPDH 
+ Serum - Serum 
FIGURE 3.5: Scriptaid does not modulate PI3K cell survival pathway components in fibroblast cell 
models of ALS and controls. a) Western blots probing for PTEN, pAKT, AKT(pan), and loading 
control GAPDH in primary C9ORF72 patient fibroblasts and age and sex matched controls revealed 
a significant downregulation of b) PTEN and c) pAKT) in control cell serum starved conditions 
compared to basal conditions, and significantly lower levels of PTEN and pAKT in patient cells 
compared to controls in basal conditions. d) A significant reduction in total AKT levels were found 
in control but not patient cells and e) the ratio of pAKT:AKT revealed a significant reduction of 
pAKT at 3μM doses in control cells compared to basal controls, Representative western blot shown.  
(Data are mean of  n=9 independent experiments and normalised to GAPDH loading control.  Where 
more than one membrane was required, each membrane contained both a basal and vehicle 
control for comparison- see chapter 2 section 2.4.3. ±SEM *p=<0.05, **p=<0.005 ***p=<0.0005 , 
****p=<0.0001 analysed with  two-way ANOVA) 
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3.5 DISCUSSION  
 
3.5.1  NSC-34  CELL MODELS  AND SCRI PT AID  
 
Evidence has suggested that apoptotic motor neurons have low levels of histone 
acetylation (Rouaux et al., 2003), indicating the use of a HDAC inhibitors to release 
transcriptional repression may be an alternative strategy to enhance survival of cells in 
ALS. Previous studies have found that HDAC inhibitors, in similar NSC-34 mutant SOD1 
expression models to those used in this study, protected against oxidative stress 
(Rouaux et al., 2007). The study used three HDAC inhibitors, valproic acid (VPA), 
sodium butyrate (NaBu) and trichostatin A (TSA) which all rescued NSC-34 cells from 
oxidative stress induced cell death (Rouaux et al., 2007). Other models of motor 
neuron disease including Spinal Muscular Atrophy (SMA) have also seen successes in 
HDAC inhibition studies (Sumner et al., 2003, Kernochan et al., 2005). In SMA, a 
mutation in the gene SMN1 causes a reduction in SMN protein product. While this is 
partially compensated by SMN2, SMN2 produces an unstable truncated protein due to 
exon 7 exclusion during transcription (Sumner et al., 2003). It has been found that 
HDAC inhibitors, including VPA, increase protein levels of SMN by activating the SMN2 
promotor in NSC-34 cells (Sumner et al., 2003, Kernochan et al., 2005). These studies, 
along with work showing Scriptaid can successfully manipulate the PI3K cell survival 
pathway to increase neuronal cell survival (Wang et al., 2012a, Wang et al., 2015a), 
added to a body of evidence that suggested PTEN manipulation through the use of 
HDAC inhibitor Scriptaid could be a valid therapeutic strategy in ALS. However, in the 
above work when NSC-34 G93A models of ALS, along with WT-SOD1 and pIRES 
controls were treated with Scriptaid with an aim to modulate PTEN and therefore 
downstream components of the pathway, MTT assays revealed a significant reduction 
in cellular viability compared to vehicle controls at even the lowest concentrations of 
the drug tested of 1μM (figure 3.1) and 0.01μM (data not shown). These findings 
suggest a high sensitivity of the cells to Scriptaid which may discount the use of this 
drug on this cell model. Nevertheless, a caveat to the use of MTT assays lies in the 
limitations of the test itself, as they are a measure mitochondrial metabolism, which 
means the readout portrayed may not be fully reflective of cellular viability if the drug 
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used causes affects outside of mitochondrial activity. Further assays complementary to 
MTT would clarify any results obtained. 
It has been suggested that the use of differentiated NSC-34 cells which display action 
potentials and processes more akin to primary motor neurons (Durham et al., 1993) 
may be better models for neurotoxicity testing than undifferentiated cells.  Work by 
Maier et al. in 2013 found undifferentiated NSC-34 cells were more vulnerable to 
cytotoxic agents including glutamate cytotoxicity than those differentiated by retinoic 
acid application. They found differentiated cells had a lower proliferation rate, and 
increased protein expression of well-known neuronal markers Choline 
acetyltransferase (ChAT) and microtubule associated protein 2 (MAP2). They also 
found differentiated cells had increased BCL-2 mRNA, a downstream component in the 
PTEN-AKT cell cascade,  which they thought helped confer a higher resistance to 
apoptosis (Maier et al., 2013). It is important to note that cell model sensitivity may 
not reflect the in vivo situation and the results seen may highlight the un-differentiated 
cells vulnerability when looked at in isolation. Therefore, before overlooking the use of 
NSC-34 cell models with Scriptaid, future work could try differentiated NSC-34 cell 
models of ALS as an alternative approach. 
In previous studies, NSC-34 cells with experimentally reduced PTEN protein expression 
via PTEN knockdown (KD) have shown functional changes in the expression of key 
downstream proteins in this pathway, including increased phosphorylation of AKT and 
pro-survival pathway activation (Kirby et al., 2011). The same study identified that 
PTEN KD increased survival after oxidative stress to NSC-34 cells transfected with 
mutant G93A SOD1, an increase from 47% to 68% (Kirby et al., 2011). This work 
highlights the positive benefits to activation of this pro-survival pathway via PTEN 
manipulation in these cells, therefore other methods of PTEN manipulation, for 
instance the use of direct inhibitors of PTEN, such as BpV compounds (Walker and Xu, 
2014) may be an additional option to consider for future work with these cell lines. 
 
3.5.2  F IBRO BLAST  CELL MO DELS :  TO XI CIT Y ASS AY S  
 
When biochemical assays were performed to ascertain levels of toxicity for the use of 
Scriptaid treatment on fibroblast cells, MTT assays first revealed a steady decline in 
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cellular viability with dose and suggested that concentrations of 30µM and 50µM were 
too high to use on the cells, resulting in unfavourable declines in viability. These results 
fit with previous reports of the drug which have reported a similar reduction in survival 
rates at concentrations above 10μM (Su et al., 2000). On the other hand, 
concentrations of 3µM and 10µM did not negatively affect cellular viability. Although 
the assays did not reveal any significant improvement in cell survival or growth with 
addition of the drug, these cells were currently not under stressed conditions, 
therefore treatment with Scriptaid may not improve cell survival at this stage.  
LDH assays revealed no significant toxicity at all doses tested (figure 3.3) and as the 
higher concentrations of 30μM and 50μM did not show any increased cytotoxicity, we 
can say the declines in cellular viability witnessed in the MTT assay at these doses were 
not indicative of cell death. This result, coupled with the MTT and CyQuant assays, 
suggests in fibroblast cells Scriptaid treatment is non-toxic, particularly at doses 10μM 
and below.  
In conclusion, the fibroblast cells displayed a lower sensitivity to Scriptaid at 
concentrations of 10µM and 3μM, in comparison to NSC-34 cells used in previous 
experiments which showed significant declines in cellular viability at these doses 
(figure 3.1). Fibroblast cells in this instance are better cellular models of ALS for the 
continued investigation into the effects of Scriptaid on cell survival pathways 
compared to the NSC-34 cell models.  
 
3.5.3  F IBRO BLAST  CELL MO DELS :  PHOS PHATI DY LIN OSITI DE  3-KIN AS E  
(PI3K)  P AT HW AY  CO MPONENT S  
 
From our experiments, western blots revealed patients had significantly lower levels of 
total PTEN expression compared to controls under basal conditions (figure 3.5 b). This 
interestingly links with gene expression profiling studies performed in 2011, which 
found 34 genes involved in apoptosis were differentially expressed in human samples 
of motor neurons from SOD1-ALS patients compared to controls, and included a 
decrease in PTEN expression (Kirby et al., 2011). Here, the patient cells used also 
exhibited reduced PTEN in basal conditions, highlighting a common pathway is altered 
in two genetic subtypes of ALS, suggesting disease could cause or create an aberrant 
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reduction in this protein. One possible explanation for this could be that patient cells 
with ALS attempt to reduce total PTEN levels in an effort to promote cell survival via 
reduced inhibition of the PI3K pathway. However, whether these findings are a cause 
or consequence of disease and how it affects downstream components in the pathway 
remain to be elucidated. Further studies to examine the effect of reduced PTEN in 
other genetic subtypes and sporadic ALS cell models, as well as examine the effect on 
other cascade components including BAD and S6 kinase, would confirm the extent of 
PI3K pathway activation in ALS. 
Next, examining the effect of reduced total PTEN protein in basal patient cells on AKT 
phosphorylation, we found no change in relative pAKT protein as a result (figure 3.5 c). 
The reason for a lack of increased AKT phosphorylation with reduced total PTEN could 
lie in dynamic changes the phosphorylation status of PTEN. As described above we 
observed changes in total PTEN which includes both phosphorylated and un-
phosphorylated forms. Phosphorylated PTEN is the inactive form of the protein, 
therefore if the ratio of pPTEN to total PTEN is in favour of the active form, higher 
levels of pathway inhibition could prevent the activation of AKT and thus inhibition of 
the cell survival pathway. Although attempts to re-probe the western blot membranes 
used above for pPTEN were made by stripping the membrane of previously labelled 
proteins, unfortunately blots failed to provide a conclusive band at the appropriate 
weight, most likely due to the dynamics of phosphorylated PTEN protein being too low 
to detect under the conditions tested. It has previously been reported that the 
phosphorylation and regulation of PTEN is a complex and multifactorial mechanism. 
PTEN phosphorylation can be controlled by multiple entities (Torres and Pulido, 2001, 
Miller et al., 2002) and the subcellular localisation of PTEN, in particular membrane 
binding has also been found to modulate its regulation and roles (Ross and Gericke, 
2009, Li et al., 2009, Chang et al., 2008a, Goh et al., 2014, Rahdar et al., 2009). 
Additionally, PTEN has also been suggested to regulate its own phosphorylation status 
(Tang and Eng, 2006). It was not within the scope of the project, or a primary aim to 
optimise the conditions for visualizing the dynamics of phosphorylated PTEN in 
fibroblasts, or examine the relationship between the intracellular localisation of PTEN 
and its phosphorylation status, particularly as the drug did not show any effect. 
Nonetheless, investigations to optimise assay conditions to identify PTEN 
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phosphorylation levels and the subcellular localisation of PTEN would be a next step 
for further investigations in these cell models. 
The literature proposed that Scriptaid could modulate PTEN and components of the 
PI3K cell survival pathway with positive effects in neuronal cell models. However, 
unfortunately the drug had no effect on total PTEN protein levels compared to vehicle 
control, and importantly no significant effect on AKT activation. A reduction in pAKT 
protein was found in control cells compared to basal conditions, and a trend towards 
higher levels of pAKT protein was found with increasing dose. However, no significant 
changes were found in pAKT compared to vehicle control at any concentration tested, 
suggesting that the drug had no positive effect on this pathway and the reduced 
activation of AKT in control cells was due to a serum starvation effect. As discussed 
above, pPTEN expression levels here may reveal more interesting findings, as studies 
have identified changes in pPTEN but not total PTEN with Scriptaid, where the drug 
was found to increase the phosphorylated form but not total PTEN protein (Wang et 
al., 2015a). It is highly possible that the total PTEN protein measured above is masking 
subtle changes in phosphorylated PTEN, and therefore the ratio of phosphorylated to 
total PTEN available. However, even if this was revealed there are still no positive 
effects on pAKT to indicate pathway activation suggesting that Scriptaid does not 
modulate the PI3K pathway to generate increased AKT phosphorylation and thus 
increase cell survival. 
When the cells were exposed to additional stressors via serum withdrawal, control 
cells saw a significant reduction in PI3K pathway components, causing a reduction in 
PTEN protein expression in all stress treated conditions. This finding agrees with our 
observation of patient cells showing lower total PTEN protein in disease, as it indicates 
the cells could also be under stressed conditions. However, as Scriptaid treatment had 
no effect on the total PTEN protein expression as it did not reduce total PTEN further 
to give greater cell survival activation, it suggests the stressed conditions had a 
maximal effect on this measure. Of note, studies in lung cancer cells found TSA a HDAC 
inhibitor belonging to the same family as Scriptaid, helped to restore PTEN protein 
levels to endogenous levels, in artificially reduced PTEN lung cancer cell lines (Noro et 
al., 2007), but had no effect on cell lines with higher levels of PTEN, implying total 
PTEN protein levels may not be altered by HDAC inhibition unless already aberrantly 
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reduced in the cell. In this work, whilst we do see significantly lower levels of PTEN in 
patients compared to controls and a reduction in PTEN in controls with serum 
starvation, Scriptaid unlike other HDAC inhibitors did not modulate patient protein 
levels of PTEN after application. The primary fibroblast cells used in this study are 
otherwise healthy cells, with ALS patient fibroblasts not exhibiting deterioration 
despite holding a genetic background of ALS. Therefore, although Scriptaid treatment 
has no significance to fibroblast cell PI3K pathway activation, or an effect on total 
PTEN, it is possible Scriptaid may still have a positive survival effect in other cell models 
with a genetic background for ALS which are known to deteriorate in the disease. 
 
3.6 CONCLUSION  
 
In conclusion, the NSC-34 cell models were identified to be too vulnerable to the 
toxicity of Scriptaid to be viable cell models to continue investigating its effects on the 
PI3K pathway in disease. When primary human fibroblasts were used, although they 
revealed minimal toxicity to the drug, they also gave minimal PI3K pathway 
modulation and failed to increase AKT phosphorylation levels to indicate increased 
activation of the pathway. Whilst this suggests that PTEN has yet known activities, this 
result could also be due to fibroblast cells not being susceptible to the disease effects 
of ALS, where the motor neurons are the primary cells affected. Subsequent chapters 
will therefore continue to focus on developing a model that more accurately reflects 
ALS, to examine if PTEN modulation can significantly promote the survival of cells in 
disease. 
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4.1 INTRODUCTION  
 
4.1.1  MODELLIN G C9ORF72-RELATED ALS  WIT H INDUCED PLURIPO TENT  
STEM CELL-DERIV ED MODELS  
 
After the discovery of GGGGCC hexanucleotide repeat expansion in the non-coding 
region of the gene C9ORF72 was found to be the most common mutation for the 
pathogenesis of ALS, as discussed above it soon became apparent that the long GC rich 
expanded repeat proved technically challenging for many aspects of molecular cloning 
and targeting (Donnelly et al., 2013a). Nevertheless, it is not surprising that only two 
years after the discovery, these difficulties were circumvented when the first studies 
developing iPS cells from patient somatic cells with C9ORF72-related ALS were 
published.  
An initial important observation from the iPS-derived cells produced, related to the 
stability of the repeat expansion after the processes of somatic cell reprogramming 
and cell model generation. Studies found that the transition from somatic cell to iPS 
cell did not delete the expansion; however of note, repeat instability has been 
reported. This included both increases and decreases in expansion length found in iPS 
cells and differentiated counterparts. (Almeida et al., 2013, Sareen et al., 2013, 
Donnelly et al., 2013a). The reasons behind these changes in repeat length most likely 
stem from clonal variation and selection of fibroblasts of differing repeat sizes 
(Almeida et al., 2013, Sareen et al., 2013, Donnelly et al., 2013a). However, somatic 
heterogeneity within a single cell type and variability in repeat size in different regions 
of patient brains has also been reported (Beck et al., 2013), suggesting that the 
discrepancies in repeat length may simply reflect these endogenous traits. This 
heterogeneity also creates difficulties in identifying correlations between the 
expansion size and disease-related features such as onset, severity and progression. 
A second observation was that the differentiation of iPS cells to generate post-mitotic 
neurons was not affected by the presence of the repeat expansion (Almeida et al., 
2013, Sareen et al., 2013). However interestingly, although mature and electrically 
active motor neurons have been generated, contrasting findings in their electrical 
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properties have been reported. Mammalian neurons are known to have a resting 
membrane potential at around -60mV and have the ability to generate multiple trains 
of both voltage induced and spontaneous action potentials (Baranyi et al., 1993). In 
comparison iPS-derived motor neurons do not quite recapitulate the in vivo adult cell 
state with a tendency towards immature motor neuron electrophysiological properties 
such as low spontaneous action potential generation and a lack of repetitive firing 
(Sances et al., 2016). ALS motor neurons from iPS cells have been found to exhibit 
hyper-excitability, with faster firing rates due to increased sodium currents and 
reduced potassium currents (Wainger et al., 2014, Kanai et al., 2006, Devlin et al., 
2015). In contrast, slower firing rates and reduced synaptic activity have also been 
reported (Sareen et al., 2013, Devlin et al., 2015); possibly a compensatory feature of 
prolonged iPS cell-derived motor neuron tissue culture and differentiation. 
So far studies with C9ORF72 have primarily focussed on how the pathogenic mutation 
causes disease, gathering interesting evidence for or against different mechanisms of 
action including: haploinsufficiency (Harms et al., 2013), RNA toxic gain of function 
(DeJesus-Hernandez et al., 2011), and non-ATG (RAN) translation resulting in toxic 
products of di-peptide repeat proteins (DRPs) (Mori et al., 2013b). Subsequently, 
differentiated iPS cell- derived neurons have been found to contain RNA foci (Almeida 
et al., 2013, Sareen et al., 2013, Donnelly et al., 2013a), hallmarks of the 
hexanucleotide repeat expansion (DeJesus-Hernandez et al., 2011) which are proposed 
to be indicative of the importance of RNA toxicity in C9ORF72 pathogenesis. In 
addition, RNA binding proteins have been found to be associated with foci in some 
(Sareen et al., 2013, Donnelly et al., 2013a) but not all (Almeida et al., 2013) 
investigations, adding to the theory that these foci aberrantly sequester RNA binding 
proteins from their normal binding partners.  
Here, we wanted to develop iPS cell derived neuronal and motor neuronal cell models 
to investigate ALS. Therefore, this chapter focuses upon the important first stage of 
characterisation and investigation of these newer cell models of disease, including 
comparison between patients and controls, and evaluation against previously 
established iPS cell models from other groups. 
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4.2 AIMS AND OBJECTIVES  
 
The aims of the work described in this chapter were to optimise and characterise 
induced pluripotent stem cells, derived from three C9ORF72- related ALS patients and 
their healthy matched controls, and their differentiated counterparts, with the aim to 
successfully differentiate the cells into motor neurons to be studied as a cell model of 
C9ORF72-related ALS. The iPS cells were generated by our collaborating group at 
Tongji University School of Medicine, Shanghai, China, by retroviral transduction of 
four Yamanaka factors: Oct4, c-myc, Sox-2 and Klf4. They were then characterised for 
pluripotency by labelling the reprogrammed cells for expression of markers associated 
with pluripotency. Next cells were differentiated comparing protocols previously 
established in the literature to optimise the differentiation of cells into a motor 
neuron-like fate. The cells generated were then characterised for markers that indicate 
progression into a neuronal and motor neuronal identity. Following this, the cells were 
quantified for total motor neuron yield obtained as percentage of cells in the mixed 
population that expressed dual Tuj1 (neuronal) and ChAT (mature motor neuronal) 
marker expression. 
Whilst immunocytochemical staining for markers of pluripotency can be a good 
indicator of the cells terminal identify after differentiation, representation of markers 
alone does not indicate if the neuron is functional. For this reason our next aim was to 
perform electrophysiological experiments to confirm the firing properties of the cell, 
measuring for action potential generation after a depolarising stimulus, as a measure 
to characterise motor neuron maturity. This was achieved through whole cell patch 
clamping techniques. 
 
Finally, to show our methods for the generation of iPS cells and the differentiation of 
iPS cells to motor neurons did not remove the C9ORF72 expansion from ALS patients, 
we also aimed to characterise the cells for C9ORF72-ALS specific hallmarks. We 
assessed the iPS cells and differentiated iPS cells for the presence of sense and 
antisense RNA foci, and then whether these lead to detectable dipeptide repeat 
proteins and changes in TDP-43 localisation; markers commonly associated with ALS 
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cell models. Moieties were quantified for number, and subcellular localisation in 
comparison to previously established findings. 
 
 
4.3 INDUCED PLURIPOTENT STEM (IPS)  CELL GENERATION AND 
DIFFERENTIATION  
 
4.3.1  CHAR ACT ERIS ATION  O F I N DUCED PLURIPOT EN T ST EM  ( IPS)  CELLS  
 
The iPS cells were generated in our collaborating lab by Yang and colleagues at Tongji 
University School of Medicine, Shanghai, China, from three primary human dermal 
fibroblasts from patients with C9ORF72-related ALS, along with their healthy matched 
controls (figure 4.1 a). To verify the identity of the fibroblasts immunocytochemical 
(ICC) staining confirmed the presence of TE-7 (figure 4.1 b), an anti-fibroblast antibody 
frequently used in the literature (Haynes et al., 1984). Fibroblasts were subsequently 
transduced with retroviruses expressing Oct4, c-myc, Sox-2 and Klf4, or GFP as a 
control to re-programme the somatic cells to pluripotency using previously described 
protocols (Takahashi and Yamanaka, 2006, Takahashi et al., 2007, Yang et al., 2014b) 
(figure 4.1 c). 
 
To validate that the fibroblast cells had been successfully reprogrammed, iPS cells 
were examined for their morphological and biochemical similarities with human 
embryonic stem cells. The cells had lost their fibroblast-like appearance to form large 
colonies of tightly packed cells with defined edges, with cells displaying a large nucleus 
to cytoplasm ratio, a morphology associated with human embryonic stem cells (figure 
4.1 d, figure 4.2, figure 4.3). Colonies also showed a uniform density, confirming no 
spontaneous differentiation (figure 4.1d), however alkaline phosphatase staining, a 
marker of embryonic stem cell pluripotency (O'Connor et al., 2008), confirmed that the 
cells were pluripotent and undifferentiated (figure 4.1 e, f).  
 
Using markers of pluripotency, it was found both human embryonic stem cells (figure 
4.1 g) and the iPS cells generated (figure 4.1 h) expressed Oct4 and Sox2, transcription 
factors which induce pluripotency, as well as cell surface antigens SSEA-3, SSEA-4, TRA-
1-60, and TRA-1-81. Alongside this, the iPS cell lines also displayed a normal human 
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karyotype with no abnormalities observed (figure 4.1 i). Finally, to confirm the cells 
ability to form cell types from all three germ layers, iPS cells were transplanted into the 
hind limb of severe combined immune deficiency mice which resulted in the formation 
of teratomas containing tissue of ectodermal (figure 4.1 j), mesodermal ( figure 4.1 k, l) 
and endodermal (figure 4.1 m) origin. 
 
The collaboration of, the collection and generation of IPS cells in China and work 
conducted in Sheffield was all done with prior ethical permission in place. Human 
fibroblasts have have (STH14653 REC: 07/Q2305/9) NRES Committee Yorkshire & the 
Humber approval. After arrival in Sheffield, cells were cultured in iPS media containing 
basic fibroblast growth factor (bFGF) on a feeder layer of mitomycin C treated mouse 
embryonic fibroblasts (MEFs), and additional confirmatory tests were performed to 
conform that the cells remained undifferentiated. To replicate the conditions the iPS 
cells were kept under in China, we re-confirmed expression of pluripotency markers 
TRA-1-60 and SSEA-4 by dual staining with an additional marker of pluripotency and 
one of the transcription factors used to reprogram the fibroblasts, c-myc (figure 4.2 
and 4.3). Therefore we confirmed in our hands that the findings reported to us from 
China were correct before commencing work. Together, as cells remained 
morphologically and biochemically similar to human ES cells, these findings 
demonstrate the fibroblast cells had been successfully re-programmed to a pluripotent 
state. 
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Figure 4.1: iPS cells can be generated from human patient and control fibroblast cells. a) Human dermal fibroblast cells stained for b) TE-7 to confirm fibroblast identify, c) 
fibroblasts transfected with GFP retroviruses, d) Flat multicellular iPS cell colony with cells containing a high nucleus to cytoplasm ratio, e) and f) iPS Colonies demonstrate 
expression of alkaline phosphatase. Comparison of g) human embryonic stem (ES) cells to h) control human iPS cells reveals expression of the same markers for nuclear 
pluripotency (Sox-2, Oct4) and embryonic cell surface markers (SSEA-3, SSEA-4, TRA-1-60, TRA-1-81). i) IPS cells generated display a normal human karyotype. Injection of iPS cells 
into NOD/SCID mice causes teratoma formation made of j) neural ectodermal tissue; k) cartilage mesodermal tissue; l) muscle mesodermal tissue m) and primitive gut endodermal 
tissue (Abbreviations: Oct 3/4, octamer-binding protein 3/4; SOX2, sex determining region Y (SRY) -box 2; SSEA3/4, stage specific embryonic antigen 3/4; TRA-1-60/1-80, tumour 
rejection antigen 1-60/ 1-80  Scale bar=) (Work conducted by Yang et. al Tongji University School of Medicine, Shanghai, China)
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Figure 4.2: Characterisation of iPS cells generated from human dermal fibroblasts for markers of pluripotency . Control and patient iPS cells revealed positive dual expression 
for a) and f) TRA-1-60; b) and g) c-myc when stained via immunocytochemistry. c) and h) Hoechst labels nuclei blue.  d) and i) merge.  e) and J) zoom of insert (Abbreviations: 
TRA-1-60, tumour rejection antigen 1-60; c-myc, cellular-avian myelocytomatosis. Scale bar=200μM d) and i); Scale bar= 50μM e) and j))  
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Figure 4.3: Characterisation of iPS cells generated from human dermal fibroblasts for markers of pluripotency . Control and patient iPS cells revealed positive dual ex pression 
for a) and f) SSEA-4; b) and g) c-myc when stained via immunocytochemistry. c) and h) Hoechst labels nuclei blue. d) and i) merge. e) and J) zoom of insert (Abbreviations: 
SSEA-4, stage specific embryonic antigen 4; c -myc, cellular-avian myelocytomatosis. Scale bar=300μM d) and i); Scale bar= 200μM e) and j)
C
o
n
tr
o
l 
C
9
O
R
F7
2 
               SSEA4          c-Myc              Hoechst          Merge 
a b c d e 
f g h i j 
99 
 
 
4.3.2  D IFFERENTI ATION  O F I NDUCED PLURIPO TENT  STEM  ( IPS)  CELLS  TO  
MOTOR  NEURON S   
 
To differentiate iPS cells into cells of a neural lineage, and more specifically into motor 
neurons, attached colonies were first grown in an iPS media containing bFGF, as well 
as Rho kinase inhibitor Y27632 and LDN193189 which were added to enhance single 
cell survival and induce a default neural identity via SMAD inhibition respectively 
(Chambers et al., 2009). This promoted the formation of embryoid bodies (EBs) as well 
as the beginning of neuralisation. The neuralisation process continued from days 3 to 
16, in which cells were cultured in a neural induction media comprising mainly of 
DMEM:F12 and knock-out serum (partially purified bovine serum albumin) which 
prevents spontaneous differentiation and reduces astrocyte formation promoted by 
the addition of FBS (Li et al., 2015). Over the course of neural induction, retinoic acid 
was added from day 5 onwards to promote caudalisation. This was followed by sonic 
hedgehog (SHH), as well as smoothened agonist purmorphamine (PUR) which together 
act to promote sonic hedgehog activation and thus ventralisation of the developing 
cells (Ericson et al., 1996, Jessell and Sanes, 2000). During this period of neural 
induction, brain derived neurotrophic factor (BDNF) was also added for neurotrophic 
support (Jones et al., 1994). From day 17 to the end of differentiation and beyond, day 
42+ (6 weeks), cells were maintained in neurobasal media supplemented with three 
additional neurotrophic factors: insulin-like growth factor 1 (IGF-1), glial derived 
neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), used to promote 
the maturation of motor neurons. This protocol was followed as it recapitulates the 
process of embryonic motor neuron development in vitro of blastocyst pluripotency, 
gastrulation, neuralisation, caudalisation, ventralisation, and maturation (figure 4.4). 
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Figure 4.4: Schematic representation of the iPS cell differentiation protocol to generate motor 
neurons. iPS colonies from day 0 undergo neural induction by addition of various factors isolated 
from embryonic motor neuronal development. By day 14 neuronal progenitors are formed 
expressing TuJ1 and by day 28 cells express specific MN markers Hb9, islet 1/2 as well as neuronal 
marker MAP2. At the end of the differentiation protocol and beyond, cells express mature motor 
neuronal marker ChAT as well as continued Hb9 expression. (Abbreviations: iPS, induced pluripotent 
stem; bFGF, basic fibroblast growth factor; RA, retinoic acid; BDNF, brain derived neurotrophic 
factor; SHH, sonic hedgehog; PUR, purmorphamine; IGF, insulin -like growth factor 1; GDNF, glial 
derived neurotrophic factor; CNTF, ciliary neurotrophic factor; CAMP, Adenosine 3’, 5’- cyclic 
monophosphate; MN, motor neuron; c-myc, cellular-avian myelocytomatosis; SSEA-4, stage specific 
embryonic antigen 4; TRA-1-60, tumour rejection antigen 1-60; Tuj1, β III tubulin;;  Hb9, homeobox 
gene 9; MAP2, microtubule associated protein 2 ;  ChAT, choline acetyl transferase) 
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Figure 4.5: Neurons generated from iPS cells express neuronal specific dendritic marker 
MAP2 in both a) control and b) patient cells from 4 weeks of differentiation. (Abbreviations: 
MAP2, microtubule associated protein 2. Scale bar = 300μM) 
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4.3.3  D IFFERENTI AT ED IN DUCED PLURI POT ENT  ST EM  ( IPS)  CELLS D IS P LAY 
NEURO NAL AN D MO TO R NEURON AL SP ECI FI C  MARK ERS  
 
 
First, to confirm that the differentiation of iPS cells was directed towards a neuronal 
fate, cells were analysed longitudinally throughout differentiation. Cells were fixed and 
stained for neuronal marker microtubule associated protein 2 (MAP2) which is 
localised to neuronal dendritic processes. Immunocytochemical (ICC) staining revealed 
positive expression of MAP2 in cells from 4 weeks onwards, with extensive processes 
and branches emerging from multiple cells (figure 4.5). This suggests that a subset of 
cells had gained a neural identity from our differentiation protocol.  
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Next, to verify if the differentiated cells generated with this protocol were progressing 
towards a spinal lower motor neuronal identity, cells were immunostained for LIM 
homeodomain markers specific for motor neurons including islet 1/2, a transcription 
factor involved in regulating the differentiation of motor neurons in the neural tube, 
and Homeobox gene 9 (Hb9) another motor neuron specific transcription factor 
important in specifying motor neuron fate (Arber et al., 1999). In an additional level of 
validation, cells were dual stained with a neuronal specific class of β III Tubulin (Tuj1), 
which stains the processes of neuronal cells. 
  
Results revealed positive dual expression of islet1/2 and Tuj1, labelling both patients 
and controls from 4 weeks of differentiation (figure 4.6). Additionally, cells revealed 
positive dual staining for Hb9 and Tuj1 (figure 4.7) in both patients and control cells, 
with staining found from 4 weeks onwards. Hb9 and islet 1/2 staining were mainly 
nuclear and co-localised with Hoechst nuclear stain, however some processes towards 
the nuclear periphery also stained, which is in line with previous reports of 
immunostaining with these markers (Dimos et al., 2008, Karumbayaram et al., 2009). 
Interestingly, larger processes could be found in cells which were tightly packed 
together (figure 4.4, figure 4.6), with long and extensive outgrowth from EBs which 
had not broken up during the process of differentiation. These groups of cells (figure 
4.6) were not disease specific and could be found in both patient and control 
conditions, along with areas of dispersed single cell populations (figure 4.5). Remaining 
EBs during differentiation is an observation which matches previously established 
reports in iPS cell to motor neuron differentiation studies (Dimos et al., 2008). 
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Figure 4.6: Neurons generated from iPS cells express markers specific to neuronal and motor neuronal lineages. a -d) control and e-h) patient iPS-derived cells 
express dual positive staining for islet 1/2 a transcription factor that regulates motor neuron differentiation in the neural  tube, along with Tuj1, a neuronal specific 
class of β III tubulin and a pan neuronal marker, found in axons and cell bodies from 4 weeks of differentiation (Abbreviations: Tuj1, β III tubulin. Scale bar = 300μM)  
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Figure 4.7: Neurons generated from iPS cells express markers specific to neuronal and motor neuronal lineages. a-d) control and e-h) patient iPS-derived cells express dual positive staining for Hb9 
a motor neuron specific transcription factor found in cellular nuclei and processes, along with Tuj1, a neuronal specific class of β III tubulin expressed in neuronal processes and cell bodies from 4 
weeks of differentiation (Abbreviations: Hb9, homeobox gene 9; Tuj1, β III tubulin. Scale bar = 300μM)
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4.3.4  OPTI MI SATION  O F CHO LIN E ACET Y L TRAN S FERAS E 
IMMUNO CYTO CHEMI ST RY  (ICC) 
 
While Hb9 has been described as a specific motor neuronal marker (Arber et al., 1999), 
the presence of Hb9 positive expression in some glutamatergic ventral spinal 
interneurons (Wilson et al., 2005) and the reduced expression of both Hb9 and islet 
1/2 with maturity (Thaler et al., 2004) highlights problems in using these markers alone 
for mature motor neuron immunocytochemistry. Therefore, to identify mature motor 
neurons amongst a mixed population of cells, along with MAP2 and Tuj1 neuronal 
staining, and complementary to islet 1/2 and Hb9 motor neuronal specific staining, it 
was important to also confirm the expression of mature motor neuronal marker 
choline acetyltransferase (ChAT). 
 
Previous studies performed in our department have identified that ChAT antibody 
staining requires a long incubation period to achieve optimal staining of motor neuron 
cell bodies and processes. This encouraged us to optimise a time course as early 
experiments suggested no motor neurons were present in our samples.  
Our first efforts to label differentiated cells with ChAT for an incubation period of 24 
hours did not produce any visible staining, in line with previous observations from 
departmental colleagues, which lead us to optimise the protocol for 
immunocytochemistry (ICC) for this antibody, incubating the cells at 6 weeks of 
differentiation, for 48 and 72 hours. To control for the possibility that the cells were 
not mature enough to express ChAT at 6 weeks of differentiation; we also incubated 
cells differentiated up to 9 weeks for 72 hours. In addition, as a positive control we 
also incubated primary mouse motor neurons for 72 hours with ChAT to ensure the 
antibody used was functional. After a 72 hours incubation period, results confirmed 
that the staining observed was specific and motor neurons were detectable from 6 
weeks of differentiation onwards (figure 4.8).  
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Figure 4.8: Optimisation of choline acetyl transferase immunocytochemistry a) 48 hour incubation period of ChAT 
antibodies did not label mature motor neurons at 6 weeks of differentiation. However after a 72 hour incubation 
time, cells at b) 6 weeks and c) 9 weeks of differentiation, a subset of cells labelled positively for mature motor 
neuronal marker ChAT, in staining comparable to d) primary mouse motor neurons positive controls. Incubation of 
differentiated iPS cells at 6 weeks with e) secondary antibodies only revealed low level background staining.  
(Abbreviations: Ab, antibody; ChAT, choline acetyl transferase; Tuj1, β III tubulin; MN, motor neuron, . Scale bar = 
300μM) 
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4.3.5  D IFFERENTI AT ED IN DUCED PLURI POT ENT  ST EM  ( IPS)  CELLS  
EXPR ESS  MAT UR E MOT OR NEURON AL MAR KER  CHO LIN E ACET Y L 
TR AN SFERAS E  AND QUANTI FI CATION  O F I PS-  DERIV ED MO TOR  NEUR ON 
Y IELD  
 
After the successful optimisation of the ICC protocol for ChAT expression in 
differentiated iPS cells, to establish that the differentiation protocol produces mature 
motor neurons, we next dual stained patient and control iPS cells at 6 weeks of 
differentiation for ChAT and Tuj1 in all 6 cell lines. 
 
Results revealed a positive correlation of both markers in a subset of differentiated 
cells that morphologically represented MNs, with triangular cell bodies emitting 
processes including axons and dendrites. The MNs expressed ChAT, co-localising with 
the nuclei of positive populations, with some processes also staining positively for the 
marker (figure 4.9 d, h). Tuj1 expression as expected, was found to be highest in the 
processes of cells with some fainter expression visualised in cell bodies (figure 4.9 b f). 
Taken together, these results indicated that our differentiation protocol was able to 
generate mature motor neuronal cells as exemplified by recognised motor neuron 
marker expression. 
 
Next, to confirm the percentage of mature motor neurons generated amongst a mixed 
population of cells, we quantified the number of cells labelled positive for dual 
expression of ChAT and Tuj1. At 6 weeks of differentiation at the end of the protocol, 
we found controls had an average of 38.3% (±SD 8.3)cells labelled with dual ChAT and 
Tuj1 in a mixed population of cells, whilst patients had 24.9% (±SD 7.8) motor neurons 
with total cell number established by Hoechst stained nuclei (figure 4.10). However, 
despite the trend towards patients exhibiting less motor neurons than controls, there 
was no significant difference in total motor neurons produced between patients and 
control cells which suggested the presence of the disease causing mutation in patient 
iPS cells does not negatively affect the generation of motor neuron cell models from 
C9ORF72-iPS cells. 
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Figure 4.9: Neurons generated from iPS cells express markers specific to neuronal and mature motor neurons. a -d) control and  e-h) patient iPS-derived cells express 
dual positive staining for ChAT expressed in mature motor neuron cell bodies and processes, along with Tuj1, a neuronal speci fic class of β III tubulin and a pan 
neuronal marker found in axons and cell bodies, from 6 weeks + of differentiation (Ab breviations: ChAT, choline acetyl transferase; Tuj1, β III tubulin. Scale bar = 
300μM) 
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Figure 4.10: Quantification of differentiated iPS cells labelled positive for dual ChAT and Tuj1 
staining at 6 weeks of differentiation.  Results revealed control motor neurons showed 38.3% 
of the total cell population staining positively for both markers. Patient C 9ORF72 differentiated 
iPS cells showed an average of 24.9% of cells staining for both markers.  There was no 
significant difference between patients and controls in the number of motor neurons 
generated. (Data presented as percentage of total cell number at  6 weeks, mean of n=3 
independent experiments. ±SEM, analysed with two-way ANOVA)  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.6  IPS  DERIV ED-CELL SURVIVAL PO ST-D I FFER ENTIATIO N PROTO CO L  
 
As we did not observe any significant difference in the yield of motor neurons 
produced between patients and controls, we next postulated if over time, as the cells 
matured we would see a difference in survival, as exemplified by changes in the total 
cell number of patient cells compared to controls. We performed total cell counts each 
week for up to 6 weeks after the initial 6 week differentiation protocol was complete, 
bringing the total time of cell tissue culture to 12 weeks in vitro. Over three 
independent experiments, results revealed a continuous and significant weekly 
reduction in total cell number between 7 and 12 weeks in both patients and controls, 
with the steepest reduction found between 7 and 8 weeks of differentiation (figure 
4.11). Primary motor neuron cultures exhibit a decline with cultures optimally 
maintained for up to 2 weeks after plating, therefore comparatively, these results also 
suggest a 2 week optimal maintenance period after complete differentiation. 
Interestingly no difference was found between patient and control cell cultures in the 
number of iPS-derived cells over time, suggesting C9ORF72 related ALS had no effect 
of the maturation and survival of the cells post differentiation, otherwise exhibiting 
similar cell survival phenotypes. 
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Figure 4.11: Total iPS Derived cell counts.  iPS-Derived cells post differentiation revealed a significant 
decline in total cell numbers from week 7 to 12, with total cell numbers significantly and steadily 
declining each week in both patients and controls. There was no significant difference in the n umber 
of cells between patients and controls at any week post -differentiation (Data presented as percentage 
of total cell number at 7 weeks, mean of  n=3 independent experiments. ±SEM, cell number 
comparisons between each week analysed with two-way ANOVA, cell number between patients and 
controls analysed with paired t-test)  
 
 
4.3.7  CHAR ACT ERIS ATION  O F T HE ELECT ROP HY SIO LOGI CAL PROP ER TIES  O F 
IPS-  DERIV ED MOTO R NEURO NS  
 
To confirm the electrophysiological characteristics of the iPS-derived motor neurons 
generated, we performed whole cell patch clamp procedures on individual iPS-derived 
neurons which were identified by their morphology including triangular cell bodies 
emitting processes (Figure 4.12 a). We obtained recordings from multiple cells across 6 
cell lines, from three rounds of differentiation, and from 6-9 weeks of differentiation, 
to identify if we could record normal depolarization induced action potentials in our 
cells. To first measure the cells ability to fire depolarized evoked action potentials, cells 
were recorded in current-clamp mode under a depolarising stimulus of a 10 step 
protocol for a duration of 500 milliseconds, injecting current from -40pA, every 20pA. 
Unfortunately, we were unable to identify any motor neurons which were electrically 
excitable for both patient and control cells at 6 to 9 weeks differentiation, the majority 
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of cells displaying no firing or single firing action potentials (figure 4.12b). As no 
repetitive or adaptive action potentials were recorded, the lack of action potentials 
suggests an immature motor neuronal phenotype. 
In order to ascertain the electrical properties of the neurons, we checked the resting 
membrane potential (RMP), membrane capacitance, and series resistance for each 
recording across all 6 cell lines. All the recordings considered for analysis were taken 
with less than -50pA of leak current and less than 20MΩ of series resistance. Although 
patients exhibited a trend towards a lower membrane capacitance (average 17.79pF 
control and 13.58pF patients), and a lower resting membrane potential (average of -
11.22mV control and -14mV patients), results revealed no significant difference 
between patients or controls in either of these two parameters (tables 1- 3 figure, 
4.12c and d). Whilst the similarities suggest that any differences found will not be due 
to changes in the health of the cell or membrane baseline capacitance between 
patient and control cell lines, the RMP is too low to consider the neurons as a mature, 
as we expect to have values around -40 to -60 mV for a mature neuronal cell.  
 
 
Table 4.1:  Raw data for membrane capacitance (Cm) (pF) and resting membrane potential (RMP) 
(mV) for patient and control cells iPS-derived motor neurons 
 
 
 
 
 
 
 
 
 
 
Control Patient 
Cm (pF) RMP (mV) Cm (pF) RMP(mV) 
13.33 -10 12.67 -20 
28.62 -10 10.3 -10 
10.32 -12 6.61 -20 
14.11 -5 22.51 -22 
22.51 -12 11.13 -6 
11.55 -8 20.67 -8 
18.13 -20 11.2 -12 
28.85 -12 
 
- - 
10.69 -12 - - 
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Table 4.2:  Average membrane capacitance (pF) for patient and control iPS-derived motor neurons 
 Control Patient 
Average Cm (pF) 17.79 13.58429 
SD 6.885968 5.369852 
N 9 7 
 
 
Table 4.3:  Average Resting membrane potential (RMP) for patient and control iPS -derived motor 
neurons 
 Control Patient 
Average RMP (mV) -11.2222 -14 
SD 3.823256 6.047432 
N 9 7 
 
 
 
Alongside measuring the excitability of neuronal cells generated from our 
differentiation protocol, we also performed voltage clamp experiments to measure the 
transmembrane ion currents required to maintain voltage in our cells. By identifying 
general inward and outward currents we may identify why we were unable to see any 
action potentials in our recordings. Results revealed minimal inward currents with no 
significant differences between patients and controls (figure 4.12 g) which when 
normalised to individual cellular capacitance, a reading directly proportional to cell 
surface area and an indicator of the size of the cell, again revealed no significant 
patient differences (figure 4.12 i). This suggests that both patients and controls have 
little to no inward current activity. With regards to outward currents, cells revealed 
higher amplitudes of currents compared to inward currents (figure 4.12h), and when 
normalised to membrane capacitance, results showed a trend towards separation of 
patient and control outward current density under higher voltage conditions (figure 
4.12 j). This finding suggests that the outward currents are more developed than 
inward currents in our cell models.
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Figure 4.12: Electrophysiological characterisation of iPS-derived neurons reveals no electrical activity in patients 
or controls. a) iPS-derived cells were selected based on MN-like morphology. b) Sample current-clamp recordings 
from a patient ALS-derived neuron differentiated for 9 weeks. c) Average membrane capacitance and d) Resting 
membrane potential in patient and control iPS derived cells revealed no significant differences. e) control and f) 
patient sample voltage-clamp recordings from iPS-derived neurons. g) voltage-clamp to measure general inward 
currents and h) outward currents for both patient and controls. i) Inward current amplitude and j) outward current 
amplitude normalised to cell capacitance in patient and control iPS-derived neurons. (Depolarization protocol from -
80mV to +60 mV; controls n=9, patients n=7; data are mean ±SEM, analysed with paired t-test)  
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4.4 C9ORF72  AND ALS  SPECIFIC CHARACTERISATION  
 
4.4.1  IPS  CELLS AN D IPS-DERIV ED CELLS EXP R ES S  RNA  FOCI  AN D 
D IP EPTI DE REP EAT  PR OTEIN S  
 
 
The discovery of an expansion mutation in C9ORF72 classified this subtype of ALS as 
nucleotide repeat expansion disorders. As previously reported, pathogenic expansions 
in diseases such as myotonic dystrophy caused the formation of aberrant nuclear 
accumulations called RNA foci (Taneja et al., 1995), it prompted the question: are 
these pathognomonic aggregates  present in C9ORF72-related ALS models? Therefore, 
for the next step in the characterisation of iPS-derived cells, it was important to 
establish the presence of RNA foci, which are hallmarks of the hexanucleotide repeat 
expansion in cells (DeJesus-Hernandez et al., 2011) and proposed indicators of disease 
pathogenesis, whilst also checking its presence as an indicator of stability of the 
expansion in the model.  
 
Induced pluripotent stem (iPS) cell culture can hold inherent technical and practical 
limitations which can impede the generation of enough material of motor neurons for 
southern blot detection of the repeat expansion in differentiated cells. Probing for RNA 
foci can be achieved through single cell investigation which is achievable with smaller 
quantities of material through RNA fluorescence in situ hybridisation (RNA FISH). In 
addition difficulties obtaining an optimal antibody for C9ORF72 protein detection 
meant confirmation of the presence of RNA foci would act to validate this molecular 
pathology in patient cells compared to controls in the absence of western blotting or 
immunocytochemistry for the protein. Whilst RNA FISH would identify whether or not 
an expansion was made and its presence suggests stability during the time 
investigated, it does not tell us about the size of the expansion. Nevertheless, many 
studies have successfully used RNA FISH as one methodology to confirm the presence 
of the expansion in similar cell models of ALS (Almeida et al., 2013, Donnelly et al., 
2013a, Sareen et al., 2013). 
 
First, differentiated iPS cells at 6 weeks were fixed and probed using a TYE-563-labelled 
LNA (16-mer fluorescent)-incorporated DNA probe against the sense RNA 
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hexanucleotide repeat or antisense RNA hexanucleotide repeat. Both sense and 
antisense foci were detected in patient iPS cells but not controls, with sense foci found 
in 31.89% of cells, and antisense foci found in 21.64% of cells (figure 4.13 and 4.14). In 
good support that the FISH staining was specific and confirming the RNA composition 
of the aggregates, staining was only observed in C9 patients and in the absence of 
RNase A (figure 4.13 h and 4.14 d). Of note, cells exposed to the sense RNA probe at 
day 0 also exhibited foci present in patient but not control cell colonies (figure 4.13 a, 
c), suggesting that the foci do not develop over the differentiation protocol.  
 
Out of the cells with foci present, the majority of both sense and antisense foci 
observed were cytoplasmic in location, with occasional nuclear or peri-nuclear foci 
identified (figure 4.13 g, figure 4.14 c yellow arrows). However where nuclear located 
foci were identified, they contained a single aggregate, compared to cytoplasmic foci 
which tended to be present in larger numbers. Not all cells contained RNA foci, 
independently screened assays found 31.89% of total cells contained sense RNA foci, 
and 21.64% of total cells contained antisense RNA foci (figure 4.13 i, 4.14 e). The 
number of foci found per cell showed a similar distribution for both sense and 
antisense species, with 1 being the most common number of foci per cell (figure 4.15).  
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Figure 4.13: iPS Cells and differentiated iPS-derived cells from C9ORF72-ALS patients contain sense RNA foci. Fluorescence in situ hybridisation (FISH) using a sense probe to 
GGGGCC revealed the presence to RNA foci in iPS cells at day 0 c) and 6 weeks of differentiation (d-g) in patients (c-g), but not controls (a-b). Foci were mainly found in the 
cytoplasm of cells e) white arrows, but also could less frequently be found in the nuclei of cells g) yellow arrow. h) Treatment with RNase A removed foci confirming the foci 
were made of RNA. i) Around 30% of patient cells had sense foci. J) Histogram showing the number of foci found per patient cell. Hoechst labels nuclei blue (e) and g) inserts 
from d) and f) respectively. Scale bar= 50μM a),b) c), d) and f); Scale bar = 10μM e), g), h) Error bars ± SEM).  
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Figure 4.14: Differentiated IPS-derived cells from C9ORF72-ALS patients contain antisense RNA foci. Fluorescence in situ hybridisation (FISH) using an antisense probe 
to GGGGCC revealed the presence to RNA foci in iPS cells at 6 weeks of differentiation in patients (b-c) but not controls a). Foci were mainly found in the cytoplasm of 
cells c) white arrows, but also could less frequently be found in the nuclei of cells c) yellow arrow. d) Treatment with RNase A removes foci confirming the foci were 
made of RNA.  e) Around 20% of patient cells had sense foci. f) Histogram showing the number of foci found per patient cell . Hoechst labels nuclei blue (c) insert from b). 
Scale bar= 50μM a), b), c); Scale bar = 20μM c); Scale bar =10μM d)  Error bars ± SEM). 
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Figure 4.15: Comparison of sense and antisense foci number per cell. Histogram reveals antisense 
foci are more likely to be prevalent in higher numbers per patient cell compared to sense foci. (Data 
presented as percentage of total patient cells with foci, mean of  n=3 independent experiments, Error 
bars ± SEM). 
 
The heterogeneity of non-coding repeat expansion disorders has led to a number of 
hypotheses about the way in which the repeat may lead to disease in C9ORF72-ALS. 
One possibility is that hairpin secondary structures formed by the repeat mRNA can 
cause non-ATG-initiated (RAN) translation, a phenomenon which has been found in 
other repeat expansion disorders to form protein aggregates which are potentially 
pathogenic (Zu et al., 2011). A study by Zu and colleagues found that even after 
mutation of the ATG initiation codon, transcripts were still generated in all three 
reading frames and produced three protein products polyGln, polyAla and polySer. 
Mori et al. hypothesised this would occur in C9ORF72- repeat expansion disorders, and 
found translation of GGGGCC could result in five protein products with sense and 
antisense translation called di-peptide repeat (DPR) proteins. 
Given that the RNA foci were predominantly found in the cytoplasm and erroneous 
export of intronic RNA is required to produce DPR proteins we thought it was likely 
that this model would express DPR proteins. Therefore, using antibodies against DPR 
proteins for one of the DPR proteins polyGly-Ala (GA) we probed our cells via ICC. In 
the same methodology for RNA foci visualisation, we scanned the entirety of the cells 
using z-stacks on a confocal microscope to gain images from multiple planes. We found 
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Figure 4.16: iPS cells at day 0 have cytoplasmic RNA translation proteins.  
Immunocytochemistry of IPS cells at day 0 reprogrammed from b) patient fibroblasts have 
cytoplasmic GA di-peptide repeat proteins (white arrows) which are not found in a) controls. 
c) Insert of b). Hoechst labels nuclei blue (a and b Scale bar=50μM; c Scale bar =10 μM)  
patient iPS cells at day 0 contained cytoplasmic GA DPR proteins which were not found 
in control iPS cell colonies (figure 4.16). Although attempts were made, unfortunately 
we were unable to convincingly visualise other DPRs including PA GP and PR in our 
cells. 
 
These results prompted us to examine if GA DRP’s presence correlated or co-localised 
with RNA foci in patient cells, therefore we next examined the presence of sense RNA 
foci using FISH coupled with ICC for anti-GA DPR proteins. Results revealed iPS cells at 
day 0 and differentiated iPS-derived cells at 6 weeks could be found with both RNA foci 
and GA DPR proteins (figure 4.17). Images identified that both aggregate types were 
predominantly cytoplasmic in line with previous observations. The two species were 
found as single entities in individual cells, but also RNA foci and GA DPR proteins could 
be found together in the same cell (figure 4.17). Although on occasions the two species 
could be found co-localised it was rare (figure 4.17). Similar to previously found 
results, foci were present from the beginning to the end of differentiation, and were 
heterogeneous in size. 
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Figure 4.17: C9ORF72 iPS cells and differentiated iPS cells display both sense foci and GA DPR proteins . a) iPS cells reprogrammed from patient 
fibroblasts display sense RNA foci and GA DPR proteins. b) and c) differentiated iPS cells at 6 weeks show cytoplasmic RNA foci and DPR proteins 
which co-localise (yellow arrow) and exist as separate aggregates (white arrow). (Hoechst label s nuclei blue c) insert from b). Scale bar= 50μM 
a), b); Scale bar= 5 μM c)) 
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4.4.2  CHAR ACT ERIS ATION  O F I PS-  DERIV ED CELL TDP-43  LO CALIS ATIO N  
 
The sequestration of RNA binding proteins and splicing factors in non-coding repeat 
expansion disorders has been proposed as a possible mechanism of disease 
pathogenesis for ALS (Todd and Paulson, 2010). Tar DNA binding protein 43 (TDP-43) is 
an important DNA and RNA binding protein of which mutations are known to 
contribute towards the pathogenesis of ALS. Re-localisation of TDP-43 from its 
predominantly nuclear location to the cytoplasm, as well as aggregate formation is a 
well described cellular pathology of ALS and FTD cases (Lagier-Tourenne and 
Cleveland, 2009). For this reason we chose to investigate the cellular localisation and 
potential redistribution of TDP-43 in conjunction with antisense foci. Whilst not found 
in fibroblast cells, antisense foci have been previously identified to correlate with TDP-
43 distribution in the motor neurons of C9-ALS patients (Cooper-Knock et al., 2015b). 
As previously identified, we found antisense foci in patient but not control cells with 
the foci predominantly in the cytoplasm of the cells (figure 4.18 b-e). In addition we 
found that patient cells showed diffuse patterns of TDP-43 staining, expressing a 
greater proportion of TDP-43 in the cytoplasm, with 42.5% (±SD 2) of patient cells 
expressing cytoplasmic TDP-43 staining compared to 21.3% (± SD 10) of controls, 
although this difference did not reach significance (figure 4.18 a-f). We found no 
observed correlation between cells expressing antisense foci and cytoplasmic TDP-43, 
with some cells showing cytoplasmic TDP-43 and no foci (figure 4.18 a-f). 
 
As the redistribution of TDP-43 did not reveal a strong nuclear depletion phenotype, 
we decided to quantify the intensity of TDP-43 nuclear staining to determine the 
extent of nuclear TDP-43 loss, as well as total cell staining between patients and 
controls to determine total TDP-43 levels. Of note, patient cells exhibited significantly 
lower levels of nuclear TDP-43 compared to controls, as well as significantly lower total 
levels of TDP-43 in cells (figure 4.18 g).  
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Figure 4.18: TDP-43 does not co-localise with antisense foci in patient iPS-derived cells but does show reduced nuclear expression. a) control differentiated iPS cells with 
predominantly nuclear expression compared to b-e) patient cells with reduced nuclear expression and a more diffuse pattern. Antisense foci were detected in patient cells 
but not controls, however, there was no co-localisation of TDP-43 aggregates with the foci c) and e). f) Quantification of the number of cells with predominantly nuclear or 
cytoplasmic TDP-43 revealed no significant differences between patients and controls. g) Quantification of the intensity of nuclear TDP-43 compared to total TDP-43 in the 
cell revealed a significantly lower level of nuclear and total TDP -43 intensity in patients compared to controls.  Hoechst labels nuclei blue (c) insert from b). Scale bar= 50μM 
a), b), d); Scale bar = 5μM c) and e)  Data presented as percentage of total cell number f), and as percentage of control g),  mean of n=3 independent experiments, ±SEM, 
**p=<0.005 ***p=<0.0005 analysed with two-way ANOVA, Bonferroni’s correction). 
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4.5 DISCUSSION  
 
4.5.1  IPS-DERIV ED CELLULAR MO D ELS  FOR  ALS 
 
Generating motor neurons from human induced pluripotent stem cells is fast 
becoming a desirable method for the production of new cell models of C9ORF72-ALS. 
However, with the techniques having only just seen their 10th birthday, many 
variations remain not only in the yield of desirable cells produced, but also in the 
differentiation protocol used between groups around the world. Until these variations 
diminish, it continues to be an imperative step to describe the desired population of 
cells generated, by ensuring cellular descriptive markers are present, and expected 
functionality is maintained. 
 
Upon initial inspection of the cells, it was apparent we were observing a culture of 
multiple cell types, with Hoechst staining revealing several sizes of nuclei indicative of 
a mixed population. Whilst we could identify by morphology neuronal and motor 
neuronal populations displaying features such as long and branching neurites, and of 
note to motor neurons, triangular cell bodies, we also saw cells with large diffuse 
cytoplasm and a stellate like appearance which may be associated with a more 
astrocytic-like glial population. Whilst we did attempt to stain and quantify glial 
populations for Glial fibrillary acidic protein (GFAP) and S-100β, ICC experiment 
unfortunately failed to label populations of cells convincingly, and we were unable to 
optimise this procedure under the time constraints of this project. Future work to 
optimise the use of such antibodies would help to confirm the prevalence of glial and 
support cells derived from our differentiation techniques. This quantification step 
could be important, as recent work has identified that oligodendrocytes, in addition to 
astrocytes, could contribute to toxicity in motor neurons through impaired lactate 
signalling, which is ALS subtype specific (Ferraiuolo et al., 2016). ALS treatment may 
require a multiple targeted approach, as studies have recently shown that targeting 
both neurons and astrocytes through separate mechanisms can yield significant 
positive effects on survival and motor function (Frakes et al., 2017), therefore future 
work to characterise cell populations other than motor neurons will be important for 
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future studies and trials using iPS-derived cell models. Despite specific labelling in our 
studies, based on morphology, intermediary bipolar astrocytic populations with long 
projections were found present, which have been previously identified as radial glial 
rather than astrocytes, and may be related to the maturity of these cellular 
populations (Li et al., 2015). One particular observation made in reference to neuronal 
populations, was that cells found remaining in EBs or present in densely packed 
populations were more likely to be of neuronal identity, projecting longer and more 
processes therefore communicating with more neighbouring cells of both neuronal 
and astrocytic morphology (figure 4.5, 4.7). One reason for this may be that the 
neuronal cells are providing increased trophic support in large numbers, which may aid 
their growth and development as well as their connections to other cells. Indeed 
studies have found that plating larger cell numbers resulted in improved cell survival of 
iPS-derived neurons (Beaudet et al., 2015). 
 
Consistent with the literature, as these observations highlighted we were producing a 
mixed population, it was importantly for us to identify and quantify the neuronal and 
motor neuronal cells. In our population, we were able to first see cells labelled with 
markers of neuronal lineage from 2 and 4 weeks of differentiation for Tuj1 and MAP2 
respectively. A historical paper, written in 1954 by Nieuwkoop and Nigtevecht, was 
first to outline the hypothesis that the prosencenphalon or forebrain, developed by a 
default process called activation for the anterior tissues, whilst a subsequent 
transformation process occurred for posterior tissues such as the rhombencephalon or 
hindbrain, and spinal cord (Nieuwkoop and Nigtevecht, 1954). More recent work has 
proposed molecules such as retinoic acid and FGF signalling to be potential 
contributors to this developmental pathway (Stern, 2001). As Tuj1 expression was 
found in cells as early as 2 weeks into the differentiation protocol (figure 4.4), it 
suggested the default neural lineage hypothesis may indeed be correct. Our cells then 
later showing expression of motor neuronal markers (figure 4.4, 4.6, 4.7), is consistent 
with the notion that spinal cord development is the next step in the differentiation 
process, and exerts confidence in our protocol for neuronal and motor neuronal 
lineage differentiation. 
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Markers accepted in the literature for lower motor neuron (LMN) characterisation are 
Hb9 and islet 1/2, which along with Tuj1, were found to be expressed in our 
differentiated cells (figure 4.6, 4.7 ), confirming their neuronal and motor neuronal 
identity. However caution must be noted as Hb9 expression, whilst thought to be a 
specific marker for MNs is also found in interneuron cell populations (Wilson et al., 
2005), and can be absent from some populations of LMNs (Thaler et al., 2004). In turn, 
islet 1/2 expression and Hb9 expression can diminish as motor neurons mature. 
Therefore a battery of markers were used and it is the combination of all the markers 
expressed, plus the use of a mature motor neuronal marker such as ChAT that helped 
us to confirm that the cells are of LMN descent.  
 
Choline acetyl transferase (ChAT) is a cholinergic neuronal marker which can be used 
to label mature LMNs, however staining proved to be difficult in our cellular 
populations which at first was thought to be due to a lack of mature motor neuronal 
development (figure 4.8). Yet, after optimisation of the staining protocol, labelling 
motor neuronal populations at 6 weeks and beyond (figure 4.8 b, c) indicated that our 
protocol for differentiation was able to generate populations of mature motor 
neuronal cells. Interestingly, it is also possible to further define MN types generated 
such as rostral or caudal by identifying Hox gene expression patterns which modulate 
the differentiation of different motor neuron subtypes in development (Lippmann et 
al., 2015, Philippidou and Dasen, 2013). One example would be to define LMNs into 
lateral motor column (LMC) and axial muscle innervating medial motor column (MMC) 
subtypes, by analysing gene expression profile markers, such as retinoic acid 
dehydrogenase for LMC-LMNs (Sockanathan and Jessell, 1998). These steps are going 
to become increasingly important in the use of differentiated MNs from iPS cells for 
the analysis of ALS subtypes such as bulbar or lower limb onset, and are possible 
future extensions to the immunocytochemical characterisation performed here. 
 
An important point to make with motor neuron differentiation protocols is that 
different groups use varying protocols to achieve MN cultures, a point which was 
reviewed in a recent publication, with protocols found to produce yields of motor 
neurons ranging from 20% to 95% (Sances et al., 2016). We have obtained a mixed 
population of cells as identified by morphology, however we have generated a 
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subpopulation of motor neurons as characterised by marker staining to be 38.3% in 
controls and 24.9% in patients, and is a yield comparable to recent studies and 
characterisation techniques (Lopez-Gonzalez et al., 2016). Despite the trend towards 
reduced MN cell numbers in patient samples, this difference was not significant, which 
is in line with previous reports of differentiation of iPS cells to motor neurons (Devlin 
et al., 2015, Donnelly et al., 2013a). Interestingly, an overall figure of 31.62% of motor 
neurons across both patients and controls was found which is akin to the yield of 30% 
of motor neurons obtained by Amoroso and colleagues who used a very similar 
protocol to ours. They utilised the same factors for similar time periods, and also 
started differentiation with EB formation and neural induction, followed by motor 
neuron generation and neural maturation (Amoroso et al., 2013).  
 
At the time of MN differentiation, the studies which obtained higher yields of MNs, up 
to 95% had not yet been published (Du et al., 2015), and as the optimisation and assay 
development for a new protocol for MN would take a considerable amount of time 
and resource, within the scope of this project it was decided to use previously 
established protocols for MN generation (Yang et al., 2014b). However, future studies 
could adopt a different approach in aim to increase MN cell yield from differentiation. 
Recent studies have found that changing the concentration of retinoic acid and 
purmorphamine throughout differentiation, for instance from 0.1μM to 0.5μM (RA) 
and 0.5μM to 0.1μM (PUR), coupled with use of CHIR99021 to activate Wnt signalling, 
can increase LMN yield to 95% (Du et al., 2015). Manipulation of RA throughout 
differentiation may also help to deliver motor neurons of more specific LMN 
populations (Maury et al., 2015, Lippmann et al., 2015) therefore may be a strategy 
that works to improve our differentiation in two ways. Additionally, future work to 
establish the percentage of glial cells for instance astrocytes, and other neuronal 
subtypes such as interneurons would be interesting to reveal the make-up of the total 
population. Such studies would also point towards mechanisms by which we can refine 
our differentiation protocol to increase the yield of MNs produced, which may enable 
us to successfully purify mixed populations to achieve close to 100% MN’s. 
 
When we observed total cell counts for 6 weeks after the differentiation protocol was 
complete, cells saw a steady decline in survival over time, and interestingly no 
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difference was seen between patients and controls in rates of survival (figure 4.11). 
This result matches previously reported studies on iPS derived motor neuron cell 
death, which have also found no difference between C9ORF72 patients and control cell 
survival (Sareen et al., 2013, Devlin et al., 2015, Donnelly et al., 2013a). However, more 
recent work has found, upon closer biochemical analysis, increased cleaved caspase-3 
is found in patient cells indicative of aberrant apoptotic activation (Dafinca et al., 
2016). Employing caspase-3 cleaveage assays in further work on our cells may reveal 
similar sub-levels of degeneration not thus found from our cell counts, and could be 
key to identifying a cell death phenotype in our models. In other studies, SMA-iPS 
derived cell models and non-disease controls produce a comparable percentage yield 
of MNs at the end of the differentiation protocol. However, beyond this, longitudinal 
observations note a greater reduction in SMA-iPS derived patient cell numbers 
compared to controls, in what the authors describe as a possible degenerative 
phenotype of the model (Ebert et al., 2009). An explanation for a lack of a 
degenerative phenotype could stem from the fact the iPS cells are embryonic in 
nature, and as ALS is a disease found with increased prevalence with age, the iPS-
derived motor neurons produced may not yet express the lifetime of stress and 
triggers required for the onset of disease. The finding that SMA iPS cell models do 
show degeneration post-differentiation may support this, as SMA is usually a 
childhood disease. One lab have thought of an inventive solution to the problem, by 
over-expressing progerin, a truncated Lamin A protein found in premature aging 
disease Hutchinson-Gilford progeria syndrome (HGPS), in iPS- derived cells (Miller et 
al., 2013). The study not only confirmed that age-related markers are not re-developed 
over culture in iPS-derived cells, but also found that overexpression of progerin 
resulted in an increased degenerative phenotype. As the work was performed in 
neuronal cell models of Parkinson’s disease, it provided potential new mechanisms to 
improve iPS cell derived models for late-onset diseases. In addition, newer techniques 
to directly re-programme human somatic cells to neurons could be used in future 
experiments as complementary models to those investigated here (Mertens et al., 
2015). This is because the direct conversion to motor neurons does not cause the 
complete removal of epigenetic features developed in the life of the somatic cell; 
features which may be important in conferring an aged phenotype in the 
differentiated cells of interest.  
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Interestingly, the results in SOD1 iPS-derived models see different results to C9ORF72 
iPS-derived cell models, with patient cells in one study found to display a more 
aggressive cell death phenotype with increased apoptosis compared to controls 
(Kiskinis et al., 2014). As SOD1 ALS onset is in adults, why do we see a cell death 
phenotype in the iPS-derived MNs of SOD1 models but not C9ORF72?  As mouse 
models of C9ORF72 have also failed to produce a strong degenerative phenotype that 
models ALS as well as SOD1 mouse models have done previously, it highlights distinct 
phenotypes and pathways to disease which may not be so easily comparable. A reason 
for this could be that C9ORF72 ALS is more likely to lead to pathogenesis though 
exposure to lifetime cellular stressors compared to SOD1-related ALS, which may 
explain why some people have been found to contain the C9ORF72 mutation without 
developing ALS. It is possible, a “second hit” of additional cellular stressors such as 
increased oxidative stress may help C9ORF72 cell models mirror the human phenotype 
more accurately. Alternatively, it has been suggested that multiple events are required 
for ALS to occur, with a paper by Al-Chalabi et al. has suggested from population 
modelling studies that 6 steps are required which if identified could reveal a pathway 
towards disease (Al-Chalabi et al., 2014). Additionally, work to elucidate the 
differences between these two models of ALS- iPS derived cell models, for instance via 
direct comparison of MNs cell yield, cell survival, and manipulation of survival 
pathways, could reveal if the differences found in survival between these models are 
due to fundamental and thus important differences in ALS pathogenesis, or are 
artefactual through differences in iPS cell model differentiation and cell culture 
between laboratories. 
  
Mature primary motor neurons repetitively fire action potentials in response to a 
depolarizing stimulus, so in a measure of the iPS-derived motor neuron maturity, 
whole cell patch clamp electrophysiological recordings were taken on individual iPS 
derived motor neurons to measure depolarization evoked action potential firing. 
Although it is expected to see action potentials in the time frame of 6 to 9 weeks of 
differentiation, some studies note recordings of action potentials as young as 4 weeks 
into differentiation where cells are found to express increased spontaneous firing and 
hyperexcitability (Wainger et al., 2014). Alternatively, others have found that at later 
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time points (9 weeks and beyond) iPS derived neurons show normal spontaneous and 
depolarisation induced action potentials (43 cells out of 60) (Sareen et al., 2013). This 
prompted us to identify if we could record normal depolarization induced action 
potentials in our differentiated motor neurons. The results obtained show that 
unfortunately were unable to record repetitive firing action potentials evoked by a 
depolarising stimulus in the majority of cells, with only a few cells displaying single 
action potentials (2 out of 100), in waveforms which displayed wide spikes (figure 
4.12b). The lack of action potential generation and the shape of those that were 
generated suggest an immature phenotype of the cells (Sances et al., 2016, Johnson et 
al., 2007, Cashman et al., 1992). Of note, it has been previously described that cell lines 
can display varying action potential firing rates across different rounds of 
differentiation (Wainger et al., 2014), therefore it may also be appropriate to measure 
multiple further rounds of differentiation at these time scales for confirmation. 
 
Membrane capacitance is a measure of a cells ability to hold charge for a particular 
voltage across the membrane, and is a commonly used measure in electrophysiology. 
The membrane capacitance is proportional to the size of the cell; a large cell will have 
a larger membrane which holds more channels, therefore would display a higher 
capacitance, which is why we used this parameter to normalize the values of the 
currents in voltage-clamp mode. While, iPS derived motor neuron models do display a 
lower capacitance than in vivo animal models (Gogliotti et al., 2012), the capacitance 
measured in our cells for both patients and controls was particularly low (figure 4.12c) 
especially in comparison to previous reports of capacitance in similar cell models 
(Wainger et al., 2014). This suggests cells with low levels of excitability, of a smaller 
size with less complex cytoarchitecture and arborisations, less membrane surface area, 
and therefore fewer channels. Despite the low measured cellular capacitance, the 
capacitance measured in controls (17.70pF) was similar to those recorded in immature 
hES-derived neurons recorded by other groups at 4 weeks of differentiation (17.0pF) 
(Johnson et al., 2007). As they found an increase in capacitance with extended tissue 
culture, they suggested capacitance can act as a measure of maturity developing in 
cells which supports prolonged tissue culture times for our cell models prior to 
recording. As motor neurons are large cells, the low capacitance recorded again 
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suggests an immature phenotype representative of smaller underdeveloped cells in 
our culture. 
 
A spinal motor neuron holds a hyperpolarized resting membrane potential to aid 
action potential generation and electrical signal transmission in the cell, therefore by 
measuring this parameter in iPS-derived motor neurons it acts as an additional form of 
characterisation. Of note, similar discrepancies were found in the resting membrane 
potential which were measured to be higher in our cultures compared to previous 
reports (figure 4.12d) (Wainger et al., 2014, Sareen et al., 2013). Although a 
depolarised resting membrane potential is common in iPS cells (Sances et al., 2016), 
the higher resting membrane potential as observed in our cell models may point to an 
increase in sodium channel inactivation which will act as a preventative measure for 
the generation of action potentials (Wainger et al., 2014). Other motor neuron like cell 
models such as NSC-34 cells show a similar relationship between the ability to fire and 
resting membrane potential; NSC-34 cells with a resting membrane potential above -
20mV are unable to fire action potentials (Cashman et al., 1992). Again, this aberrant 
measure found in our cells reflects an immature neuron that requires further 
development in culture, with previous studies showing over several weeks significant 
hyperpolarisation of cell membranes with time in culture (Johnson et al., 2007).  
 
To confirm whether or not collective outward or collective inward-bound currents 
were responsible for the lack of action potentials, voltage-clamp recordings were 
made on both patient and control cells. Results revealed larger out-bound currents 
than in-bound currents (figure 4.12 g-j). When there is no depolarising current entering 
the cell this could be due to a lack of mature and developed sodium channels, 
potentially offering another explanation for the lack of firing in these cells. Further 
studies to block specific ion channels in iPS-derived motor neurons would help to 
answer this question. Another explanation for this difference could be that the 
outward channels are trying to compensate for an already high resting membrane 
potential (table 4.1) to reduce the RMP to a more mature hyperpolarized level 
(Johnson et al., 2007, Wainger et al., 2014). 
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Of note, two caveats of the electrophysiological recordings obtained above are: firstly, 
we have been selecting cells based on morphology, rather than by labelling for motor 
neuron markers, which means in some instances we may be recording from neurons 
which are not motor neuronal due to the mixed population of cells present. Whilst 
previously published work has also been known to use trapezoidal cell bodies and 
emitting processes as selection criteria (Sareen et al., 2013), recently, we have made 
successful attempts to generate our own lentiviral particles that transfect Hb9 
expressing motor neurons only. Due to the time limitations of this project we were 
unable to utilise this technique to visualise motor neurons for electrophysiological 
recording. However, future attempts will use this marker to pinpoint and isolate motor 
neuronal cells in our cultures. Secondly, our voltage-clamp recordings are currently 
examining general outbound and general in-bound currents without the use of ion-
channel blockers to isolate specific currents. This more general measure has previously 
been performed in similar iPS cell models of ALS (Dafinca et al., 2016), and although 
we can say that the inbound currents are largely composed of sodium, and the 
outbound currents of potassium, future work to employ the use of channel blockers 
would isolate and define currents further. Tetrodotoxin (TTX) to block sodium channel 
inbound currents, 4-aminopyridine (4-AP) would eliminate fast inactivating potassium 
currents, Tetraethylammonium (TEA) could be employed to diminish further sustained 
potassium outbound currents, and 6-cyano-7-nitroquinoxaline-2-3-dione (CNQX) could 
be used to block AMPA-receptor mediated currents important for synaptic activity. In 
order to see pure or larger inward currents (Sodium and calcium currents), future work 
will use potassium blockers to block outward potassium current.  The inward currents 
of calcium or sodium can be further isolated by adding calcium or sodium channel 
blockers. 
 
 
4.5.2  RNA  FO CI ,  D I-P EP TIDE REP EAT  P ROT EIN S ,  AN D TDP-43  I N IPS  
CELL MO DELS  OF ALS 
 
The presence of RNA foci has long been reported for non-coding expanded nucleotide 
repeat disorders such as myotonic dystrophy (Taneja et al., 1995). It has been shown 
that the expanded repeat is transcribed in both the sense and antisense direction to 
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form pre-mRNA with complex secondary structures. These structures due to their size 
and complexity can aberrantly alter transport, translation and RNA binding protein 
interactions, whilst also aggregating with themselves and RNA binding proteins to form 
the foci structures visualised in disease (Todd and Paulson, 2010). To add to this, due 
to the RNA foci sequestering RNA binding proteins, it prevents them from undergoing 
their roles elsewhere in the cell thus adding to the problem.   
 
As C9ORF72-ALS cases contain a non-coding repeat expansion, it was important to 
identify whether or not RNA foci were present, to confirm presence of the mutation 
and show the expansion had survived iPS generation and differentiation. Southern 
blotting was not performed on the iPS cells or originating fibroblasts. However, of note 
lymphoblastoid cells from patient sample 3009 were found to have two expansions 
present, one of 50 repeats and another of more than 2000 repeats (Cooper-Knock et 
al., 2013). Due to an unavailability of lymphoblastoid cell lines for the remaining two 
patients, these have not been sized, however repeat-primed PCR from blood DNA 
samples has identified these patients have more than 30 repeats. Results identified 
that both sense and antisense foci were found in differentiated patient iPS cells but 
not controls (figure 4.13, 4.14) correlating with previous reports which have found 
similar structures in C9ORF72-ALS cases and suggesting that the C9ORF72 repeat 
expansion was still present in patient cells (Almeida et al., 2013, Mizielinska et al., 
2013, Lagier-Tourenne et al., 2013, Donnelly et al., 2013a, Cooper-Knock et al., 2015b).  
 
To show that the expansion was retained in undifferentiated cells, iPS cells at day 0 
were examined for sense foci. Interestingly, sense foci were found at day 0 in iPS cells 
as well as post-differentiation at 6 weeks, suggesting the foci found post-
differentiation were not generated during the motor neuron directed protocol. 
Coupled with previous studies finding RNA foci in fibroblasts from patients with 
C9ORF72 ALS (Lagier-Tourenne et al., 2013), this result suggests that the 
reprogramming of fibroblast to iPS cells and the subsequent iPS cell differentiation, 
does not remove hallmarks of the disease, validating the use of differentiated iPS cells 
as models of C9ORF72-ALS due to their ability to recapitulate disease associated 
pathology (Cooper-Knock et al., 2015b). Further validation of whether or not foci 
remain throughout cell model development could be gained from future work 
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screening the originating fibroblasts used to differentiate these iPS cells for both sense 
and antisense RNA foci. 
 
We found 31.89% of cells contained sense foci, and 21.64% of cells contained 
antisense foci. Out of those found, for both sense and antisense the majority of cells  
contained 1-3 foci per cell, fitting with previous reports of the number of foci found in 
C9ORF72 cell models (figure 4.15) (Lagier-Tourenne et al., 2013, Sareen et al., 2013, 
Mizielinska et al., 2013). Differences in the number of cells with foci as well as the 
number of foci per cell were found between sense and antisense foci. More cells were 
found with sense foci (31.89%) compared to antisense foci (21.64%), yet cells with 11 
or more foci per cell were only observed in antisense conditions (figure 4.13, 4.14, 
4.15). This relates to previously reported findings that antisense foci are found in cells 
less frequently in the total cell population but when they are observed, a higher 
number of species were found per cell (Mizielinska et al., 2013, Lagier-Tourenne et al., 
2013). As tissue culture conditions were consistent, it highlights a potential difference 
in the rate of foci formation or degradation for sense or antisense foci, or possible 
differences in their nuclear export mechanisms, particularly as we made an observed 
finding of larger antisense foci then sense. Additionally, at the time these experiments 
were conducted, the techniques to visualise both sense and antisense foci together in 
cells were still in the process of optimisation. If the foci already counted are not 
coincident then around 50% of cells in the total population are expressing foci. 
Identifying coincident expression of both sense and antisense foci in future work 
would reveal total foci expression at any time as well as any relationships between the 
two. 
 
The foci found were predominantly cytoplasmic which is in contrast to previously 
identified RNA foci studies in ALS (Almeida et al., 2013, Mizielinska et al., 2013, Sareen 
et al., 2013, Lagier-Tourenne et al., 2013). However, the presence of cytoplasmic foci is 
not unusual (Cooper-Knock et al., 2015b), and has been reported to be more 
commonly found in iPS-derived cells (Donnelly et al., 2013a). One explanation for 
increased cytoplasmic foci could be related to the cellular population studied. As 
differentiated iPS cells from a mixed population were analysed, presumably a subset of 
the cells were post-mitotic (of neuronal identity) and others mitotic (glial supporting 
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cells), therefore it is possible that foci in mitotic cells which were once in the nucleus 
may have been pushed out into the cytoplasm at the end of mitosis and so were 
excluded when the nuclei reform; a possibility which has been suggested in foci 
observations in mitotically active fibroblasts (Lagier-Tourenne et al., 2013). Foci have 
been found in iPS-derived neuronal cells, glial cells and non-neuronal cells (Lagier-
Tourenne et al., 2013), and cytoplasmic foci in motor neurons have also been 
previously reported (Cooper-Knock et al., 2015b). Foci expression in a variety of cells 
may mean their presence is context specific; as motor neurons develop to maturity 
gene expression changes will manipulate what proteins are expressed and if they are 
more vulnerable to the presence of foci species. To clarify which cells are more likely 
to contain nuclear or cytoplasmic foci of both species, future work to co-label sub-
populations of iPS-derived cells with glial and neuronal markers would identify this and 
perhaps highlight cell specific patterns. 
 
Due to the G- rich content of the repeat expansion, it has been suggested that complex 
secondary structures could be formed from long sense strands of RNA sticking 
together in parallel and anti-parallel fashions. One of these structures termed G-
quadruplexes is commonly formed from G-rich sequences and is a sense specific 
occurrence frequently found in 5’ un-translated regions, intron 1, and 3’ un-translated 
regions of RNA (Huppert et al., 2008, Eddy and Maizels, 2008). This is of particular 
relevance to the 5’-intron-1 situated C9ORF72 mutation. Indeed, C9ORF72 repeat 
sense RNA transcripts have been found to fold into G-quadruplex stable secondary 
structures (Fratta et al., 2012, Kovanda et al., 2015), with implications for RNA binding 
protein sequestration and foci formation. Interestingly, 3’ G-quadruplex RNA 
structures have been found to be vital for neurite localisation for a subset of neural 
mRNAs (Subramanian et al., 2011). Whilst it remains to be identified if 5’ G-
quadruplexes contribute to mRNA localisation, with predominantly cytoplasmic RNA 
foci identified in our studies, it could be possible that if mRNA G-quadruplexes are 
formed in the iPS-derived neurons, they too could be acting as localisation signals, 
attracting RNA foci elsewhere in the cell and explaining why we have generated a high 
proportion of cytoplasmic RNA aggregates.  
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The presence of cytoplasmic sense and antisense foci suggests nuclear export of the 
RNA sequences, particularly as mRNA export adaptors have been found to co-localise 
with the RNA entities (Cooper-Knock et al., 2015b). However, an important point to 
note is that if mRNA is found in the cytoplasm of the cells, it also means foci would 
have access to the translation machinery in this location. If the RNA is formed of 
complex secondary structures, for instance hairpin loops and G-quadruplexes, this 
could trigger non-ATG initiated (RAN) translation (Zu et al., 2011, Pearson, 2011). 
Expanded polyglutamine repeats formed by multiple CAG trinucleotides are found in 
disorders such Huntington’s disease, spinal spinocerebellar ataxia and myotonic 
dystrophy (Pearson, 2011). Transcription of the repeat containing DNA can be bi-
direction, both sense and antisense, resulting in the formation of two potentially toxic 
mRNAs for translation which when translated through typical AUG translation or RAN 
translation can result in the formation of additional protein products (Pearson, 2011, 
Zu et al., 2011). These in addition to the toxic RNA aggregates are thought to be 
pathogenic. If the expansion in C9ORF72 related ALS was translated into protein 
through this mechanism, it too would create additional intracellular aggregates of di-
peptide repeat proteins it generates from sense and antisense bi-directional 
translation (Mori et al., 2013b, Mori et al., 2013a).  
 
Out of the DPR protein antibodies tested, GA DPR proteins associated with sense 
translation of RNA, were found in both iPS cells at day 0 as well as in differentiated 
cells (figure 4.13, figure 4.14). This matches previous reports where this pathology has 
also been found in C9ORF72-related ALS (Mori et al., 2013b, Ash et al., 2013, Almeida 
et al., 2013). We were unable to identify other DPR proteins in our cells however this 
could be because some studies have reported GA to be the most commonly found DPR 
protein in cells  due to being the most aggregation prone (Zhang et al., 2014). 
However, it is important to note if the GA antibody has the strongest affinity this 
statement could be artefactual. The distinct aggregation of the GA protein is also of 
interest, particularly as studies have identified aggregated DPR proteins to be more 
toxic than diffuse staining (Wen et al., 2014), a pattern which could be indicative of 
disease progression. Interestingly, papers reveal different levels of toxicity with DPR 
proteins with some stating PR to be the most toxic (Wen et al., 2014) while other state 
GA as more toxic (Zhang et al., 2014). Wen et al. predict in their results that PR is so 
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toxic it kills motor neurons cells faster than other DPR proteins, thus the reason we 
may not be able to see other DPR proteins could be due to the premature death of the 
cells containing them before visualisation was possible. Future work utilising 
techniques such as dot blot analysis for DPR proteins (Dafinca et al., 2016) while a less 
quantitative technique, could offer an alternative method of detection to ICC where 
the limits of detection for these species are relatively low. 
 
We also observed sense RNA foci co-localised with GA DPR proteins (figure 4.17). 
Although co-localisation of the two entities suggests a possible interaction, additional 
studies will need to be undertaken to identify if similar to antisense reports they are 
mutually exclusive (Gendron et al., 2013), as well as to identify what percentage of foci 
are co-localising and whether or not there a relationship between them. The DPR 
proteins may cause pathogenesis by aberrantly sticking to foci and other proteins in 
the cell, disrupting RNA processing and transport. Certainly synthetic DPR products 
have previously been identified to bind to both nucleoli of cells and RNA binding 
protein hnRNPA2 causing cell death (Kwon et al., 2014), whilst poly-GA has been found 
to specifically bind with and sequester Unc119, a transport factor important for 
neuronal axonal functionality and vital for neuronal cell branching (May et al., 2014). In 
very recent work, GA has been found to co-aggregate with p62, Rad23b and Mlf2 in 
mouse and patients, however similarly to our work the presence of GA aggregates did 
not correlate with neuronal loss or cell death suggesting their contribution to disease 
may be prior to disease onset or part of the asymptomatic portion of ALS (Schludi et 
al., 2017). Indeed, additional recent work has found similarly GP DPR proteins are 
present in significant levels in asymptomatic C9- ALS carriers compared to non-
diseased controls, but did not correlate with disease onset and damage to axons 
suggesting again this could be a marker for “pre-ALS”(Lehmer et al., 2017). An 
interesting additional step for our work would be to establish if antisense foci co-
localise with antisense DPR proteins, anti-PA or anti PR, especially as antisense foci 
have been found in some studies to be more abundant in cells (Lagier-Tourenne et al., 
2013, Mizielinska et al., 2013) implying antisense DPR proteins could also be more 
abundant. 
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TDP-43 mutations are known to cause familial and some sporadic cases of ALS, with re-
distribution of the DNA/ RNA binding protein from the nucleus to the cytoplasm and 
the generation of inclusions in the neurons of ALS patients becoming a common 
pathological marker (Lagier-Tourenne and Cleveland, 2009). Miss-localised TDP-43 has 
also been recently identified to be present in circulating monocytes of ALS patients, 
suggesting this proteinopathy could be used to aid diagnosis (De Marco et al., 2017). 
For this reason, we were interested in characterising our differentiated iPS cells for 
TDP-43 distribution, coupled with screening for our more abundant RNA aggregate, 
antisense RNA foci (figure 4.18). As previously identified, patient cells were found to 
have antisense RNA foci while controls did not. Patient cells were also found to have a 
trend towards increased cytoplasmic TDP-43 staining compared to controls, with a 
diffuse granular pattern observed, which was found in cells bearing RNA foci (figure 
4.18 c, e). Although no significant changes in the number of cells expressing miss-
localised TDP-43 were found, the diffuse granular pattern of TDP-43 yet the presence 
of RNA foci prompted us to quantify the intensity of TDP-43 staining in both the cell as 
a whole and the nucleus. Results revealed that C9 patient cells expressed not only 
significantly lower total levels of TDP-43 in the nucleus, but also significantly lower 
total staining for the protein (figure 4.18 g). Interestingly studies have reported mixed 
results in TDP-43 localisation in patient cells (Lagier-Tourenne and Cleveland, 2009, 
Mizielinska et al., 2013, Bilican et al., 2012, Almeida et al., 2013, Zhang et al., 2015a) 
which may be related to the extent of disease pathology and possibly progression. The 
less apparent nuclear loss and more diffuse cytoplasmic staining found in our patient 
cells may point to an intermediary stage in TDP-43 aggregate formation; particularly as 
we did not observe many TDP-43 inclusions in our cells indicative of a more severe 
TDP-43 proteinopathy. Work looking at FUS miss-localisation has similarly found 
intermediate phenotypes in mice models, including incomplete nuclear clearance of 
FUS, which the authors suggest could represent an early stage of ALS (Scekic-Zahirovic 
et al., 2017). Similar to previous studies (Lagier-Tourenne et al., 2013), we too did not 
identify co-localisation of RNA foci with TDP-43 aggregates, potentially because of the 
low levels of TDP-43 inclusions observed. Again, there have been mixed reports 
documenting the relationship with foci and TDP-43, with some studies reporting no 
relationship between TDP-43 and RNA foci  (Mizielinska et al., 2013, Lagier-Tourenne 
et al., 2013), while others find an association between the two (Cooper-Knock et al., 
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2015b). However, it has not been ruled out that RNA foci and TDP-43 proteinopathy 
may be two independent hallmarks of ALS pathology. In addition, a final note of 
caution must be included as we know we are looking at iPS cells differentiated from a 
clonal population. Therefore, whilst there may be significant changes in TDP-43 
intensity, it is possible that we are showing a decrease in TDP-43 intensity due to 
clonal variation rather than a potentially pathogenic redistribution. However, to 
mitigate this possibility, we have always represented our data as three patients versus 
three controls. 
 
So far, findings in our work identify iPS cells and iPS-derived cells which contain some 
of the features of C9ORF72-ALS reported in previous studies. However, from the work 
performed above we cannot confirm if these are indicative of toxic gain of function 
mechanisms alone, or rule out that our model does not also have C9ORF72 
haploinsufficiency mechanisms towards disease. Nevertheless, it remains to be 
identified if these markers of disease are a cause or a consequence of ALS. Questions 
arise as to why the foci, if prominent in pathogenesis, do not cause disease earlier in 
life, and why when present in unaffected cells of the body such as fibroblasts they do 
not contribute to that cells death. Longitudinal studies to examine if pathogenic 
markers like foci and DPR proteins occur before disease onset may shed light on this. 
Positively, work using antisense oligonucleotides reducing the levels of sense RNA foci 
have been found to rescue toxic effects found in iPS-derived cell models of C9ORF72-
ALS (Sareen et al., 2013, Donnelly et al., 2013a) which suggests they may contribute to 
disease. To add to this, further work needs to be done to identify the effect of 
removing the more abundant species of antisense foci, as well as work to identify how 
the foci cause these toxic effects, which may explain why removing them is a valid 
therapeutic strategy. 
 
 
 
4.6 CONCLUSION  
 
Overall, the work described in this chapter highlights the development of a promising 
cell model of C9ORF72- ALS. We have been able to successfully reprogram fibroblasts 
cells to pluripotency and have generated stocks of iPS cells for 6 cell lines. In addition, 
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we have demonstrated the ability of these cells to be differentiated into neuronal and 
motor neuronal linages, expressing common markers widely associated with these 
fates. Although there is work left to be done with regards to improving their electrical 
maturity, whilst this is a limitation of the model that needs improving to better model 
the disease, these steps are possible with changes to the environment in which the 
cells are currently cultured. As the models generated express molecular pathological 
hallmarks of the C9ORF72 mutation, via the expression of RNA foci and DPR protein 
products, this confirms their ability to recapitulate several newly discovered features 
of the disease. Next, we will be able to take these cell models forward to identify if 
modulation of PTEN has a positive effect on the PI3 cell survival pathway, which may 
translate into increased cell survival and therefore the development of disease 
modifying therapeutics agents aimed at this target. 
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5.1 INTRODUCTION  
 
5.1.1  PTEN  IN HIBI TION  AND KNO CK DOW N I N NEUR ONAL CELL MO DELS  
 
Inhibiting the action of PTEN has been long established to provide a therapeutic 
benefit to neuronal cell models of neuronal injury and neurodegenerative disease. Due 
to this, research groups have employed different approaches to achieving this aim, 
including the use of small molecules to inhibit PTEN, as well as PTEN knockdown (KD) 
via short hairpin RNA (shRNA).  
Taking a look of some of the successes in PTEN KD studies, PTEN depletion has been 
found to rescue the growth of motor neuronal processes in SMA models of motor 
neuron disease (Ning et al., 2010); significantly improve the regeneration of adult 
spinal neuronal axons after injury (Liu et al., 2010); and activate intrinsic regenerative 
outgrowth of peripheral adult sensory neurons (Christie et al., 2010). Comparatively, 
Bisperoxovanadium (BpV) compounds previously believed to be specific PTEN 
inhibitors have shown that inhibition can prevent the degeneration of neurons after 
injury (Walker and Xu, 2014, Walker et al., 2015, Chen et al., 2015, Mao et al., 2013). 
The differences between these two methods are important to their relative effects on 
the cellular activities of PTEN and thus generate distinctive outcomes. Knockdown via 
shRNAs can affect longer term gene expression as well as cause off-target effects, 
whilst inhibition with titratable modulating compounds may provide a method to more 
specifically target the catalytic roles of PTEN in the PI3K pathway. Although both are 
valid methods, recently work has identified caveats in using BpV compounds to inhibit 
PTEN as they were found to inhibit other phosphatases (Spinelli et al., 2015). This lack 
of specificity calls into question potential safety concerns in relation to their further 
use in human clinical trials. 
The limitations of both methods have led researchers to identify new compounds and 
techniques that target PTEN in the PI3K cascade, and Scriptaid is an example of an 
established compound that has been re-purposed for this pathway. Scriptaid as 
discussed in Chapter 3 of this thesis, was identified by Wang et al. in 2012 to promote 
cell survival and protect against traumatic brain injury via the PI3k pathway (Wang et 
al., 2012b). The HDAC inhibitor was found to increase the phosphorylation of both 
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PTEN and AKT, a finding which was verified again in later work (Wang et al., 2015a). 
This positive effect was found in multiple cell types including neuronal cells and glia, in 
a mechanism postulated to act through cellular interactors of PTEN including GSK3-β, 
and provided an indirect route for activating this pathway for neuro-protection. As a 
cell permeable pan-HDAC inhibitor, Scriptaid has been found to inhibit HDAC activity at 
highly potent doses with half maximum inhibition (IC50) of total HDAC activity, -log 6.73 
± 0.02 (0.19μM) identified (Hahnen et al., 2008). For individual HDAC activity Scriptaid 
inhibits HDACs 1, 2, 3 and 6 with IC50’s  of less than 10nM (Shi et al., 2011b). 
Furthermore, studies in cultured PANC-1 cells and MDAMB-468 cells have found that 
Scriptaid presents a low toxicity, with 6μM doses resulting in a significant increase in 
histone acetylation, yet maintaining 80% cell survival (Su et al., 2000).  
Having previously tested Scriptaid in two cell models of ALS (see Chapter 3), whilst the 
first ALS model of SOD1 NSC-34 cells proved to be too sensitive to treatment with the 
drug, the second model of patient and control fibroblast cells was not. Even though 
subsequent findings showed no significant effect of the drug on cell survival, we found 
that basal C9ORF72 patient fibroblast cells expressed significantly lower levels of total 
PTEN protein compared to their controls. This result prompted us to try Scriptaid in a 
cell model which more accurately represented the motor neuron cells affected in ALS 
as well as the previously tested neuronal cell models in other Scriptaid treatment 
studies (Wang et al., 2015a).  
 
5.2 AIMS AND OBJECTIVES  
 
Using the generated and characterised iPS-derived cell models of ALS and controls 
described in Chapter 4, our aims were to identify if manipulation of PTEN via inhibition 
or reduction of PTEN protein expression in the PI3K pathway positively benefited 
survival pathways in these cells. 
Using shRNA techniques we identified the effect of PTEN knockdown (KD) upon iPS- 
derived cells. To confirm whether or not PTEN KD was successful and to validate the 
functionality of the lentiviral particles used, we first performed PTEN KD, followed by 
protein level determination of total PTEN protein and downstream components in the 
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PI3K pathway, through western blotting in two cell models including HEK293 cells as a 
work-up model given the complexity of iPS-derived cells, followed by iPS-derived cells. 
Next, we aimed to further validate the success of PTEN knockdown in neuronal cell 
populations specifically, immunocytochemistry was used to visualize PTEN reduction in 
neuronal cells dual stained for a neuronal specific marker TuJ1 as well as PTEN.  As our 
previous findings had identified a steady decline in total cell numbers between 7 and 
12 weeks of differentiation, we wanted to identify if PTEN knockdown performed at 
the end of the differentiation protocol, reversed this decline by causing a positive 
increase in total cell numbers.  
Finally, with the objective to find a quick and translatable form of PTEN manipulation, 
we used Scriptaid, a PTEN modulator identified to activate the PI3K pathway resulting 
in a positive neuroprotective effect. We first established whether the iPS-derived cells 
were vulnerable to application of the drug, by performing MTT and LDH assays for 
cellular viability and cytotoxicity effects respectively. These experiments would also 
serve to identify the maximum dose and optimal incubation period for the use of 
Scriptaid on iPS-derived cells. We then applied Scriptaid during the 6 week 
differentiation protocol and subsequently quantified the effect that treatment had on 
both patient and control motor neuron cell numbers generated at the end of the 
differentiation protocol.  
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5.3 PTEN  KNOCKDOWN FOR A THERAPEUTIC EFFECT ON ALS  CELL 
SURVIVAL  
 
Firstly, to validate the PI3K pathway as a therapeutic target in the cells generated, we 
decided to perform PTEN knockdown through the use of shRNA lentiviral particles 
which would confirm activation of key components in this cell survival pathway. As 
well as this, by monitoring cell numbers after PTEN knockdown, we also were able to 
identify whether reducing total PTEN protein and activating the PI3K cell survival 
pathway resulted in a beneficial increase in iPS-derived cell number in C9ORF72 ALS 
patients and controls.   
 
5.3.1  SUCCESS FUL PTEN  KN OCK DOWN  IN  HUMAN EMBR YONI C K I DN EY  
(HEK293)  CELLS  
 
To validate the viral and control constructs specificity, we used human embryonic 
kidney (HEK293) cells as a preliminary and less time-intensive cell model compared to 
iPS-derived cell models. Using GFP lentiviral particles of the same viral titre as PTEN 
lentiviral particles, we established that an MOI of 5 was sufficient to transduce the 
cells (data not shown). We then exposed HEK293 cells to lentiviral particles for PTEN 
knockdown and performed western blotting, probing for PTEN, pAKT and AKT to 
determine their protein expression levels. Results revealed an MOI of 5 was sufficient 
to reduce total PTEN protein to a relative level of 5.24, from a relative level of 100 for 
untransduced (UT) controls (figure 5.1 a, b). Knockdown also caused a concomitant 
increase in relative pAKT levels from 100 (UT) and 106 (Scram), to 281 (PTEN KD) 
without modulating total AKT protein levels (figure 5.1 a, c, d). These findings 
confirmed that the virus was able to activate pAKT through PTEN knockdown, and 
therefore could be used in following experiments on iPS-derived cell models for the 
same effect. 
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FIGURE 5.1: Successful PTEN knockdown in HEK293 cells. a) Knockdown of PTEN after exposure to 
lentiviral particles for PTEN reduction caused a  b) reduction in total PTEN protein and a c) 
concomitant increase in pAKT in the PI3k cell survival pathway. d) total AKT(pan) was not affected 
and e) The ratio of pAKT to total AKT(pan) revealed concomitant increases after PTEN knockdown 
compared to controls. MOI =5, n=1. Abbreviations: GAPDH, Glyceraldehyde 3-phosphate 
dehydrogenase; KD, Knockdown; PTEN, phosphatase and tensin homologue deleted on chromosome 
10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
5.3.2  SUCCESS FUL PTEN  KN OCK DOWN  IN  I PS-DERI VED CELLS  
 
Next, to confirm that PTEN can be reduced successfully in iPS-derived cell populations, 
patient and control iPS-derived cells at 6 weeks of differentiation were exposed to 
lentiviral particles for PTEN knockdown, and the results were compared to 
untransduced and scrambled lentiviral particle controls. Western blotting for 
components in the PI3K pathway revealed a significant reduction in both pPTEN and 
total PTEN protein levels after exposure to the virus for 7 days (figure 5.2 a, b, d). 
Although this resulted in a concomitant increase in pAKT unfortunately this increase 
did not reach significance when analysed by unpaired t-test comparing to scrambled 
control (figure 5.2 c). Total levels of AKT remained similar across all conditions, and 
results for the amount of pAKT available in the total population although not 
significant showed a trend for an increase in ratio of pAKT to total AKT after PTEN KD, 
confirming knockdown of PTEN is responsible for increases in the active form of the 
protein which could contribute towards promotion of cell survival (figure 5.2 g).  
As PTEN knockdown was performed in a mixed population of differentiated iPS-
derived cells, we wanted to identify if neuronal populations were specifically affected 
by PTEN knockdown, particularly as pAKT increases did not reach to significant levels 
which could suggest some populations of cells were not targeted. Obtaining a pure 
population of iPS-derived motor neurons can be technically challenging (Sances et al., 
2016) particularly when faced with low yields of MN’s, therefore we decided to use 
immunocytochemistry techniques to dual label cells for total PTEN expression 
alongside the neuronal specific marker Tuj1.  
Results demonstrated that neuronal populations were targeted by the viral mediated 
knockdown of PTEN, because iPS-derived cells after exposure to lentiviral particles for 
PTEN knockdown were found to express lower levels of PTEN staining compared to 
controls (figure 5.3). Both large populations of closely packed cells and single cell 
populations exhibited a reduced expression of PTEN in its endogenous cell body 
location after PTEN knockdown. This result was found in both neuronal cells and non-
neuronal cell populations, highlighting that knockdown was achieved across different 
147 
 
cell types, however some populations of clumped cells may not have been as 
effectively transduced with the virus as single cell populations (figure 5.3 e, f). 
Together these results confirm the successful knockdown of PTEN in iPS-derived cells 
including neuronal populations, validating the use of this technique for the next stage 
of experimentation; to identify if downregulation of PTEN results in a positive change 
to iPS-derived cell number in ALS.  
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Figure 5.2: Successful PTEN Knockdown in iPS derived cells. a) Western blots reveal a significant 
reduction in b) pPTEN and d) total PTEN, compared to scrambled control. A non-significant 
increase in c) pAKT was found after PTEN KD. No significant changes in e) total AKT f) 
pPTEN:PTEN and a non-significant increase in g) pAKT:AKT(pan) were observed. MOI =5, n=3. 
Representative western blot shown. (Data are mean of  n=3 independent experiments of pooled 
cells and normalised to GAPDH loading control. ±SEM,  **p=<0.005, ***p=<0.0005 analysed with 
unpaired t-test)  
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Figure 5.3: PTEN Knockdown in iPS-derived cells successfully reduced PTEN expression in 
neuronal populations. IPS-derived cells showed expression of PTEN in primarily in the cell body of 
cell in a) an d) untransduced and b) and e) Scrambled conditions. c) and f) Cells exposed to 
lentiviral particles showed a reduced expression of PTEN in the cell body, compared to control 
conditions. Representative image shown of pooled cells (Abbreviations: PTEN, phosphatase and 
tensin homologue deleted on chromosome 10; Tuj1 , β III tubulin. Scale bar = 300μM a) to c); Scale 
bar= 50μM d) to f))  
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5.3.3  PTEN  KNO CK DOW N MODULAT ES I PS-DERIV ED CELL SUR VIVAL 
POST-D I FFER ENTI ATIO N  
 
Having confirmed successful PTEN knockdown was achieved in iPS-derived cells to 
produce an associated increase in AKT activation; we next performed PTEN KD on iPS-
derived cells at 6 weeks of differentiation and monitored total iPS-derived cell counts 
in real time up to 12 weeks of differentiation. The results would identify if PTEN 
manipulation via knockdown had an effect on total iPS-derived cell number. Although 
PTEN depletion in other stem cell models has been previously reported not to affect 
the differentiation  of the cells into all three germ linages (Duan et al., 2015), we 
decided to perform the inhibition at the end of the differentiation protocol to avoid 
any negative effects due to the reported important role of PTEN in preventing stem 
cell neoplastic transformation (Duan et al., 2015). 
Both patient and control cells in all conditions showed a steady decline in cell numbers 
from 7 to 12 weeks of differentiation, matching previously identified results for basal 
total iPS-derived cell counts (chapter 4, figure 4.11). However, PTEN knockdown was 
found to induce a significant increase in C9ORF72 patient cell numbers compared to 
PTEN knockdown performed in control cells at 7 to 9 weeks of differentiation, as well 
significant increases compared to C9ORF72 scrambled and untransduced controls at 
the same week of differentiation (figure 5.4). These results suggest that whilst the total 
population of iPS-derived cells does decline with increasing culture length, total cell 
numbers specifically in patient populations can be protected for up to 3 weeks post-
PTEN manipulation, highlighting PTEN manipulation could have a positive effect on cell 
survival. 
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Figure 5.4: PTEN KD causes a significant increase in total iPS-derived cell number at 7 to 9 
weeks of differentiation.  iPS derived cells reveal a steady decline in total cell numbers from 7 to 
12 weeks of differentiation, in both patients and controls. PTEN knockdown caused a significant 
increase in total iPS-derived cell number in patient cells at 7, 8 and 9 weeks of differentiation 
compared to PTEN knockdown in control cells.  (Data presented as percentage of total cell 
number of matched untransduced control, mean of  n=3 independent experiments from pooled 
cells. ±SEM,**** p=<0.0001 analysed with two-way ANOVA, Bonferroni’s correction)  
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5.4 IPS-DERIVED CELL PTEN  INHIBITION THROUGH SCRIPTAID 
TREATMENT  
 
After confirming that the reduction of PTEN expression results in a measurable 
increase in AKT phosphorylation and increased cell number in iPS derived cell 
populations, we decided to investigate the use of a therapeutic molecule with more 
realistic potential for clinical translation than a knockdown approach, which at the 
time of investigation still held difficulties in translating gene therapies to patients. 
Scriptaid, as mentioned above, was proposed as a likely therapeutic agent for research 
due to its therapeutic and neuroprotective effect for damaged neuronal cells (Wang et 
al., 2012a). 
 
5.4.1  IPS-DER IVED CELLS SHOW  LOW  SEN SITIVIT Y  TO  SCRIP TAI D TR EAT MENT   
 
Previously identified, NSC-34 cell models of ALS treated with Scriptaid were found to 
show an increased vulnerability to treatment with the drug (Chapter 3, figure 3.1), 
therefore we wanted to verify if the known active concentrations (Su et al., 2000, 
Wang et al., 2015a) were compatible with differentiated iPS cell models. The 
experiments would also act to optimise the appropriate concentration and incubation 
length to treat the cells with, as we exposed cells to a range of concentrations over 
two time periods. For this, MTT assays were performed after treatment to measure 
the cellular viability when the cells were exposed to 3μM, 10μM and 30μM 
concentrations for 24 hours and 48 hour, time points derived from previous use of 
Scriptaid in the literature (Wang et al., 2012a). Results at both 24 and 48 hour 
incubation periods revealed no significant declines in cellular viability at all three 
concentrations tested compared to vehicle control, which suggests that Scriptaid does 
not have a toxic effect on the viability of the total iPS-derived cell population (figure 
5.5).  
In a second assay, iPS derived cells were examined for changes in cellular cytotoxicity 
via quantification of LDH released into the media. This test would counteract any 
caveats of solely using MTT assays (see Chapter 3) and would also highlight any 
additional effects that may be of importance to the survival biochemistry of the cells. 
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In the same multiplexing methodology employed in the fibroblast cell assays (see 
chapter 3), the MTT assay utilised the cells that were attached to the bottom on the 
multiwall plate, allowing the remaining media to be used for LDH reads to obtain 
directly comparable results. Assays examining LDH release on exposure to Scriptaid 
showed at both 24 and 48 hour incubation periods a trend towards increased LDH 
cytotoxicity with increasing concentration compared to vehicle control, however no 
significant effects on cellular cytotoxicity were identified therefore there is no 
measureable toxicity (figure 5.6). These results suggest, similarly to the MTT findings, 
that the cells exhibit a low level of cytotoxicity to Scriptaid. 
Overall, iPS-derived cells did not display a significant toxic response to treatment with 
Scriptaid prompting continued investigation into the activities of this drug on the cells, 
selecting 3μM for 24 hours as the desired dose and length of incubation. 
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Figure 5.5 The effects of Scriptaid on iPS-derived cell viability as measured by MTT 
assay. Pooled cells from 3 matching C9ORF72 and control iPS-derived cells revealed 
no significant changes in cellular viability  between vehicle and any treated condition 
at both a) 24 and b) 48 hour incubation periods. a) At 24 hours both patients and 
controls exhibited a trend towards reduced cellular viability with increasing Scriptaid 
concentration, with patients more affected by this trend compared to controls. b) At 
48 hours incubation periods, both patients and contro ls showed a steeper decline in 
viability at 3uM doses compared to 24 hour incubation periods. (Data presented as 
percentage of vehicle control, mean of n=3 independent experiments on pooled cells. 
±SEM. Analysed with two-way ANOVA, Bonferroni’s correction.) 
a 
b 
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Figure 5.6 Determination of LDH cytotoxicity after Scriptaid treatment on iPS -derived cells. 
a) At 24 hour incubation periods and b) 48 hour incubation periods there was a trend towards 
increased cellular cytotoxicity witnessed in both patients and control s with increasing 
concentration, but no significant effects were identified . (Data presented as percentage of 
LDH cytotoxicity, mean of n=3 independent experiments on pooled cells. ±SEM, Analysed with 
two-way ANOVA, Bonferroni’s correction)  
a 
b 
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5.4.2  SCRI PT AID TR EAT MEN T DOES  NO T ACTIV AT E CO MPON ENT S  O F THE CELL 
SURVIV AL PATHWAY  
 
In light of the KD result we wanted to look for pAKT activation at the three doses 
originally tested to show whether or not Scriptaid had engaged the pathway in iPS-
derived cells. Therefore, we performed western blots on iPS-derived cells at the end of 
the differentiation protocol that had been treated with Scriptaid for 24 hours at 3μM, 
10μM and 30μM concentrations, and probed for total PTEN, total AKT and pAKT. The 
patient iPS-derived cells had not shown a reduced cell number compared to controls in 
our studies (chapter 4 figure 4.1), therefore similar to the assay performed on 
fibroblast cells (chapter 3), we decided to induce a stressed condition through serum 
withdrawal from the cells (Simm et al., 1997, Arrington and Schnellmann, 2008).  
Results identified that Scriptaid did not elicit a significant positive change to total PTEN 
levels, nor a significant positive increase in pAKT expression or total pAKT available 
(figure 5.7), suggesting that the drug did not activate the cell survival pathway as 
intended. As Scriptaid treatment did not reveal a significant positive effect on total 
motor neuron cell number, this could be due to an insignificant effect of Scriptaid on 
PI3K pathway components. The only noted effects were a reduction in pAKT found 
upon serum withdrawal in control cells compared to basal conditions, a result also 
found in fibroblast cells (figure 5.7c). Interestingly, dissimilar to fibroblast cells which 
found patents exhibited significantly lower levels of total PTEN (chapter 3 figure 3.5), 
iPS-derived cell populations showed that levels of PTEN between patient and control 
cells were similar. This indicates that the transition from fibroblast to differentiated iPS 
cell could have caused an increase in total PTEN expression in patient cells to sit more 
closely to that of controls, highlighting a fundamental difference in PTEN control in 
different cell types, which may aberrantly affect the survival of the cells in disease 
(figure 5.7 b). 
As Scriptaid was recently identified to cause changes to PTEN by increasing the levels 
of the phosphorylated inactive form of the protein (Wang et al., 2015a), we also 
decided to identify to what degree pPTEN was affected by the drug compared to basal 
levels, by performing the same experiment as above but this time probing for pPTEN in 
addition to total PTEN. We found that Scriptaid caused a significant reduction in pPTEN 
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in cells compared to vehicle control and caused no effect on the total amount of 
pPTEN available (figure 5.8) suggesting Scriptaid does not have a positive effect on 
PTEN via inhibition. Of note, these experiments did identify in basal cells a higher level 
of pPTEN expression in patient cells (figure 5.8b), highlighting an increased inhibition in 
disease. However, when we look at the total PTEN available, although there is a trend 
towards higher pPTEN levels, there is no significant difference in basal conditions 
between patients and controls, implying the positive effects of PTEN inactivation may 
not be realised into cell survival benefits for the cells; a result which is validated by 
reduced AKT phosphorylation also found in patient cells in basal conditions (figure 
5.7c). 
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Figure 5.7. Scriptaid treatment to iPS derived cells does not positively impact PI3K Pathway 
components. a) Western blots reveal: b) no significant changes in total PTEN protein expression, 
c) a significant reduction in pAKT levels with serum withdrawal . d) No significant changes in 
total AKT expression, apart from a significant reduction of total AKT protein with 3μM control 
cells compared to basal controls. e) The ratio of pAKT:AKT(pan) reveals no significant change to 
the total amount of pAKT available.  Representative western blot shown. (Data are mean of  n=3 
independent experiments of pooled cells and normalised to GAPDH loading control.  Where more 
than one membrane was required, each membrane contained both a basal and vehicle control 
for comparison- see chapter 2 section 2.4.3. ±SEM *p=<0.05, **p=<0.005, analysed with two-
way ANOVA) 
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Figure 5.8 Scriptaid has no positive effect on pPTEN but basal pPTEN expression is significantly 
higher in patient cells. A) Western blots reveal b) a significant difference between patient and 
control pPTEN and a s ignificant downregulation of pPTEN in both patients and control when 3μM 
scriptaid treatment is applied to iPS-derived cells. c) there is no significant change in the total 
pPTEN available  between  basal, vehicle or treated conditions. Representative west ern blot 
shown. (Data are mean of  n=3 independent experiments of pooled cells and normalised to GAPDH 
loading control. ±SEM *p=<0.05, ****p=<0.00005 analysed with two-way ANOVA) 
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5.4.3  SCRI PT AID TR EAT MEN T DOES  NO T MO DULAT E MOTOR  NEURON  CELL 
NUMBER  
 
Given that differentiation is a long process, selecting a paradigm is difficult and there is 
a multitude of possible variations. After much consideration we went for these 
paradigms in the first instance, balancing toxicity with predicted active dose and likely 
dynamics. As the effect of small molecule inhibitors is dynamic and therefore more 
subtle then a knockdown approach, we considered two paradigms both from the 
beginning of differentiation as an appropriate start point, one of which was a single 
dose and the other being multiple weekly doses. For a single application, a dose of 
3μM was added to the cells for 24 hours on day 0, or at 2, 4 or 6 weeks into the 
differentiation protocol, and the cells were allowed to mature to the end of 
differentiation after which we would be able to identify from motor neuron cell counts 
of dual ChAT and Tuj1 labelled cell populations, if Scriptaid addition during the 
differentiation protocol has a positive effect on motor neuron generation at the end. 
The time points of application were chosen based on key points within our protocol, 
including the beginning of differentiation on undifferentiated iPS cells, 2 weeks of 
differentiation when the cells express neuronal marker Tuj1, 4 weeks of differentiation 
which is the earliest identified expression of mature motor neuronal marker ChAT, and 
at the end of differentiation. For multiple applications, in a parallel experiment we also 
applied Scriptaid at the same concentration on iPS cells from the beginning of 
differentiation (Day 0), and then each week subsequently throughout the 
differentiation process, to identify if repeated administration would also result in a 
positive effect on motor neuron cell generation. In the first instance, we were 
interested in the functional output of MN count after Scriptaid treatment; we then 
would later investigate the mechanism of action and activity of the drug further. 
When cells were treated with Scriptaid for a single application at either Day 0, week 2, 
week 4 or week 6, motor neuron cell counts revealed no significant increases in motor 
neuron cell number generated by the end of the differentiation protocol for both 
patients and controls (figure 5.9 a - d), suggesting Scriptaid does not positively benefit 
motor neuron generation or increase survival of cells when applied in these conditions. 
Parallel assays applying Scriptaid for multiple applications at weekly time points 
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throughout differentiation starting from day 0 and ending at week 6, identified again 
no significant increases in cell number in either patients or controls (figure 5.9 e).  
Notably, a significantly negative effect on motor neuron numbers was found under 
some conditions. This included a significant decline in motor neurons generated in 
patient cells treated with Scriptaid at 2 weeks of differentiation compared to control 
cells treated with Scriptaid at the same timepoint (figure 5.9b). Additionally, a 
significant decline in motor neuron cell number was found in control cells treated with 
Scriptaid at 4 weeks of differentiation compared to vehicle control (figure 5.9c). 
Collectively, these results suggest that Scriptaid had on average little to no measurable 
positive effect on cells to increase iPS-derived motor neuron cell number. 
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a b 
c d 
e 
Figure 5.9: Scriptaid treatment during differentiation does not increase motor neuron cell 
number. iPS cells were treated with 3μM Scriptaid for a single treatment during the differentiation 
protocol at a) Day 0 b) 2 weeks c) 4 weeks and d) 6 weeks of differentiation. IPS cells were also 
treated with Scriptaid for e) multiple applications at weekly intervals from day 0 to 6 weeks of 
differentiation. At the end of the differentiation process cells were counted for the number of dual 
stained ChAT and Tuj1 positive motor neurons generated. Results found no significant increases in 
motor neuron number generated with Scriptaid treatment f or a)-d) either a single treatment or for 
e) for multiple treatments.  b) A significantly lower number of motor neurons were generated by 
patient cells treated with Scriptaid compared to control cells treated with Scriptaid when the drug 
was applied for a single application at 2 weeks of differentiation. c) A significantly lower number of 
motor neurons was generated by control cells treated with Scriptaid compared with vehicle treated 
control cells when Scriptaid was applied for a single application at 4 we eks of differentiation (Data 
presented as percentage of total cell counts,  mean of n=3 independent experiments of pooled cells. 
±SEM, Analysed with two-way ANOVA, Bonferroni’s correction,-=vehicle control, += Scriptaid 3μM, 
# between +ChAT/+Tuj1 positive cells (motor neurons)) 
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5.5 DISCUSSION  
 
Promoting the survival of the cells which die in ALS through the manipulation of cell 
survival pathways could be a valid therapeutic strategy to ameliorate progression of 
the disease. Indeed, evidence from previous studies in iPS-derived motor neuron 
models of spinal muscular atrophy, a disease in which the motor neurons are also 
affected, has found inhibition of apoptotic pathways can reverse cell death 
phenotypes previously seen in the models (Sareen et al., 2012). Therefore, based on 
this theory, the aim of our research was to identify if manipulation of PTEN could 
promote cell survival pathways and thus the survival of cells affected by C9ORF72-
related ALS. 
In validation of the mechanism to inhibit PTEN for the activation of the PI3K cell 
survival pathway, we found PTEN knockdown caused a concomitant increase in 
activated phosphorylated AKT (figure 5.2), a component of the PI3K cell survival 
cascade which when activated causes increased cell survival through reduced cellular 
apoptosis. Furthermore, we identified that PTEN knockdown also caused a positive 
effect on C9ORF72-ALS iPS-derived cells by increasing cell numbers significantly 
compared to control cells undergoing the same treatment (figure 5.4). We can 
postulate that this increase in cell number is due to an activation of cell survival 
pathways. However, these positive effects in patient cell number were only realised 
from 7 to 9 weeks of differentiation, after which no significant survival benefits were 
found in patient cells compared to controls (figure 5.4). As the concomitant increase in 
pAKT was not significant, we may find that with increased PTEN knockdown, through 
increasing transfection efficiencies from 90% to 95-100%, it may yield significant 
differences in AKT activation and thus prolong the survival benefits witnessed. 
However, overall these results agree with existing findings that PTEN inhibition or 
reduction in neuronal cell models can increase cell survival (Mao et al., 2013, Kirby et 
al., 2011, Christie et al., 2010, Yang et al., 2014b) and have validated this target for a 
potential beneficial effect in disease. Interestingly, recent work has found that partial 
knockdown of PTEN results in a rescue of the toxicity observed in an inducible cell 
model of C9ORF72- ALS; a knockdown which interestingly did not affect the number of 
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RNA foci in these cell models (Stopford et al., 2017). This work with not only further 
supports this mechanism of protection for ALS, but also suggests PTEN manipulation to 
reduce its activity has a positive effect which is independent of RNA foci hallmarks of 
C9-ALS, potentially suggesting the foci could be a consequence of disease rather than a 
cause of cell death. 
Taking these results forward, we chose to utilise Scriptaid as a novel therapeutic target 
for PTEN manipulation due to the positive effects found in cell models of neuronal 
injury. We were also aware that the use of such drugs could lead to faster translatable 
results to humans, due to the historical use of similar compounds already in existence 
(Takai and Narahara, 2010, Yoo and Ko, 2011, Ryu et al., 2005) in comparison to the 
slow progress of viral vector mediated therapy at the time of investigation. Studies 
with Scriptaid identified no significant negative effects on cellular viability or 
cytotoxicity, matching previous reports of low toxicity (Su et al., 2000) (figure 5.5, 5.6). 
However, when Scriptaid was applied throughout the differentiation process in 
multiple applications, or at single time points, no positive effect on total motor neuron 
cell numbers was revealed, implying Scriptaid did not increase motor neuron yield 
when used during differentiation (figure 5.9). We applied Scriptaid at multiple stages in 
differentiation to identify when it was best to add the treatment; if added too early we 
may have inhibited differentiation, however too late and the cells may have already 
started a cascade towards cell death before any interventions had the opportunity to 
offer protection. Our results identified no single application which would significantly 
increase final motor neuron cell number, despite adopting incubation lengths and 
protocols utilised in the literature for a similar effect (Wang et al., 2015a) and using a 
concentration reported within the optimal dose for activity (Su et al., 2000, Wang et 
al., 2015a). When the extent of PTEN manipulation was quantified using western blot 
analysis, probing for PTEN, pPTEN, AKT and pAKT, no significant positive effects on 
these components which would suggest an inhibitory response was adopted by the 
cells was identified (figure 5.7, 5.8). In contrast, we saw a reduction in pPTEN, the 
inactive form of the protein, and no changes in the amount of pPTEN available (figure 
5.8). This suggests in contrast to previous reports, that Scriptaid does not inhibit the 
activity of PTEN via increasing PTEN phosphorylation; at least in the cell models and 
conditions tested here. The inability of Scriptaid to upregulate key components in the 
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PI3K pathway may explain the lack of positive effect on motor neuron cell number 
after its application; by failing to increase AKT phosphorylation, cell survival pathways 
are not activated, so motor neurons would be less likely to convey the increased 
survival mechanisms as a result.  
In the work by Wang and colleagues, Scriptaid was found to prevent a decrease in 
pAKT caused by induced traumatic brain injury, however in our studies no significant 
reductions in pAKT were identified, meaning unlike their cell models there was no 
significant patient phenotype in this pathway component for Scriptaid to restore. 
Additionally, Scriptaid in more recent work was found to have an indirect effect on 
PTEN, which was thought to offer a neuroprotection through increasing GSK3β mRNA 
which in turn acts to control the phosphorylation status of PTEN by increasing 
phosphorylation and therefore inactivation to initiate a disinhibition of the PI3K 
pathway (Wang et al., 2015a). In our iPS cell models we did witness significantly higher 
levels of pPTEN in patient cells compared to controls under basal conditions (figure 
5.8), therefore it could be possible that in our cell models PTEN phosphorylation had 
already reached its upper limit, possibly in an endogenous protective activation in 
disease. Therefore, the addition of Scriptaid could have little to no further effect on a 
saturated phosphorylation status.  
Scriptaid is a HDAC inhibitor with roles acting to control epigenetic gene expression (Su 
et al., 2000). Cell to cell differences in the expression of genes and protein markers 
means that these drugs are likely to have different effects across cell types (Wang et 
al., 2012b). Consequently, one possible explanation for a lack of effect on motor 
neuron-like cell models could be due to differences between neuronal cell gene 
expressions. Certainly, when comparing traumatic brain injury, the model the original 
study was conducted upon, to motor neuron disease, we are likening an acute insult 
and fast death of neuronal cells in days or even minutes after assault, against a disease 
which propagates over a patient’s lifetime, from chronic accumulation of toxicity 
culminating in the death of motor neurons. These differences will be reflected in the 
gene expression profiles of these cells which would have a counteracting effect on how 
a drug such as Scriptaid would provide its protective properties. In addition, as it is 
possible to have a disease-causing mutation such as C9ORF72 without developing ALS, 
this suggests environmental and epigenetic triggers may also be required to initiate 
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pathogenesis. These epigenetic variations are lost in iPS cell generation, where we 
have effectively reset a cells epigenetic state. Without this variation between patients 
and controls we may be losing any disease specific effects on cell survival. It is still 
possible that Scriptaid’s positive therapeutic effect on the survival of cells remains in 
cells which have retained disease specific epigenetic changes, such as primary 
neuronal cell models of ALS, or newer models of motor neuron generation such as 
iMN’s from neural progenitor cells which do not lose their epigenetic hallmarks (Meyer 
et al., 2014). 
Although, Scriptaid was unsuccessful in promoting the survival of iPS-derived cell 
populations, interesting patterns in PI3K pathway components have been revealed in 
basal iPS-derived cells. Total PTEN levels of both patients and controls are at similar 
levels in iPS-derived cells (figure 5.7), however in the fibroblast cells the iPS cells 
originated from, C9ORF72 patient cells showed significantly lower levels of PTEN 
(Chapter 3 figure 3.5). Whilst this result could be a reflection of the differences 
between studying a mixed population of cells versus a clone, it also could suggest a 
modulation of PTEN protein expression in the conversion of fibroblast to iPS-derived 
cell identity. Fibroblasts are not affected in ALS, whilst motor neurons are, therefore 
these subtle changes in PTEN expression may reflect some of the differences between 
a surviving or dying phenotype of the cells. Higher levels of total PTEN in patients could 
mean increased inhibition through PTEN dephosphorylating PIP3, therefore this would 
result in less activation of cell survival pathways in iPS cell models of ALS. In contrast, 
the lower levels of PTEN found in our patient fibroblasts cells compared to controls 
could reflect a phenotype which confers increased survival to due lower levels of total 
PTEN to inhibit the pathway, thus increasing cell survival. Contradictory to the iPS-
derived cell models studied here, but similar to the results found in our fibroblast 
models, laser captured micro-dissected motor neurons from ALS patients have been 
found to express lower levels of total PTEN expression compared to controls (Kirby et 
al., 2011). However, it is important to note that the cells in the study by Kirby et al. 
were obtained after the patient’s death, and had therefore successfully survived the 
disease. The reason for their survival could be due to modulation of total PTEN protein 
in these cells, however as the study did not examine pAKT levels, it is hard to predict if 
these changes were translated into activation of cell survival pathways for a positive 
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effect. In our iPS-derived cell models we also examined pAKT expression and found 
with relative higher levels of PTEN, we see an expected relative lower level of pAKT. 
However, in comparison with fibroblast cell models, pAKT expression is also 
significantly reduced in patient cells implying that, although there is a downregulation 
of this pathway, compensatory mechanisms in the cell may be activated to promote 
fibroblast cell survival. These discrepancies between patient cell models could also 
suggest an aberrant signalling cascade in disease, to which motor neurons are 
potentially selectively vulnerable. Studies have found pAKT expression can remain 
unaffected in ALS patient tissue despite significant changes in PI3k protein levels and 
activity, implying aberrant activities of this canonical signalling pathway in ALS (Wagey 
et al., 1998). As well as this, other survival pathways have also found irregularities in 
motor neuron disease, with significant caspase-3 and caspase-8 dysregulation and 
increased motor neuronal cell death in iPS-derived cell models of SMA (Sareen et al., 
2012). Their study interestingly found no modification of signalling molecules Bcl2 and 
Bax which are found downstream of the PI3K cell survival pathway. However, it would 
be appropriate to understand the behaviours of components upstream of the PI3k 
pathway such as PTEN, AKT and PI3k for comparison, particularly as factors such as cell 
models used (SMA vs. ALS), differentiation protocols, and detection methods may all 
play into cell survival pathway protein expression (Sareen et al., 2012).  
Of note, across multiple assays we see patient specific effects.  For example, when 
looking at the stress component of the Scriptaid treatment assays, when cells are 
exposed to serum withdrawal, both patient models of fibroblasts and iPS-derived cells 
are less sensitive to serum withdrawal compared to controls (Chapter 3 figure 3.5, 
figure 5.7). Similarly, for PTEN knockdown, only the patient cell lines are susceptible to 
increases in cell number. One possible explanation for this could be due to patients 
conveying aberrant PI3k regulation as a cause or a consequence of disease, becoming 
least reactive to additional external stressors such as serum withdrawal and 
exemplifying a possible subtle difference in cell survival cascade regulation in disease. 
Although under basal conditions we see no difference in the cell viability between 
patients and controls, subtle changes in the biochemistry and intracellular pathways 
reflecting a possible early stage of the disease may be present. Many studies have also 
shown a lack of prominent MN cell death or ALS phenotype in iPS-derived ALS motor 
168 
 
neurons yet still show small biochemical and molecular changes (Kiskinis et al., 2014, 
Sances et al., 2016). It is possible that these cell models may reflect an early stage of 
disease which has yet to progress into the full disease phenotype, for example, PTEN 
dysregulation in the early phases of ALS, showing increased phosphorylation of PTEN 
possibly in order to promote or maintain survival. Without an obvious apoptotic 
phenotype in iPS-derived models, future work to age cellular models to try and 
recapitulate the motor neuron death seen in ALS, subsequently followed by PTEN 
inhibition might yield a more beneficial result. Additionally, due to technical difficulties 
in isolating pure populations of iPS-derived motor neurons due to low yields of motor 
neurons obtained, although PTEN knockdown was successfully achieved in neuronal 
populations, we were unable to perform cell counts on a pure population of motor 
neurons. Future experiments adopting newer techniques to obtain yields of up to 95% 
through the modification of differentiation factors  (Du et al., 2015) may increase both 
motor neuron yield and maturity. This would subsequently make the isolation of motor 
neurons easier and help us to confirm the benefits of PTEN manipulation on motor 
neurons independently of other cell populations. Finally, as a further stage to this, 
experiments to also target PTEN manipulation to the disease affected motor neurons, 
specifically through the use of viral or Hb9 promotor, would identify a safer, more 
translatable PTEN manipulation with this methodology, particularly as we observed 
PTEN knockdown across different cell types in the population. 
 
5.6 CONCLUSION  
 
Overall, although we were able to validate the targeting of PTEN in the PI3K pathway 
as a potential target in iPS-derived cell models of C9ORF72 ALS, Scriptaid as a molecule 
for PTEN inhibition and promotion of this cell survival pathway has failed to produce 
the desired result. Future work could identify more specific and safer targeting of 
PTEN, potentially through the use of better molecules or utilising most recent 
advances in gene therapy allowing targeting of specific cell populations.  
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6.1 LESSONS LEARNED FROM C9ORF72  IPS  CELL MODELS OF ALS 
 
The generation of iPS cells from the somatic cells of humans has revolutionised the 
study of human disease by providing close replica models of human cells where the 
use of post-mortem material or primary human cells is either not sufficient or not 
possible. For neurological diseases, iPS cell technology theoretically provides the 
opportunity to generate a supply of human neuronal cells for examination and 
experimental manipulation. In ALS, the degeneration of motor neurons is a primary 
cause of the disease phenotype, therefore resourcefully, scientists have been utilising 
the ability to generate “motor-neurons-in-a-dish” to investigate disease causation and 
attempt to find a therapeutic angle to ameliorate symptoms and progression of a 
devastating disease. In the above work, our aim was to generate iPS-derived motor 
neuronal cell models of C9ORF72-related ALS, as a background to investigate PTEN 
manipulations, including comparing against the originating fibroblasts from which the 
iPS cells were derived. However, as a relatively novel technique, yet to be universally 
refined in laboratories across the world, prior to investigating of the effects of PTEN 
manipulation on cell survival, our characterisation revealed important findings to be 
noted for the success of future iPS cell differentiations in our hands. 
The first observation from our differentiated iPS cells was that we had generated a 
mixed population of cells, however dual neuronal markers Tuj1 and mature motor 
neuronal marker ChAT staining revealed a population of motor neuron cells to be 
38.3% in controls and 24.9% in patient populations (figure 4.9, 4.10). Although a trend 
towards lower motor neuron numbers was found in patient samples, no significant 
difference was found between patient and control motor neuron number, in-line with 
previous work of a similar investigative nature (figure 4.10) (Devlin et al., 2015, 
Donnelly et al., 2013a). Whilst these numbers reveal successes in our ability to 
generate motor neuronal cells through our protocol (Yang et al., 2014b), the cell 
counts also reveal an opportunity to not only identify the fate of the remaining cells in 
the population but also highlight that optimisation of motor neuron yield could be 
undertaken for future differentiations. 
171 
 
With limited international standardisation of iPS cell differentiation protocols, 
variations in motor neuron yield are common place, with results ranging from 20% to 
95%  being recently reported (Sances et al., 2016). Differences in the protocol can be 
found in every stage of the process, and include: variation in the time for total 
differentiation; time to initiate neural induction, ventralisation, and maturation; 
factors used for differentiation; concentrations of factors and reagents used; length of 
incubation period for factors, and point of application in differentiation; time of cell 
dissociation and plating; cell numbers plated; time assays are performed; as well as 
differences in vessel and coatings used. Whilst we were able to optimise some of these 
processes during our differentiations, including cell numbers plated and the timings for 
the end of our experiments, unfortunately within the time and scope of this project, 
we were unable to explore further areas such as our factor and reagent choices which 
may have had a positive effect on final motor neuron yields. Future studies could 
employ some of the more recently published techniques in this area. For example, a 
study by Du et al. has successfully used Wnt signalling activation along with varying the 
concentrations of retinoic acid and purmorphamine throughout differentiation, to 
achieve highly pure yields of motor neurons of up to 95% over a shorter protocol (Du 
et al., 2015). Future studies could also identify the constitution of the rest of the 
population of differentiated iPS cells generated by our protocol, including the number 
of additional neuronal populations such as interneurons, and the percentage of 
astrocytes and other neural support cells. If such findings reveal for example a higher 
proportion of astrocytes, it may aid us in identifying which factors should be 
modulated to reduce their prevalence, and guide us to where within our protocol 
modifications could be made. Using an alternative protocol or a similar approach to Du 
and colleagues could be beneficial in two ways. Firstly, by increasing the total yield of 
motor neurons it would reduce the need for often yield-limiting further purification 
processes such as fluorescence activated cell sorting, utilised by some labs to obtain a 
pure yield of desired cell populations. As cell counts similarly to the above work are 
often made by marker expression, this alone does not identify the percentage of 
functional cells, therefore this work would be supported by electrophysiological 
recordings. However additionally, by generating higher yields of motor neurons, it 
would also save time in generating multiple batches of differentiated cells; save 
resource using less factors and using those that were obtained more efficiently; and 
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finally it would save money, particular as the differentiation process requires the use 
of expensive reagents in what can soon become an expenditure too large for many 
labs to run effectively. 
 
Along with increasing the number of motor neurons generated, another method for 
future differentiations may lie in improving the ability of the models to replicate ALS. 
In our models we could find no significant difference between patient and control cell 
number over time or increased cell death in patient cells specifically (figure 4.11). 
While we cannot rule out from our studies subtle biochemical changes such as 
caspase-3 dysregulation (Dafinca et al., 2016) which could be relevant to identifying 
this phenotype in our models, it is important to note that iPS-derived cell models of 
motor neurons have shown varying levels of patient associated cell survival 
phenotypes. Whilst some iPS cell models of MND such as SMA have found a 
degenerative phenotype in patient cells (Ebert et al., 2009), and SOD1 iPS-derived 
models similarly showing survival differences (Kiskinis et al., 2014), many studies in iPS-
derived models of  C9ORF72-related ALS have struggled to identify a similar phenotype 
(Sareen et al., 2012, Devlin et al., 2015, Donnelly et al., 2013a).  Interestingly, it is not 
uncommon for iPS cell models of ALS to present mild or partial phenotypes of disease 
(Dimos et al., 2008, Mitne-Neto et al., 2011, Wainger et al., 2014). The reported 
different findings across diseases which ultimately result in the death of the same cell, 
exemplify how different genetic causes reflect distinct mechanisms of action, and 
highlight how a “one-size-fits-all” therapeutic may not work in the face of the 
complexities of motor neuron biochemistry.  
As iPS cells represent an embryonic-like state, the relatively short length of time from 
iPS cell to fully differentiated neuron may not be long enough to imitate life-long 
cellular stresses which could act as a second trigger for C9ORF72- related ALS 
pathogenesis. Moreover, iPS cells have effectively had their epigenetic status erased 
(Mertens et al., 2015), and these features may be the prominent cause to cellular 
degeneration in specific forms of ALS. Our differentiation and culture period went up 
to 12 weeks, however studies have found cells as old as 4 months display increased 
patient associated phenotypes including DNA damage (Lopez-Gonzalez et al., 2016). 
This suggests that further studies should prolong culture periods to gain an increased 
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aging phenotype. However, as we show a progressive loss of total cell number over 
increased culture length (figure 4.11), to do this we would unlikely be able to maintain 
the volume of cells required to successfully perform such analysis with our current 
protocol. As iPS derived motor neurons from C9ORF72 patients have been found to 
display increased oxidative stress and DNA damage (Lopez-Gonzalez et al., 2016), 
artificial induction of oxidative stress or experimentally induced aging (Miller et al., 
2013) on our cell models may improve their ALS phenotype. Alternatively, newer 
techniques to generate cell models from a direct conversion of human somatic cells 
may provide a simpler solution. A recent study by Mertens et al. identified that iPS 
cells derived from human fibroblasts convey an edited transcriptome that is no longer 
representative of the donor cell, including the loss of key ALS identifiers (Mertens et 
al., 2015). As many of these gene signatures are developed over a patient’s lifetime, 
consequently this loss of age-associated features in iPS cells could be a reason behind 
the variable recapitulation of disease found in iPS cell derived models. Future studies 
to use models which involve a direct conversion of somatic cells to the cell of interest 
could act as complementary models to iPS-derived motor neurons. Studies have 
identified that direct conversion techniques developing iastrocytes are able to 
replicate characteristics of primary ALS tissue well, exerting the same toxic responses 
to motor neurons as spinal cord-derived astrocytes (Meyer et al., 2014, Haidet-Phillips 
et al., 2011). Studies comparing motor neurons which have maintained age-related 
epigenetic patterning against iPS-derived motor neurons, generated from the same 
originating fibroblast cells, would identify the importance of these signatures for the 
model to recapitulate C9ORF72- related ALS more effectively.   
We have successfully generated motor neurons that positively express mature motor 
neuronal markers, motor neuronal specific markers and multiple neuronal markers; 
however future avenues may also lie in improving the electrical maturity of iPS-derived 
motor neurons generated in our protocol. Electrophysiological recordings revealed an 
immature phenotype in the motor neurons generated, with cells conveying a lack of 
repetitive action potential firing on exposure to a depolarising stimulus, wide spikes, 
low capacitance, and a highly depolarised resting membrane potential (Table 4.1-3, 
figure 4.12). Whilst some of these features are common in iPS cell models (Gogliotti et 
al., 2012, Sances et al., 2016) in comparison to other groups improvements can be 
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made in the electrical excitability (Wainger et al., 2014, Sareen et al., 2013). As 
differentiation was continued for up to 12 weeks in our studies, steps to improve the 
maturity of the cells rather than increasing tissue culture lengths, could include 
changes to the differentiation protocol mentioned above to rapidly generate mature 
motor neurons, for example at 2-3 weeks rather than 4-6 weeks. Indeed preliminary 
data from our lab has found that utilising a shorter differentiation protocol and 
utilising Compound C, an AMP kinase inhibitor, at the start of the protocol for neural 
induction (Qu et al., 2014), has improved the electrical maturity of the cells (data not 
shown). Whilst this work will continue, additionally, other methods to improve the 
electrical maturity of cells could also include using co-cultures with astrocytes which 
has been shown to improve both the hyperpolarisation of resting membrane 
potentials and synaptic activity (Johnson et al., 2007). These steps would ensure there 
is an increased timeframe after motor neuron generation for maturation in culture 
before total cell numbers decline. 
 
6.2 MOLECULAR HALLMARKS OF C9ORF72  ALS  IN IPS-DERIVED 
CELL MODELS  
 
Since the discovery of C9ORF72 to be the most common genetic cause of ALS (Renton 
et al., 2011, DeJesus-Hernandez et al., 2011) researchers have identified several 
molecular features found to be specifically associated with C9ORF72-related ALS. RNA 
foci, aggregated material transcribed from both sense and antisense RNA transcripts 
appearing as punctate species upon RNA FISH are one of those features, and the 
discovery of them in patient tissue has added to the debate of how the mutated 
repeat expansion causes disease. Many groups have elucidated that the presence of 
RNA foci is indicative of a toxic gain of function mechanism being causal or at least 
contributing towards disease pathogenesis (van Blitterswijk et al., 2012, Harms et al., 
2013). In our cells, in addition to corroborating a mechanistic cause of disease, due to 
their identification in patient tissue alone, we decided to employ them as markers of 
the hexanucleotide repeat expansion in our cells.  
Sense and antisense probes were able to successfully identify foci from both species in 
our differentiated patient iPS cells, however were absent in our controls (figure 4.13, 
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4.14). This result is in confirmation with multiple reports of iPS-derived cells with a 
C9ORF72 background (Almeida et al., 2013, Mizielinska et al., 2013, Lagier-Tourenne et 
al., 2013, Donnelly et al., 2013a, Cooper-Knock et al., 2015b), and the identification of 
foci in undifferentiated iPS cells, also confirmed that the expansion remained in patient 
cells throughout the iPS cell to differentiated cell transition and were not generated  
during the process. Sense and antisense RNA foci were found in 31.89% and 21.4% of 
cells respectively and of either species, 1-3 foci per cell was found to be the most 
frequent number (figure 4.15), corroborative with a number of reports which also find 
lower foci numbers to be common (Lagier-Tourenne et al., 2013, Sareen et al., 2013, 
Mizielinska et al., 2013). However, the finding that our foci were predominantly 
cytoplasmic (figure 4.13, 4.14) whilst dissimilar to some previous reports (Almeida et 
al., 2013, Mizielinska et al., 2013, Sareen et al., 2013, Lagier-Tourenne et al., 2013), has 
been noted to be a more common occurrence in iPS cells and differentiated 
counterparts (Donnelly et al., 2013a, Lagier-Tourenne et al., 2013, Cooper-Knock et al., 
2015b). These results show that our models recapitulated aspects of disease pathology 
including the aberrant molecular biology newly associated with disease (Cooper-Knock 
et al., 2015b), thus bringing us a step closer to creating a more accurate model of 
human ALS. 
 
In addition to foci observations, in our cells we were also able to witness GA di-peptide 
repeat protein aggregates as a second feature of aberrant molecular pathobiology in 
our cell models (figure 4.16, 4.17) (Mori et al., 2013b, Ash et al., 2013, Almeida et al., 
2013). Similarly to foci visualisation, we identified DPR proteins in iPS cells in their 
differentiated and undifferentiated states, suggesting again the formation of these 
proteins does not occur during the differentiation period. GA has been reported to be 
the most common DPR protein in tissue due to its high ability to form aggregates 
(Zhang et al., 2014). In addition, recent studies have found interesting correlations 
between age and toxicity, with GA DPR’s noted to cause increased toxicity to neuronal 
cells with increasing age (Flores et al., 2016), and DPR proteins found to be prevalent 
at higher expression levels in older rather than younger cultures of iPS-derived 
neurons (Lopez-Gonzalez et al., 2016). Ultrastructural analysis has revealed dynamic 
physical changes to DPR protein secondary structure, including an increased 
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propensity for β-pleated sheet formation with age (Flores et al., 2016), which suggests 
steps to improve the aging phenotype within our models may help to identify other 
DPR proteins. Our cells also exhibited distinct aggregations of GA DPR proteins, which 
some studies have proposed as a sign of increased toxicity (Wen et al., 2014). However 
as we did not identify any cell death phenotype in the studies performed here, it is 
possible we are witnessing an early stage of neurotoxicty in the cells, a possibility 
which could fit with the six-step theory of ALS (Al-Chalabi et al., 2014). Alternatively, 
whilst many studies advocate for their toxic contribution to disease, we cannot rule 
out the possibility that these aggregates are initiated as a protective mechanism. 
Future work to optimise the visualisation of the remaining DPR proteins would be of 
interest, to clarify conflicting reports on their toxicity (Wen et al., 2014, Zhang et al., 
2014).  
The unusual re-distribution of TDP-43 protein from the nucleus to the cytoplasm in ALS 
is now a well described hallmark of the disease which has also been shown in iPS cell 
models.  Studies have found that undifferentiated ALS patient iPS cells contained 
indications of aberrant TDP-43 such as increased soluble full-length TDP-43 and 
increased detergent resistant C-terminal fragments of TDP-43 (Bilican et al., 2012), 
implying similar to other hallmarks of disease, the generation of iPS cells from somatic 
cells does not remove these traits. However, the reports of the relationship between 
TDP-43 and C9ORF72 has generated mixed results (Lagier-Tourenne and Cleveland, 
2009, Mizielinska et al., 2013, Bilican et al., 2012, Almeida et al., 2013, Zhang et al., 
2015a), which is also the case for the relationship between TDP-43 and RNA foci 
(Lagier-Tourenne et al., 2013, Mizielinska et al., 2013, Cooper-Knock et al., 2015b). 
Therefore examining TDP-43 distribution and foci presence in our iPS derived cell 
models was of interest. We found that foci and TDP-43 pathology could be identified 
together in cells, however there were no significant increases in the number of patient 
cells with re-location of TDP-43 to the cytoplasm (figure 4.18). We did find patient cells 
expressed a granular diffuse staining pattern compared to controls and patient cells 
were also identified to contain lower levels of nuclear TDP-43 protein after 
quantification of staining intensity (figure 4.18). The lack of a strong TDP-43 phenotype 
may be reflective of the inability of our cell models to fully recapitulate this part of 
disease pathology, and it is possible, given the length of time to differentiate and the 
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dramatic reduction of total cell number over extended culture, cells with a heavy 
pathology are lost in this process potentially akin to pathology material. The 
contrasting findings in other C9ORF72 studies, coupled with inconsistent iPS cell 
differentiation techniques between them, exemplifies how the variability in the 
generation of the cells could be producing a spectrum of ALS phenotypes. These could 
range from severe with strong phenotypic characteristics of disease, to mild. As our iPS 
cell models also do not show a distinct cell death phenotype and express an 
intermediate TDP-43 pathology, it is possible our models represent a milder 
representation of the disease. 
 
6.3 CELL SPECIFIC VARIATION OF PTEN  IN ALS 
 
Phosphatase and Tensin Homologue Deleted on Chromosome Ten (PTEN), is a key 
component in the ubiquitous PI3k cell survival pathway. As a tumour suppressor, its 
roles in preventing the activation of AKT, and thus through a canonical cascade, the 
inhibition of cell survival and the increase in apoptosis, have created an increased level 
of interest into how this protein can be targeted for beneficial therapeutic effects. The 
death of motor neurons in ALS prompted us to investigate what happens when we 
manipulate PTEN in cell models of ALS, and whether or not this manipulation promotes 
the survival of these cells in disease. 
As a pathway that is present in every cell of the body, each cell will have various 
degrees of pathway activation. Indeed our studies across two different cell models of 
ALS has found that patient fibroblast cells under basal conditions exhibit significantly 
lower levels of total PTEN protein expression compared to their controls (figure 3.5). 
However, when the same fibroblast cells are converted to iPS cells and differentiated 
into neuronal and motor neuronal identities, the total levels of PTEN expression are 
similar between patients and controls, with no significant difference between them 
(figure 5.5). Whilst we recognise this findings could be an artefact from comparing a 
mixed population (fibroblasts) with a clone (iPS cells), the differences between patients 
and controls may reflect variation in control of cell survival; as motor neurons are 
specifically vulnerable to cell death in ALS, their methods of control in the PI3k 
pathway may be aberrantly regulated as a cause or a consequence of disease. As 
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fibroblast cells are unaffected in ALS, they could promote mechanisms which maintain 
cell survival, including maintaining low levels of total PTEN protein to reduce the 
inactivation of AKT. Correspondingly, differences in cellular response to PTEN 
manipulation performed via PTEN knockdown have been found between cells of a 
mesodermal origin such as fibroblasts, compared to those of a neuronal origin (Duan 
et al., 2015) . Duan et al. found that mesenchymal stem cells and fibroblasts 
underwent cellular senescence after PTEN knockdown but exhibited no changes in AKT 
phosphorylation status. However in neural stem cells, PTEN deficiency resulted in 
neoplastic transformation and activation of AKT through increased phosphorylation 
(Duan et al., 2015). Further work expanding the investigations in iPS-derived cell PTEN 
protein levels, may help further identify if there are indeed intrinsic cellular differences 
in PI3K cell survival pathway regulation which may be emulated in the variance in total 
PTEN expression found between patients and controls in our two cell models. 
Our results found that experimental reduction of PTEN through knockdown leads to a 
concomitant increase in pAKT and can result in an increase in cell number of 
differentiated patient iPS cell populations at 7 to 9 weeks of differentiation (figure 5.2 
5.4). As only patient cells were affected, this coupled with a change in total PTEN 
expression from fibroblast to iPS derived cells, could suggest ALS specific regulation in 
the cell models which more closely replicate the cells affected in ALS. This difference 
may be irregular cell survival pathway activation in these cells, which could then lead 
to increased cell death, and may explain why patient cell numbers are more affected 
by PTEN knockdown. Further to the above study, neural stem cells deficient in PTEN, 
whilst able to differentiate into neuronal cell populations, were also found to be more 
resistant to stress induced cell death (Duan et al., 2015). As our results showed, PTEN 
deficient cells were more successful in maintaining cell numbers in total iPS cell 
populations, compared to their counterparts, one conclusion could be that removing 
the action of PTEN in this pathway could help to improve resistance to cell death in 
these cells. A caveat to the above work is that our studies examined one parameter of 
PTEN knockdown; the effect on total cell population numbers rather than specifically 
in motor neurons. Recent studies have highlighted how differentiated PTEN-deficient 
neural stem cells confer higher numbers of neuronal class III β-Tubulin (Tuj1) positive 
neurons, in a protein phosphatase dependent mechanism (Lyu et al., 2015), therefore 
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further studies to isolate not only neuronal population numbers but also to quantify 
key neuronal and motor neuronal proteins such as Tuj1, Hb9 and ChAT could reveal 
interesting neuronal specific effects. 
As PTEN in its phosphorylated form indicates inactivation of the protein, we also 
quantified this in differentiated iPS cell models. Unfortunately, due to an inability to 
measure pPTEN within its dynamic range in fibroblast cells, we were unable to make a 
comparison between fibroblast and differentiated iPS cells pPTEN levels from our 
studies. However results in iPS-derived cells revealed significantly higher 
phosphorylation of PTEN in patient cells compared to controls under basal conditions 
(figure 5.9). This finding suggests that in patient cells there is an effort to inactivate 
PTEN, which could promote increased cell survival pathway activation and thus cell 
survival in disease. However, this increased phosphorylation is not translated into 
increased total phosphorylated PTEN available in the cell (figure 5.9), nor does it 
translate into increased AKT activation (figure 5.8) which could again suggest irregular 
pathway control in disease, as we would expect to see high pPTEN to cause a positive 
effect on AKT phosphorylation. A recent study examining the regulation of PTEN 
phosphorylation in the c-terminal tail has highlighted some interesting results which 
may explain why firstly we were unable to visualise pPTEN in fibroblast cells. The c-
terminal tail of PTEN hosts 4 phosphorylation sites Ser380, Thr382, Thr383 and Ser385, 
which are known to contribute towards the conformation change which closes PTEN to 
membrane binding and thus inactivating its catalytic activity (Bolduc et al., 2013, 
Rahdar et al., 2009). However, the order of their phosphorylation and whether or not 
phosphorylation of all of these sites was required for this reaction has until recently 
been unidentified. In a controversial new study, Chen and colleagues identified that 
phosphorylation at a single site cannot dominantly cause this conformational change, 
however a successive and progressive phosphorylation is required of all 4 or at least 3 
of these sites to inactivate the protein (Chen et al., 2016). Whilst this study remains to 
be validated in other laboratories, it could suggest a more dynamic nature of PTEN 
phosphorylation than previously thought which could be regulated by multiple 
partners intracellularly, further adding to the complexity of PTEN regulation in the cell. 
Of note, this study also identified that p380 phosphorylation was key in the ability of 
pPTEN to be visualised by their western blotting techniques. Whilst pPTEN (ser380) 
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antibodies were used in our studies, the phosphorylation of the other sites still 
remains unknown. Taking this into account, as there are limitations of using antibodies 
to measure PTEN phosphorylation, future studies to use antibodies sensitive to 
additional residues for probing individually, in turn, and together, would clarify the 
phosphorylation status of PTEN, however nevertheless analysis of such findings should 
be interpreted with care. 
 
6.4 SCRIPTAID AS A PTEN  MANIPULATOR  
 
As a novel and alternative method of PTEN inhibition, Wang et al. identified that 
Scriptaid a HDAC inhibitor, could protect neurons from traumatic brain injury through 
PI3k pathway manipulation by increasing PTEN inactivation, and thus AKT 
phosphorylation and cell survival (Wang et al., 2012a, Wang et al., 2015a). As 
additional studies also reported that HDAC inhibition on cerebellar granule cells 
offered neuroprotection against glutamate induced excitotoxicity (Leng and Chuang, 
2006, Biermann et al., 2010), the similarity in neuronal specific targeting and pathways 
implicated in ALS  pathogenesis prompted us to investigate HDAC inhibition as a 
method of PTEN manipulation in our cell models of disease. However, when Scriptaid 
was tested in our first model of ALS, fibroblast cells, it had no significant effect on AKT 
phosphorylation status (figure 3.5). Whilst this suggests a lack of the ability of Scriptaid 
to modulate the PI3k pathway as described in the literature, we recognised it could be 
an indicator that these otherwise healthy cells are not susceptible to any protective 
effects of the drug, particularly as previous work has been described in neuronal cells. 
Therefore, as the cells assayed were not akin to the neurons affected in ALS, we 
postulated the lack of activated cell survival pathways seen with addition of this drug 
was due to this, and thus proceeded with generating a cell model which more closely 
replicated the cell damaged in disease.  
Nonetheless, when similar studies were performed in iPS –derived cell models of ALS, 
Scriptaid did not cause a positive change in motor neuron cell number when applied 
throughout differentiation, and when investigated further, Scriptaid did not illicit an 
increase in cellular AKT phosphorylation (figure 5.7, 5.8). As mentioned above, the 
basal levels of pPTEN in our patient iPS cells were significantly higher than controls. 
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However, when we examined the effect of Scriptaid on this, rather than see an 
increase in PTEN phosphorylation after treatment we saw a reduction in pPTEN in both 
patients and controls suggesting that the drug does not act as described in the 
literature (figure 5.8). Of note, later work by Wang and colleagues has suggested that 
the neuroprotective effect of Scriptaid via PTEN inactivation is a non-direct mechanism 
of action. They described how knockdown of GSK3β, an interactor of PTEN, abolished a 
Scriptaid-mediated phosphorylation of PTEN, and as Scriptaid exposure increased 
GSK3β mRNA, the authors suggested that regulation by Scriptaid was through non-
HDAC cellular targets (Wang et al., 2015a). HDACs have numerous non-histone targets, 
therefore in light of these more recent findings, further work to examine the changes 
to other cellular cascade interactors in the PI3K, pathway including GSK3β, could reveal 
why Scriptaid has failed to illicit the required response in our cells. The response from 
Scriptaid could be reliant upon a combination of cell-to-cell HDAC expression, activity, 
and non-HDAC targeting. Each cell type and tissue holds varying levels of HDAC 
expression and activity which can even be stage-specific (Morrison et al., 2007, 
Simoes-Pires et al., 2013). Evidence has shown how some HDACs can promote 
neuronal survival (Chen and Cepko, 2009) whilst others are suggested as viable targets 
for inhibition in neurodegeneration (Simoes-Pires et al., 2013). Because of this 
variability, the cell specific effects of HDAC inhibition may have wider implications for 
their therapeutic use. While Scriptaid has been described as a potential therapeutic for 
the survival of degenerative and damaged neuronal cells, it has also been proposed as 
a novel cancer therapeutic. As a HDAC inhibitor, by promoting reduced transcriptional 
repression it is thought to modulate the role histone deacetylation plays in cancer cell 
growth, and has been shown to slow down the growth and promote apoptosis of 
endometrial and ovarian cancer cells specifically, not affecting non-cancerous cells 
(Takai et al., 2006). In breast cancer cell lines, Scriptaid was found again to inhibit 
apoptosis, slow growth, and increase oestrogen receptor (α-ER) expression in α-ER 
absent cell lines, the loss of which is an indicator of accelerated disease progression 
(Giacinti et al., 2012). Scriptaid also has been shown to increase the sensitivity of cells 
to radiation-induced cell death, indicating that Scriptaid may be an excellent 
therapeutic coupled with radiotherapy to target radio-resistant cells by increasing the 
number of DNA double strand breaks and promoting cell cycle arrest (Kuribayashi et 
al., 2010). Whilst in neuronal cells, Scriptaid is thought to promote cell survival through 
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the AKT pathway (Wang et al., 2012a), in glia, HDAC inhibition targeted a different 
pathway, promoting Jun N-Terminal kinase (JNK) induced apoptosis in glioblastoma 
multiform and supported the idea that Scriptaid induced apoptosis in cancer is 
mediated  by DNA damage repair responses and cell cycle inhibition (Sharma et al., 
2010). With these studies in mind, it may be a property of Scriptaid or HDAC inhibition 
to treat cells according to the prerequisites of the cells gene and protein expresion. Of 
note, as studies have identified that PTEN can associate with chromatin to control 
gene transcriptional repression (Duan et al., 2015) using Scriptaid for a therapeutic 
effect in cell survival may result in a number of effects on gene expression that may be 
difficult to predict due to a potential combination of PTEN modulation and HDAC 
inhibition with the drug. Therefore, the use of HDAC inhibition with dynamic 
compounds such as Scriptaid, may need cautious monitoring to guarantee not only the 
success of the therapy, but also to control any potential off-target effects. 
 
6.5 FINAL CONCLUSIONS  
 
The first conclusion to be derived from this body of work is related to the development 
and use of iPS cell models for the study of ALS. We have successfully generated iPS-
derived neuronal and motor neuronal models of ALS which recapitulate many features 
of disease. However whilst these models act as an excellent human models for 
neuronal cell investigations, we must recognise caveats in their use, including their 
ability to fully model C9ORF72-related ALS. We have found, similar to others, an 
intermediate representation of disease, which although shows molecular 
pathobiological hallmarks of ALS does not replicate cell death and degeneration to the 
same extent of other forms of MND or primary animal cell models. Certainly steps to 
refine our models, for instance by improving the electrical activity and aging 
phenotype, should be undertaken in future work. Nevertheless even with these 
improvements, studies are now beginning to unravel how each subtype of ALS from 
C9ORF72 to SOD1 now represents distinct subtypes in relation to pathobiology and 
response to treatment (Ferraiuolo et al., 2016); findings which will have significant 
consequences upon the translational benefits of ALS research.   
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The above body of work, has identified some key findings related to the study of PTEN 
in cell models of ALS, which with further investigation could lead towards the 
reduction of motor neuron cell death and the promotion of cell survival in disease. 
Comparing against the same genetic background for directly comparable results, we 
have identified some potential key differences in the quantities of PTEN protein and 
downstream cascade components between fibroblast cell and iPS derived cell models 
of ALS. C9ORF72 ALS patient fibroblast cells display significantly lower total PTEN 
protein compared to their control counterparts, yet once converted to iPS cell and 
differentiated towards the fate of motor neurons, the cells no longer display this 
difference, a finding that additional investigations could further validate. As PTEN 
knockdown was found to cause a concomitant increase in the phosphorylation of AKT, 
thereby increasing the activation of well described cell survival pathways, it validates 
the manipulation of this pathway for this purpose in iPS-derived cell models. 
Additionally, as PTEN knockdown was identified to cause a positive increase in total 
iPS-derived cell survival between 7 and 9 weeks post differentiation, specifically in 
patient cells, it demonstrates the unique differences in PTEN regulation between 
patient and control models can be a targeted towards a beneficial effect. Whilst the 
effects of Scriptaid as a PTEN manipulator were not realised above, it shows us how 
direct targeting of the protein is likely to be the most viable method for PTEN 
manipulation for the complex and dynamic roles and regulation of PTEN and PI3K 
pathway components. What these findings mean in the context of C9ORF72-ALS 
patient therapies, including whether or not PTEN manipulation to improve motor 
neuron cell survival will translate into prolonged life and slower disease progression 
for the patient, remains to be elucidated. Nevertheless from our studies above, 
tentative first steps have been made in this direction.   
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